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ZUSAMMENFASSUNG 
 
Die Mitose ist ein hochgradig geordneter Prozeß der sicher stellt daß das duplizierte 
Genom gleichmäßig auf die Tochterzellen aufgeteilt wird. Gelingt dies nicht, so geht 
genetische Information verloren was zu Aneuploidy führt, wie es oft in Krebszellen 
beobachtet werden kann. Mehrere mitotische Kinasen sind das Ziel des sogenannten 
„Checkpoint“, welcher DNS Schäden detektiert. Die wichtigsten Kinasen hierbei sind 
Cdk1, Aurora A und Plk1. Aurora A, welche im Mittelpunkt dieser Studie steht, wird 
durch Schäden an der DNS während der G2 Phase inaktiviert. Dies führt zu einem 
ATM/ATR-Chk1 abhängigen Zellzyklus Arrest.  
 
In dieser Studie werden die molekularen Mechanismen untersucht, welche zu DNS 
Schadens-bedingter Inhibition von Aurora A Aktivität führen. Wir konnten auch 
zeigen, daß Aurora A, ein Ziel der IR-induzierten DNS Schäden, während der Mitose 
ist. Wir haben einen Synchronisationsansatz benutzt welcher die Zellen in der Mitose 
blockieret, während welcher die Aurora A Kinase Aktivität am höchsten ist. Als Maß 
für die Aktivität, haben wir die Phosphorylierung von Aurora A an der „T-loop“ 
Aminosäure, T288 getestet, indem wir einen spezifischen Antikörper benutzt haben. 
Das Resultat bestätigt ein reduziertes Phospho-Signal, welches Indikativ ist für die 
reduzierte Kinase Aktivität. Indem wir den Verlust der Phosphorylierung an T320 
gemessen haben, konnten wir bestätigen daß Protein Phosphatase 1 (PP1) aktiviert 
wurde durch mitotische DNS Schäden. Diese ist eine Cdk1 abhängige 
Phosphorylierunsstelle in PP1. Dies deutet an, daß PP1 die Phosphatase ist welche für 
die Aurora A T228 dephosphorylierung verantwortlich ist. 
 
Während der Mitose ist TPX2, ein Mikrotubulus assoziiertes Protein, der 
Hauptregulator von Aurora A. TPX2 bindet Aurora A und erleichtert dessen 
Lokalisierung an den mitotischen Spindelapparat und zusätzlich aktiviert es Aurora A 
indem es T228 vor einer dephosphorylierung durch PP1 bewahrt. Diese Interaktion 
sorgt dafür daß die Kinase währen der Mitose in einer aktiven Konformation bleibt. 
Wir haben eine Inaktivierung von Aurora A durch mitotischen IR Schaden 
beobachtet, welche mit dem auseinanderfallen des Aurora A-TPX2 Komplexes 
korelliert. Dies wiederum ist das Resultat eines verminderten TPX2 Protein Niveaus. 
Zusammenfassung 
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Indem wir Cycloheximid benutzt haben um die Protein Synthese zu inhibieren 
konnten wir feststellen daß als Antwort auf mitotische DNS Schäden, TPX2 sehr 
unstabil wurde. TPX2 wird durch die APC-Cdh1 Proteasom Kaskade degradiert. Wir 
konnten zeigen, daß eine Reduktion der TPX2 Gesamtpopulation signifikant  durch 
Post-translationale Kontrollmechanismen  beeinflußt wird, da das TPX2 mRNA 
Niveau durch DNS Schäden unbeeinflußt blieb. Ein erster Versuch, diese Kaskaden 
zu identifizieren deutet einen Defekt während dem Prozeß der Translationsinitiation 
an. Dies wird reflektiert durch die Reduzierte Menge an TPX2 welche mit den aktiv 
translatierenden Einheiten, den Polysomen Assoziiert. 
 
Zusammengefaßt deuten unsere Resultate darauf hin, daß mitotische DNS Schäden 
die Instabilität von TPX2 erhöht. Dadurch daß weniger TPX2 neu synthetisiert wird, 
kommt es zu einem Ungleichgewicht des existierenden Protein Haushalts. Dies 
beeinflußt den Aurora A-TPX2 Komplex, was wiederum dazu führt daß die pT288 
Phosphorylierungsstelle von aktivem PP1 angegriffen wird und somit Aurora A 
inaktiviert. 
Summary 
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SUMMARY 
 
Mitosis is a highly ordered collection of events that ensures that the duplicated 
genome is distributed to the daughter cells equally. A failure to do so results in loss of 
genetic information leading to aneuploidy, a condition frequently associated with 
cancer. Several mitotic kinases are targets of the DNA damage checkpoint, among 
which Cdk1, Aurora A and Plk1 are the most significant. Aurora A, the focus of study 
presented in this thesis, was shown to be inactivated by DNA damage induced in the 
G2 phase, leading to cell cycle arrest in an ATM/ATR-Chk1 dependent manner.  
 
In the present study, we addressed the molecular mechanism leading to DNA damage-
induced inhibition of Aurora A activity. We show that Aurora A is also a target of IR-
induced DNA damage occurring in mitosis. We used a synchronization approach that 
arrests cells in mitosis where Aurora A kinase activity is at the peak. As a measure of 
its activity, we tested the phosphorylation of Aurora A at the T-loop residue, T288, 
using specific antibody. The results confirmed a decreased phospho-signal, indicative 
of reduced kinase activity. We confirmed that protein phosphatase 1 (PP1) was 
activated by mitotic DNA damage by scoring the loss of phosphorylation at T320, a 
Cdk1-dependent phosphosite in PP1, indicating with high probability that this is the 
phosphatase responsible for Aurora A T288 dephosphorylation. 
 
During mitosis, TPX2, a microtubule-associated protein, is the main regulator of 
Aurora A. TPX2 binds to Aurora A facilitating its localization to mitotic spindles and, 
in addition, activates it by protecting T288 from PP1-mediated dephosphorylation. 
This interaction ensures that the kinase is locked in an active conformation throughout 
mitosis. Upon IR-induced mitotic damage, we observed inactivation of Aurora A in a 
manner that was directly linked to disruption of the Aurora A-TPX2 complex. This, in 
turn, was the result of decreased TPX2 protein level. By employing cycloheximide to 
prevent any nascent protein synthesis, we found that in response to mitotic DNA 
damage, TPX2 became highly unstable, being degraded by the APC-Cdh1 
proteasome pathway with faster kinetic than in control cells. We showed that decrease 
of the overall population of TPX2 was also significantly contributed by post-
transcriptional control mechanisms, as the TPX2 mRNA level remained unvaried in 
the presence of damage. An initial attempt to identify these pathways indicated a 
Summary 
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defect in the process of translation initiation, as seen by the reduced level of TPX2 
mRNA that was able to associate with the actively translating units, the polysomes.  
 
Collectively, our results indicate that upon mitotic DNA damage, increased TPX2 
protein instability and, particularly, lack of new TPX2 synthesis results in an overall 
unbalance of the existing protein pool in a manner that affects the Aurora A-TPX2 
complex. This, in turn, exposes the pT288 site to activated PP1 resulting in 
inactivation of Aurora A.  
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1. INTRODUCTION 
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1.1. PROTEIN KINASES AND PHOSPHORYLATION 
 
Phosphorylation is the most prevalent post-translational modification that regulates 
several processes such as signal transduction, cellular metabolism, growth and 
differentiation, cell cycle transitions and apoptosis. The effect is mediated by 
modifying the structure, localization, function and stability of the phosphorylated 
proteins. Enzymatically, this is mediated by class of enzymes called protein kinases 
(PKs). 2% of the human genes encode for PKs, classified majorly as eukaryotic PKs 
(ePKs), making them one of the largest families of genes in eukaryotes (Ubersax and 
Ferrell, 2007). There are, however, also some atypical PKs (aPKs) that although 
possess kinase activity, do not have any structural homology to the ePK catalytic 
domain (Manning et al., 2002). 
 
The basic mechanism of action of PKs involves transfer of the phosphate group from 
donors such as ATP or GTP to a serine (ser), threonine (thr) or tyrosine (tyr) residue 
in the substrates (Fig. 1). Once the substrate is phosphorylated, it is released from the 
kinase and ADP/GDP is recycled.   
 
 
 
 
 
 
 
Figure 1- Mechanism of 
action of a protein kinase. (See 
text for explanation). (Adapted 
from Ubersax and Ferrel, 
2007)   
 
 
Structurally, protein kinases are similar owing to the presence of a catalytic domain 
that consists of a small N-terminal lobe of β-sheets and a large C-terminal lobe of α-
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helices (Ubersax and Ferrell, 2007). Together, the catalytic domain is made up of 12 
sub-domains encompassing the two lobes (Fig. 2) (Ferrari, 2006). The cleft between 
the two lobes holds the ATP. The subdomain I contains a glycine-rich motif called the 
P-loop, while a region called the activation segment is present in sub-domains VII and 
VIII (Ferrari, 2006). The activation segment contains one or two phosphorylation sites 
that regulate activation of many kinases (Johnson and Lewis, 2001). The activation 
segment consists of a Mg++-binding loop that chelates the Mg++-ATP pool, an 
activation loop that has the regulatory phosphorylation residues and a P+1 loop that 
facilitates the reaction by substrate binding (Ferrari, 2006). 
 
Specificity of a protein kinase for its substrates is a complex matching arrangement. 
Factors such as depth of the active site and domains present in the adjacent docking 
sites in the kinase, presence of targeting subunits and localization of the kinase play 
extremely important roles in determining substrate-specificity (Ubersax and Ferrell, 
2007). Examples of such regulatory events and how they contribute to the activity of 
the kinases is described in more details in the following sections. 
 
 
 
 
 
Figure 2- Structure of the catalytic domain of PKs. The 12 sub-domains that 
constitute the N- and C-terminal lobe of the catalytic domain of a protein kinase are 
shown. The asterisk represents the position of residues in the activation segment that 
activate the kinase upon being phosphorylated. Mg++-BL, Mg++-binding loop; AL, 
activation loop; P+1L, P+1 loop.  (Adapted from Ferrari S, 2006)  
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1.2. CELL CYCLE 
 
The eukaryotic cell cycle can be defined as a highly regulated series of events that 
lead to eukaryotic cell division. This essentially consists of the S (Synthesis) phase 
that allows duplication of chromosomes via DNA replication followed by the M 
(Mitotic) phase that monitors equal distribution of the duplicated genome to daughter 
cells. These two phases are separated by gap (or growth) phases, G1 and G2. In G1 
phase important decisions are made to either commit to division or to exit from the 
cell cycle. The G1 and G2 phases also provide additional time for the cell to prepare 
for growth and host control mechanisms that allow progression to the next phase only 
under optimal conditions (both intrinsic and extrinsic to the cell). The main players of 
the eukaryotic cell division cycle are the Cyclin-dependent kinases that are activated 
by their binding partners cyclins and regulate every event of cell cycle progression.  
 
Here, I review in detail the mechanism of activation of Cyclin-dependent kinases by 
cyclins. 
 
1.2.1. CYCLIN-DEPENDENT KINASES (Cdks) 
 
Cdks constitute a highly conserved family of ser/thr protein kinases that are the 
central components of eukaryotic cell cycle. Structurally, they consist of a catalytic 
subunit and a regulatory subunit called cyclin; binding of the latter stimulates the 
catalytic activity of Cdks. The concentration of Cdks remain constant throughout the 
cell cycle while that of cyclins vary dramatically (Morgan, 1997). This ensures that 
only Cdks specific to the ongoing phase of the cell cycle will be activated. In yeast, a 
single Cdk (Cdc28 in S.cerevisiae and Cdc2 in S.pombe) regulates all cell cycle 
events while mammalian cells have several Cdks specific to different phases (Table I) 
(De Bondt et al., 1993).  
 
1.2.1.1. Activation of Cdk by Cyclin 
  
Protein kinases have a common tertiary structure consisting of a small N-terminal 
lobe and a large C-terminal lobe within the catalytic domain. A deep cleft between 
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these two lobes forms the site of ATP-binding (Ferrari, 2006). In the absence of 
cyclins, Cdks have an unfavorable tertiary structure that on the one hand impairs 
substrate binding and on the other hand does not allow correct positioning of the 
phosphates of ATP. Therefore, in order to be able to carry out the enzymatic reaction, 
Cdks require major structural changes that are facilitated by binding of cyclins.  
 
Cyclins interact directly with the PSTAIRE helix in the Cdk N-terminal lobe resulting 
in reorientation of the residues that interact with the phosphates of ATP and facilitate 
the phosphotransfer reaction. The active site also undergoes a major change and forms 
β-strand upon cyclin binding (De Bondt et al., 1993). This allows substrate binding 
and therefore facilitates phosphorylation by Cdks (Morgan DO, The Cell Cycle: 
Principles of Control). Phosphorylation by Cdk-activating kinase (CAK) of a highly 
conserved thr residue, T160, in Cdk2 is also favored in such a conformation and this, 
in turn, strengthens the cyclin-Cdk interaction.  
 
1.2.1.2. Functions of Cdk associated cyclins 
 
Apart from binding and activating Cdks, cyclins play important functions throughout 
the cell cycle. One such function is to spatially and temporally regulate the sub-
cellular localization of the Cdks. Cyclin B exists in two forms, cyclin B1 and B2. 
Before the onset of mitosis, the cyclin B1/Cdk1 complex is largely cytosolic. In late 
prophase, however, it is rapidly translocated to the nucleus where it phosphorylates 
the nuclear lamins to initiate nuclear envelope breakdown (NEBD). Although cyclin 
B1 does not possess any nuclear localization signal (NLS), multiple phosphorylations 
at its N-terminal region govern its nuclear accumulation (Morgan DO, The Cell 
Cycle: Principles of Control). Cyclin B2 associates with the Golgi apparatus and Cdk-
dependent phosphorylations of proteins mediate fragmentation of the organelle during 
mitosis. In yeast, the S-phase cyclin Clb5 binds to the origins of replication regulating 
S-phase progression (Morgan DO, The Cell Cycle: Principles of Control). Clb5 also 
interacts with several proteins involved in DNA replication. Cyclin A/Cdk but not 
cyclin B/Cdk binds and phosphorylates p107 to regulate G1-S progression (Morgan 
DO, The Cell Cycle: Principles of Control). Cyclins, therefore, regulate Cdk functions 
also by directly interacting with their substrates.  
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A description of the cyclin/Cdk complexes of eukaryotic cell cycle is shown below. 
 
 
 
Table I- Description of A) Cdks and B) Cyclins that control the eukaryotic cell 
cycle. (Adapted from Morgan DO, The Cell Cycle: Principles of Control) 
 
In this section, I review each phase of the cell cycle in detail. 
 
1.2.2. G1-S transition 
 
As mentioned above, different cyclin/Cdk complexes drive the cell cycle and specific 
cyclin/Cdk complexes regulate entry into G1 and G1 to S transition. The major G1 
cyclins are cyclin D and E. Early cell cycle phases are dependent on transcription 
factors of the E2F family that include both repressors (E2F-4,5) and activators (E2F-
1-3). In G0 or before the ‘Start’, transcription of genes required for entry into the cell 
cycle is largely suppressed by E2F transcription repressors that are bound by pocket 
proteins, pRb (retinoblastoma), p130 and p107 (Cam and Dynlacht, 2003) (Morgan 
DO, The Cell Cycle: Principles of Control). Activator E2Fs are present in very small 
amounts in quiescent cells and their transcription is also repressed by E2F repressors 
(Morgan DO, The Cell Cycle: Principles of Control). In G0, pRb is 
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hypophosphorylated and active; this results in inhibition of transcription of genes 
(required for progression of G1) by the E2F transcription factor. This inhibition is 
mediated via two distinct mechanisms (Fig. 3): pRb can directly bind to the 
transactivation domain of E2F or it can recruit chromatin-remodeling complexes to 
the promoter region, preventing transcription (Harbour and Dean, 2000). pRb can 
simultaneously bind to histone deacetylases (HDACs) and E2F thereby promoting 
deacetylation of the promoters and transcription silencing. 
  
 
Figure 3- E2F-dependent 
transcription inhibition by Rb 
protein. Rb protein can either 
bind directly to the E2F 
transcription factor or recruit 
chromatin-remodeling enzymes 
that alter the chromatin 
resulting in transcription 
repression. (Adapted from Harbour and Dean, 2000) 
 
 
In response to growth factor stimulation (mitogens) in G0, there occurs an increased 
synthesis of the D-type cyclins through Ras and Myc activated signaling cascades, 
resulting in their assembly with Cdk4/6. This is further facilitated by decreased 
amounts of Cdk inhibitors of the Cip/Kip family (Olashaw and Pledger, 2002). Active 
cyclin D/Cdk4/6 complexes regulate G1 progression through phosphorylation of pRb 
(Fig. 4). Phosphorylation of pRb first occurs by the cyclin D/Cdk4/6 complex that 
allows transcription of genes required for G1 phase, sequesters the Cip/Kip proteins 
and facilitates activation of cyclin E/Cdk2 complex. Further phosphorylation of pRb 
by cyclin E/Cdk2 is required for complete inactivation of pRb and re-activation of 
transcription (Harbour and Dean, 2000). This full activation of transcription sets the 
stage for S-phase entry.  
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Figure 4- Control of E2F-dependent gene expression during entry into the cell 
cycle. In G0, E2F-dependent transcription of G1-S genes is repressed by interaction 
with the pRb protein. Mitogen activation of the cyclin D/Cdk complex results in 
phosphorylation of pRb, dissociating it from E2F and promotes expression of cyclin E 
and A. The cyclins then participate in a positive feedback loop to further activate 
E2F.  (Adapted from Morgan DO, The Cell Cycle: Principles of Control) 
 
1.2.3. S (Synthesis) phase 
 
Inhibition of pRb activity by cyclin D/Cdk4/6-mediated phosphorylation initiates 
entry into S-phase. Cyclin A/Cdk2 is the major driver of S-phase that is activated by 
Cdc25A-dependent dephosphorylation (Morgan DO, The Cell Cycle: Principles of 
Control). Accumulation of cyclin A in late G1 depends on its increased expression by 
E2F mediated transcription. The derepressed and active E2F transcription factor 
forms heterodimeric complex with the DP-1 protein and promotes transcription of 
genes required for S-phase (Fig. 5) (Shapiro, 2006). This is, however, only an initial 
and transient E2F activation. Multiple phosphorylations by S-phase specific Cdks 
result in shutting off of the E2F activity later in S-phase. Cyclin A/Cdk2 interacts with 
the NTD of E2F and phosphorylates S307 that inhibits the E2F-DP-1 DNA binding 
activity (Peeper et al., 1995). Cyclin A/Cdk1 phosphorylates E2F at S375 resulting in 
formation of the pRb-E2F complex promoting inactivation of E2F mediated 
transcription (Peeper et al., 1995). In addition, cyclin H/Cdk7, the Cdk associated 
with RNA polymerase II, phosphorylates E2F-1 at S408 and T433, which promotes 
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its ubiquitination-mediated degradation (Vandel and Kouzarides, 1999). Decreased 
expression of cyclin A thus initiates the inactivation of the cyclin A/Cdk2 complex, 
facilitating progression to the next phase of the cell cycle. 
 
 
 
 
 
 
 
 
Figure 5- E2F-dependent S-phase progression. (See text for explanation). (Adapted 
from Shapiro, 2006) 
 
1.2.4. G2-M transition 
 
In higher eukaryotes, entry into mitosis is primarily regulated by cyclin A and B and 
Cdk1. Cyclin B1/Cdk1 was initially identified as the maturation-promoting factor 
(MPF), a cytoplasmic activity capable of facilitating meiosis I and II in the absence of 
any hormonal stimulation in Xenopus oocytes (Duesbery and Vande Woude, 1998). 
This was later also found in mitotic cells (Lohka et al., 1988) and therefore was also 
called the mitosis-promoting factor. The cyclin B1 protein level rises during G2 and 
this allows its interaction with Cdk1 in the cytoplasm. The cyclin B1/Cdk1 complex is 
kept inactive in the cytoplasm by phosphorylation at T14 and Y15 residues by protein 
kinase Myt1 (membrane-bound) and Wee1 (soluble and nuclear) (Liu et al., 1997). 
Different localization of the two inhibitory kinases ensures complete inactivation of 
different sub-populations of Cdk1.  
 
Phosphorylation of Y15 results in blocking of transfer of the phosphate group to the 
bound substrate (Atherton-Fessler et al., 1993), while T14 phosphorylation interferes 
with binding of ATP (Endicott et al., 1994).  Once the complex is transported to the 
nucleus, CAK phosphorylates Cdk1 at T161, partially activating the kinase. This 
results in phosphorylation and activation of Cdc25 family of phosphatases by Cdk1, 
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setting a positive feedback loop for its own activation. Cdc25 phosphatases counteract 
the inhibitory phosphorylations on Cdk1, further activating it. Initial activation of 
Cdk1 starts in late G2 by dephosphorylation mediated by Cdc25B that is active in G2. 
As the cells enter prophase, the protein level of Cdc25A and catalytic activity of 
Cdc25C rises dramatically, leading to increased Cdk1 activation (Izumi and Maller, 
1993), (Lindqvist et al., 2005). 
 
Another mitotic kinase, Plk1, plays an important role in activation of Cdk1. Partially 
active Cdk1 results in Plk1 activation that allows the latter to phosphorylate and 
activate Cdc25C and inhibit Myt1, facilitating Cdk1 activation (Fig. 6) (Barr et al., 
2004). 
 
 
 
 
Figure 6- Multiple feedback loops regulate Cdk1 activity for mitotic entry. Cdk1 
phosphorylates and activates Cdc25A and Cdc25C and inhibits Myt1 and Wee1. Cdk1 
phosphorylation of Plk1 also stimulates Cdk1 activity. Cdc25B and cyclin A/Cdk 
complexes may trigger Cdk1 activation by promoting partial Cdk1 dephosphorylation 
in late G2.  (Adapted from Morgan DO, The Cell Cycle: Principles of Control) 
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1.2.5.  Mitosis 
 
The duplicated genome is divided equally to the daughter cells during mitosis, to 
ensure that each cell receives a complete set of chromosomes. This is carried out 
under 5 different phases: prophase, prometaphase, metaphase, anaphase and telophase 
culminating with cytokinesis (see Fig. 7).  
 
As cells complete replication, chromosomes undergo major structural changes 
resulting in their compaction, one of the prerequisites to the maintenance of fidelity in 
the process of chromosome segregation. This is mediated by DNA catenation with a 
specialized class of proteins called cohesins. The sister chromatids are held together 
by kinetochores at the centromeric region. As the cells enter prophase, chromosome 
condensation begins followed by centrosome separation in mid to late prophase. 
Chromosome condensation requires the protein complex called condensin and DNA 
decatenation by topoisomerase II (Ferrari, 2006). As cells progress to prometaphase, 
NEBD takes place allowing cytosolic microtubules to be in contact with nuclear 
chromatin. The kinetochores begin to be captured by the microtubules arising from 
the opposite poles of the forming spindle and this continues until all chromosomes 
have been attached. Even a single unattached kinetochore is capable of activating the 
spindle assembly checkpoint (Rieder et al., 1995) that reversibly arrests the cell cycle 
until all kinetochores are held by the microtubules. During metaphase, chromosomes 
congress to the centre of the cell to form the metaphase plate. This alignment ensures 
that upon division, each daughter cell will receive a complete set of chromosomes. 
Anaphase begins with the dissolution of cohesins mediated by the proteolytic activity 
of the anaphase promoting complex/cyclosome (APC/C) E3 ligase. APCCdc20 targets 
degradation of securin, an inhibitor of the enzyme separase, allowing activation of 
separase and cleavage of the cohesin complexes (Castro et al., 2005). This is also 
accompanied by inactivation of Cdk1 through degradation of cyclin B1, further 
facilitating mitotic exit. Nuclear envelope reforms and spindles disassemble in 
telophase, which is followed by pinching off the two daughter cells, completing the 
process of mitosis. 
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Figure 7- Mitotic events in HeLa cells. HeLa cell line stably expressing mGFP-
tubulin and mCherry red-H2B plasmids was imaged using fluorescence microscopy to 
depict different mitotic phases. (See text for details). 
 
 
1.3. CELL CYCLE REGULATION BY UBIQUITINATION AND PROTEIN 
DEGRADATION 
 
1.3.1. Ubiquitin biology 
 
Ubiquitin (Ub) is a small 76 amino-acids (8 kDa) protein that binds to the target 
proteins in a process called ubiquitination and regulates their function and degradation 
by the 26S proteasome pathway. This involves a 3-step reaction mediated via 
enzymes known as the E1 activating enzyme, E2-conjugating enzyme and the E3 
ligase. In the first step, Ub is transferred to the E1-activating enzyme in an ATP-
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dependent manner. Mechanistically, the E1 enzyme forms a thiol ester bond with the 
carboxyl group of G76 in Ub, the E2 enzyme carries the Ub transiently as a thiol ester 
and the E3 ligase transfers the Ub to the target protein by formation of an isopeptide 
bond between the carboxyl terminus of the Ub and the ε-amino group of the Lys in 
the target protein (Fig. 8) (Pickart, 2001). The Lys48 in Ub itself can be further 
conjugated by another Ub molecule, resulting in polyubiquitination (Huang and 
D'Andrea, 2006). 
 
 
 
 
Figure 8- Mechanism of protein ubiquitination. A) Steps involving the three 
ubiquitin pathway enzymes: E1, E2 and E3. B) Detailed mechanism of the final step 
of ubiquitination. (See text for details). (Adapted from Matyskiela et al., 2009)  
 
 
The extent of ubiquitination on the target protein decides whether or not it can be 
degraded via the 26S proteasome pathway. The Lys48-linked polyubiquitinated 
proteins, for example, are degraded while the Lys63 polyubiquitinated proteins play 
significant roles during the processes of signal transduction and DNA repair (Sun and 
Chen, 2004), (Huang and D'Andrea, 2006). Another modification is 
monoubiquitination that also does not target substrates for degradation. 
Monoubiquitinated proteins have been associated with functioning in diverse 
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processes such as DNA repair, gene silencing and vesicle sorting (Sun and Chen, 
2004). 
 
1.3.2. Ubiquitination and Cell cycle 
 
Various proteins central to eukaryotic cell division are regulated by Ub-mediated 
degradation. The protein level of cyclins, Cdk inhibitors (CKI) and many other 
proteins oscillate throughout the cell cycle as a result of periodic and regulated 
proteolysis. Ub-ligases are the master regulators of this process as they serve as 
primary determinants of target/substrate specificity. Two large multisubunit E3 ligase 
complexes are involved in G1-S and metaphase-to-anaphase transition: the SCF 
(Skp1-Cul1-F-box) E3 ligase complex and the APC/C E3 ligase complex, 
respectively.  
 
Structurally, the human SCF core complex consists of three invariable components: 
Skp1, Cul1 and the RING protein Rbx1 and a variable component called the F-box 
protein (Nakayama and Nakayama, 2005). The Rbx1 protein binds to the E2-
conjugating enzyme and the target protein binds to SCF via the F-box protein; the 
latter therefore confers substrate specificity for the SCF complex (Fig. 9A). With a 
combination of more than 70 F-box proteins, the SCF core components and a number 
of E2 enzymes, multiple substrates can be targeted specifically (Nakayama and 
Nakayama, 2005). The APC complex also consists of a core component, the Apc2 
and a RING subunit Apc11 (Fig. 9B) (Morgan DO, The Cell Cycle: Principles of 
Control). It is, however, much larger than the SCF complex with 11-13 Apc subunits 
present.   
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Figure 9-Multisubunit SCF and APC E3 ligase complexes. A) SCF complex consists 
of three core subunits: Skp1, Cul1 and Rbx1 and a variable component F-box protein. 
The Rbx1 interacts with the E2 enzyme and the F-box protein interacts with the 
phosphorylated substrate. B) APC complex also consists of an E2 interacting subunit 
Apc11 and binds to its substrates upon activation by the activator proteins. (Adapted 
from Morgan DO, The Cell Cycle: Principles of Control) 
 
Degradation of proteins by these ligases is carried out essentially by two distinct 
activation strategies: activation of the target and activation of the E3 ligase itself 
(Reed, 2003). The former strategy is used by the SCF complex-mediated degradation. 
Substrates of SCF complex bind their F-box proteins only if they have been 
phosphorylated at a specific site or cluster of sites (Fig. 9A), for example, by Cdks 
(Morgan DO, The Cell Cycle: Principles of Control). Unlike SCF, the APC ligase 
itself must be activated in order to promote degradation. This is achieved by two 
activator subunits of the APC complex, known as Cdc20 (cell division cycle) and 
Cdh1 (Cdc20-dependent homolog). Once activated, these two complexes target a 
number of cell cycle proteins (Fig. 10) to ensure unidirectionality and faithful 
chromosome duplication and segregation. 
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Figure 10- Important substrates of 
the SCF and APC E3 ligase 
complexes. These E3 ligases target 
various proteins at different phases 
of the cell cycle. (Adapted from 
Reed, 2003) 
 
 
Here, I briefly describe the role of each of the two E3 ligases in regulating eukaryotic 
cell cycle events. 
 
1.3.3.  SCF E3 LIGASE 
 
As mentioned above, the F-box proteins mediate substrate specificity for the SCF 
ligase complex. Several F-box proteins are known that degrade a huge number of 
proteins; of them, three main F-box proteins that are implicated in cell cycle control 
are Skp2, Fbw7 and βTrCP. A list of their substrates is shown in Fig. 11. 
 
 
 
 
 
 
Figure 11- Substrates targeted for 
ubiquitination and degradation by 
different F-box proteins. (Adapted 
from Nakayama and Nakayama, 
2005) 
Introduction 
27	  
1.3.3.1.  Functions of SCF E3 ligases 
 
Skp2 is a growth promoter and oncoprotein that is thought to regulate the G1 and S 
phases by interacting with and promoting degradation of p27, p21 and p57 CKI 
(Nakayama and Nakayama, 2006). The Fbw7 protein is instead a tumor suppressor 
that targets several oncoproteins such as cyclin E and Myc for destruction (Nakayama 
and Nakayama, 2006). βTrCP is a more versatile protein as it targets proteins 
involved in many different pathways. Wnt signaling protein β-catenin is a known 
substrate of βTrCP (Nakayama and Nakayama, 2005). Among the proteins involved 
in cell cycle regulation, it targets Cdc25 phosphatases, Wee1 and Emi (early mitotic 
inhibitor), inhibitor of the APC/C complex (Nakayama and Nakayama, 2005). 
Degradation of Cdc25A via βTrCP occurs both during S-phase and in response to 
DNA damage. Phosphorylation of S82 in Cdc25A by Chk1/2 upon damage promotes 
its interaction with βTrCP for degradation (Busino et al., 2003). Recently, it is also 
shown to target Bora (protein required for AurA activation in G2) after its 
phosphorylation by Plk1 to facilitate mitotic entry and association of AurA with its 
mitotic partners (Seki et al., 2008a). 
 
1.3.4.  APC/C E3 LIGASE 
 
As mentioned before, this is the major mitotic E3 ligase that is active during the 
metaphase-to-anaphase transition and throughout G1 to ensure degradation of cell 
cycle proteins and maintain order of the cell cycle events.  
 
1.3.4.1. Regulation of APC/C 
 
The activity of APC/C is regulated by binding of its activators Cdc20 and Cdh1 (Fig. 
12).  APCCdc20 is formed in early mitosis: the interaction of Cdc20 with APC is 
facilitated by phosphorylation of APC core components by cyclin B1/Cdk complex 
(Baker et al., 2007), while inhibitory phosphorylations at Cdh1 by the cyclin B/Cdk 
complex keep it from binding to APC at this time (Peters, 2002).  APC/C activity is 
restricted until mitosis by Emi, binding of which allows accumulation of mitotic 
cyclins and in late G1 helps inactivation of APCCdh1 to allow entry into S-phase 
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(Vodermaier, 2004). During G2 and early mitosis, Emi binds to Cdc20 preventing its 
association with the APC/C core complex. In prophase Plk1 phosphorylates and 
promotes the degradation of Emi via the SCFβTrCP E3 ligase, resulting in initiation of 
Cdc20 activation (Baker et al., 2007). Cdc20 is also regulated by the components of 
spindle assembly checkpoint (SAC) to prevent premature anaphase entry. SAC 
components contribute to this by both promoting phosphorylation and regulating the 
stability of Cdc20  (Fig. 12) (Ge et al., 2009). 
 
 
 
 
 
 
Figure 12- Regulation and function of APC/C complex during cell cycle. (See text 
for details). (Adapted from Nakayama and Nakayama, 2006) 
 
 
The switch from APCCdc20 to APCCdh1 is essential to regulate late mitotic events and 
several pathways are engaged in manifesting this switch. Degradation of cyclin B 
initiated by APCCdc20 results in decreased Cdk1 activity. This sets the stage for Cdh1 
activation as Cdk1-dependent inhibitory phosphorylations in Cdh1 are reversed by 
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protein phosphatases. In budding yeast, this is accompanied by accumulation of Sic1, 
a CKI, that further dampens Cdk activity (Peters, 2002). The Cdc14 phosphatase 
dephosphorylates both Cdh1 and Sic1 to activate the former and stabilize the latter by 
preventing its recognition by the SCF E3 ligase complex (Peters, 2002). Once 
activated, APCCdh1 also targets Cdc20 for destruction, resulting in a complete switch to 
APCCdh1 proteolytic activities (Fig. 12). 
 
1.3.4.2. Substrate recognition by APC/C 
 
Targets of the APC/C complex present specific degrons that act as signals for 
recognition of substrates by the APC/C E3 ligase. These include mainly the D-box 
(destruction box) sequence RXXLXXXN and the KEN-box (Pfleger and Kirschner, 
2000). The KEN-box sequence is preferentially recognized by APCCdh1 (Pfleger and 
Kirschner, 2000). Although these sequences are required for degradation by the 
APC/C complex, many of its substrates possess unconventional sequences, indicating 
additional unidentified sequences are also involved in this process (Matyskiela et al., 
2009). 
 
1.3.4.3. Functions of APC/C 
 
APCCdc20 mainly targets two proteins, securin and mitotic cyclins to promote the onset 
of anaphase (Table II). Anaphase is marked by dissolution of the sister chromatids 
and their movement to the opposite spindle poles to initiate chromosome segregation. 
The sister chromatids are held together by a multiprotein complex called cohesin 
(Uhlmann et al., 1999). The enzyme separase that mediates cohesin cleavage is bound 
by its inhibitor securin until metaphase. In addition, phosphorylation of separase by 
the cyclin B/Cdk complex keeps it inactive in order to prevent premature sister 
chromatid separation (Baker et al., 2007). As soon as the SAC is inactivated and an 
active APCCdc20 complex forms, it targets the destruction of securin to initiate 
anaphase. Cyclin B1 is also targeted for proteolysis by APCCdc20 resulting in 
inactivation of Cdk1 (Baker et al., 2007) and reversal of Cdk1 mediated 
phosphorylations via protein phosphatase 1 (PP1) to facilitate mitotic exit (Wu et al., 
2009).  
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Following the drop of Cdk1 activity, Cdh1 is activated and APCCdh1 dependent 
proteolysis takes over. APCCdh1 then targets several mitotic proteins for destruction 
(Table II), thereby triggering exit from mitosis. APCCdh1 mediated proteolysis 
continues throughout G1, especially to maintain low Cdk activity, a necessary 
requirement for the loading of pre-replicative complexes at origins of replication 
(Nakayama and Nakayama, 2006). APCCdh1 promotes degradation of geminin, an 
inhibitor of DNA replication factor Cdt1, allowing Cdt1 action on the origins 
(Nakayama and Nakayama, 2006). 
 
 
 
 
Table II- List of mitotic substrates of APC/C during the cell cycle. (Adapted from 
Baker et al., 2007) 
 
 
1.3.5. Interplay of SCF and APC/C during cell cycle 
 
As both the E3 ligase complexes are active during the cell cycle (although at different 
times), an interesting question is whether or not they are coordinated at some point to 
regulate the cell cycle. Although SCF targets substrates from late G1 to early M and 
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APC/C from mid M to the next G1, there occurs a remarkable overlap of their 
functions to maintain the order of cell cycle events. This is manifested in the 
following way (Fig. 13): SCFβTrCP recognizes and degrades the APC/C inhibitor Emi1 
after it has been phosphorylated by Plk1 in early mitosis. This event, in turn, results in 
activation of the APC/C mediated proteolysis. Later in G1, APCCdh1 recognizes the D 
box of Skp2 and degrades it, thereby allowing accumulation of p27 and other CKIs 
for promoting DNA replication and S-phase progression. Increased expression of 
Skp2 at the G1-S boundary promotes p27 degradation and activates the S-phase 
cyclin/Cdks, which induce the dissociation of Cdh1 from the core APC/C subunits by 
the phosphorylation of Cdh1. As a result, APC/C activity declines at the G1–S 
boundary, allowing mitotic cyclins to accumulate gradually during the following S 
and G2 phases (Nakayama and Nakayama, 2006). 
 
 
 
 
 
 
Figure 13- Coordination of cell cycle regulation by SCF and APC/C complexes. 
(See text for details). (Adapted from Nakayama and Nakayama, 2006).   
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1.4. DNA DAMAGE/CELL CYCLE CHECKPOINTS 
 
In order to ensure equal distribution of chromosomes to the daughter cells, different 
cell cycle checkpoints exist. By definition, a ‘checkpoint’ can be described as the 
guard that prevents the cell’s entry to next phase until the previous one is completed 
faithfully. A cell employs such a guard at the gate of every phase transition it makes. 
A failure of any one of these checkpoints results in a number of defects in essential 
processes like DNA replication, DNA damage repair, chromosome segregation and 
cytokinesis. The consequence of such failures (apart from apoptosis) is, in most cases, 
generation of chromosomal instability and aneuploidy, leading to cancer 
development.  
 
Fig. 14 briefly summarizes all the checkpoints known till date and this chapter 
describes in detail the importance and functionality of each of these checkpoints.  
 
 
 
Figure 14- Schematic representation of different cell cycle checkpoints. Damage 
induced checkpoints are prevalent mainly at the G1-S and the G2-M phases (written 
in red). Other checkpoints are also present that monitor cell cycle progression in an 
unperturbed cell cycle and also in response to damage. (See text for details).   
(Adapted from Chin and Yeong, 2010) 
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The molecular components of the DNA damage-signaling pathway include the 
following categories of proteins: 
 
1.  Sensor proteins: these proteins recognize the damage and include the Rad9-Hus1-
Rad1 PCNA-like sliding clamp complex, Rad17-RFC clamp loading complex and the 
MRN (Mre11-Rad50-Nbs1) nuclease complex (Lukas et al., 2004). Also, Ku70/80 
proteins act a sensor for NHEJ and recruit DNA-PK to the sites of damage. 
2. Adaptors/Mediators: these proteins associate with the sensors and signal 
transducers and provide specificity (Sancar et al., 2004). This class includes BRCA1, 
MDC1, 53BP1 and claspin (Lukas et al., 2004). 
3.  Signal transduction kinases: these are of the PI3K-family of kinases and include 
ATM, ATR and DNA-PK (Lukas et al., 2004). 
4. Effector kinases: these are the ser/thr kinases including Chk1 and Chk2 (Lukas et 
al., 2004). 
5.  Effector proteins: the final components include proteins that regulate cell growth, 
proliferation, cell cycle and apoptosis. These are the transcription factors p53 or 
E2F1, phosphatases of the Cdc25 family and protein kinases such as Cdks (Lukas et 
al., 2004), (Niida and Nakanishi, 2006). 
 
All these proteins regulate the following cell cycle checkpoints to ensure faithful 
replication and chromosome segregation. 
 
1.4.1. G1-S checkpoint 
 
Damage induced in G1 cells prevents entry into S-phase by activation of protein 
kinases ATM/ATR that target two classes of proteins: the cell cycle phosphatases of 
Cdc25 family and the tumor suppressor transcription factor p53 (Lukas et al., 2004). 
Chk1/Chk2 effector kinases directly phosphorylate Cdc25A, promoting its 
degradation via the βTRCP ubiquitin ligase (Lukas et al., 2004), (Sancar et al., 2004). 
This blocks the activation of Cdk2 that associates with cyclin E and cyclin A to 
promote loading of Cdc45 onto the chromatin for recruitment of DNA polymerase α 
to initiate replication (Lukas et al., 2004). Consequently, a rapid p53-independent G1 
arrest sets in.  
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The second pathway preventing S-phase entry is initiated much later, persists for a 
long time and requires p53. p53 is phosphorylated on S15 by ATM/ATR kinases and 
on multiple residues by Chk1/Chk2 kinases (Shiloh, 2003). This results in activation 
of p53 that promotes transcription of p21, a Cdk4 inhibitor. This, in turn, reduces the 
phosphorylation and suppression of pRB and thus S-phase promoting genes are no 
longer transcribed.  Fig. 15 schematically describes the G1/S arrest. 
 
 
 
Figure 15- The G1/S 
checkpoint. DNA damage 
is sensed by ATM after 
double-strand breaks or by 
ATR, Rad17-RFC, and the 
9-1-1 complex after UV-
damage. ATM/ATR 
phosphorylates Rad17, 
Rad9, p53, and Chk1/Chk2 
that in turn phosphorylates 
Cdc25A, causing its 
inactivation by nuclear 
exclusion and ubiquitin-
mediated degradation. 
Phosphorylated and 
inactivated Cdk2 
accumulates and cannot 
phosphorylate Cdc45 to initiate replication. Maintenance of the G1/S arrest is 
achieved by p53 that induces p21WAF-1/Cip1 transcription. (Adapted from Sancar et al., 
2004) 
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1.4.2. Intra S-phase checkpoint 
 
Damage induced in cells going through S-phase or unrepaired damage from the G1 
phase results in a delay in S-phase progression via the intra S-phase checkpoint. It is 
an extremely transient and p53-independent phenomenon. The execution of this 
checkpoint mainly occurs via the ATM-Chk1-Cdc25A-Cdk2-Cdc45 signaling cascade 
that is also involved in the G1 checkpoint mechanism (Lukas et al., 2004). Another 
pathway mediating the checkpoint function is via the ATM-dependent 
phosphorylation of SMC1 protein (Sancar et al., 2004). This, rather than being 
involved in arresting S-phase, primarily promotes recovery from damage with the 
help of proteins such as BRCA1 and Nbs1 (Sancar et al., 2004). 
 
In response to UV-induced damage or stalled-replication forks, ATR-dependent 
pathways are activated. Inhibition of replication origin firing is one of the targets of 
ATR-dependent S-phase delay. This is executed by promoting downregulation of 
Cdc7-Dbf4 protein kinase activity that facilitates Cdc45 binding to DNA (Sancar et 
al., 2004). Thus, mechanisms controlling G1 to S phase transition and S-phase delay 
partially overlap with each other.  
 
1.4.3. G2 checkpoint 
 
Cells prevent entry into mitosis by prolonging the G2 phase in response to DNA 
damage. Although the G2 checkpoint activates several signaling pathways, it 
ultimately targets the cyclin B/Cdk1 complex (Fig. 16). In the presence of double-
stranded breaks (DSBs), the ATM-Chk2 pathway is activated while the ATR-Chk1 
pathway is preferentially involved in the response to DNA replication stress (Harper 
and Elledge, 2007). ATM/ATR-dependent phosphorylation of the downstream 
kinases Chk1 and Chk2 allows rapid transduction of the damage signal to effector 
proteins that control DNA repair, cell cycle progression and apoptosis (Kastan and 
Bartek, 2004). With regard to the cell cycle machinery, phosphorylation and 
activation of Wee1 and inhibition of Cdc25 phosphatases are the key events for 
inactivation of cyclin B/Cdk1, thus ensuring that cells do not go past G2 into prophase 
(Ferrari, 2006). Activation of Wee1 results in phosphorylation of two negative sites in 
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Cdk1 that block its catalytic activity. In parallel, Chk1/Chk2 driven phosphorylation 
of Cdc25C, the phosphatase responsible for dephosphorylation of the negative sites in 
Cdk1 ATP-binging domain, leads to 14-3-3-mediated nuclear export of the 
phosphatase (Sanchez et al., 1997), (Peng et al., 1997), thus blocking its function. It is 
known that in response to UV-induced damage, the p38 kinase mediates 
phosphorylation of Cdc25B, facilitating binding of 14-3-3 and blocking access of 
substrates to Cdc25B (Lukas et al., 2004). Collectively, this checkpoint ensures that 
Cdk1 is inactive and cells do not go past G2 into prophase.  
 
 
Figure 16- Schematic 
representation of G2 
arrest. In response to DNA 
damage, ATM and ATR 
signaling pathways are 
activated that regulate the 
Cdc25 phosphatases to 
prevent activation of cyclin 
B-Cdk1 complex and 
thereby maintain a G2 
arrest. (Adapted from 
Donzelli and Draetta, 
2003) 
 
1.4.4.  Decatenation checkpoint 
 
Decatenation or disentanglement of duplicated chromosomes occurs after replication 
to ensure that each daughter cell gets a copy of the genome accurately. This is 
absolutely essential for an error-free cell division. The process of decatenation is 
mediated by a class of enzymes called topoisomerase II (topo II), that, in a two-step 
reaction allow the two DNA duplexes to be separated from each other (Wang, 1996). 
A G2 phase decatenation checkpoint functions to prevent entry into mitosis until the 
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DNA has been decatenated completely (Downes et al., 1994). This checkpoint, 
however, is very distinct from the DNA damage checkpoint that prevents entry into 
mitosis in response to DNA DSBs. Identification of this as an independent checkpoint 
owes to the existence of two different classes of topo II inhibitors that have different 
effects on the enzyme. Inhibitors like etoposide (VP-16) and adriamycin produce 
massive DSBs in DNA that activate the G2 checkpoint. Instead, catalytic inhibitors 
like ICRF-193 and ICRF-187, when given in G2, do not produce DSBs but still cause 
a mitotic delay and thus led to the identification of a checkpoint mechanism different 
from the damage checkpoint (Downes et al., 1994). The catalytic inhibitors hold the 
enzyme in a closed clamp form tethered to DNA, in which the enzyme is unable to 
cleave DNA strands due to inhibition of its ATPase activity. This is different from the 
action of the classic topo II inhibitors that stabilize the topo II DNA-cleavable 
complex, resulting in the production of massive DSBs and hence elicit a damage 
response. As mentioned above, the signals of DNA damage reach the target proteins 
in an ATM/ATR-dependent manner. The ATR kinase plays a major role upon 
administration of topo II catalytic inhibitors, as cells defective in ATR do not show a 
mitotic delay even in the presence of ICRF-193 (Deming et al., 2001). Nonetheless, 
the involvement of ATM cannot be completely ruled out as caffeine, an inhibitor of 
both ATR and ATM kinases, fails to cause a mitotic delay in the presence of ICRF-
193 (Downes et al., 1994). Furthermore, ATM activation in response to ICRF-193 
occurs in human lung cancer cell lines (Nakagawa et al., 2004). The mechanism of an 
ATR-dependent signaling, however, is better defined and is known to occur through 
inhibition of Plk1, which phosphorylates cyclin B1 to promote its nuclear localization 
allowing mitotic entry (Deming et al., 2001). Therefore, abrogating ATR function 
would not cause a mitotic delay even if the decatenation function of topo II is 
inhibited.  
 
In addition to the role of ATR, the RecQ helicase Werner (WRN) is also involved in 
this checkpoint mechanism. Cells lacking functional WRN show no mitotic delay in 
the presence of ICRF-187 and the checkpoint can be restored following ectopic 
expression of the helicase. Furthermore, in WRN deficient cells, there occurs more 
chromosomal damage and apoptosis as compared to the WT cells (Franchitto et al., 
2003). BRCA1 is also an essential component of this checkpoint, as BRCA1-mutant 
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cells do not have a completely activated decatenation checkpoint (Deming et al., 
2001). Still, more studies are needed to unambiguously define the roles of these 
proteins as contradicting results are available that deny the contribution of these 
additional proteins in decatenation checkpoint functioning (Nakagawa et al., 2004). 
 
1.4.5. Antephase checkpoint 
 
The term ‘antephase’ was coined by Bullough and Johnson (1951) and by definition 
described as a checkpoint that exists between late G2 and early prophase when the 
first signs of chromosome condensation start to appear (Matsusaka and Pines, 2004). 
A hallmark of this checkpoint is that cells exposed to various stresses in early 
prophase, specifically before NEBD begins, revert to an interphase-like state and do 
not progress into mitosis.  Early prophase cells exposed to DNA damage (Carlson, 
1969a), (Carlson, 1969b) or microtubule poisons (Rieder et al., 1995) showed 
reversible chromosome decondensation and reversion to G2, owing to the presence of 
the antephase checkpoint. This checkpoint, however, is essentially different from the 
classical G2 checkpoint, as it does not employ the PI3K-like kinases, ATM and ATR 
and is not activated in response to DNA damaging agents. The execution of this 
checkpoint, instead, depends on two proteins: CHFR (checkpoint with FHA and 
RING finger domains) E3 ligase and the p38 stress kinase (Matsusaka and Pines, 
2004) and therefore is sometimes referred as the CHFR-mediated prophase 
checkpoint (Privette and Petty, 2008). The E3 ligase function of CHFR but not the 
proteasome is required for this checkpoint. Cells that lack a functional CHFR, e.g. 
HeLa and U2OS, progress into mitosis even in the presence of microtubule poisons 
(Scolnick and Halazonetis, 2000). CHFR actively participates in delaying mitotic 
entry by retaining the cyclin B1/Cdk1 complex in the cytoplasm in response to 
microtubule poisons (Privette and Petty, 2008) and interfering with chromosome 
condensation and NEBD (Scolnick and Halazonetis, 2000). Another way by which 
CHFR acts is by prolonging the inhibitory phosphorylation of Y15 in Cdk1 to prevent 
mitotic entry (Kang et al., 2002). 
 
Inhibition of p38 kinase function also abrogates the antephase checkpoint (Matsusaka 
and Pines, 2004) and CHFR is known to act upstream of p38 kinase (Privette and 
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Petty, 2008). The p38 kinase-dependent antephase checkpoint is activated in response 
to various stresses like, UV radiation (Bulavin et al., 2001), osmolality changes 
(Dmitrieva et al., 2002) and changes in chromatin structure (Mikhailov et al., 2004). 
All these data suggest a very important role of CHFR and its downstream targets in 
preventing mitotic defects in response to a number of stresses before the cells reach a 
point of ‘no-return’ in mitosis (Fig. 17).  
 
 
 
 
Figure 17- The antephase checkpoint. (See text for details). (Adapted from Chin and 
Yeong, 2010) 
 
 
1.4.6.  Mitotic checkpoint 
 
1.4.6.1. DNA damage during mitosis 
 
Unlike the well defined G1 and G2 phase checkpoints, there is no formal mitotic 
checkpoint that monitors DNA damage occurring in mitosis. If damaged in mitosis, 
cells mount a different response depending on the stage of mitotic progression. Early 
prophase cells can revert back to G2 (Chow et al., 2003) and late prophase cells can 
arrest in prometaphase (Choi and Lee, 2008) or metaphase if the damage is severe 
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(Mikhailov et al., 2002) owing to the presence of spindle assembly checkpoint (see 
below). Damage in prometaphase and metaphase does not impede cell cycle 
progression but gives rise to chromosome segregation defects (Results Part 1 and 2 of 
this thesis). What is the ultimate fate of mitotic cells upon DNA damage? This long-
standing question in the field has been recently answered by the group of S. Jackson 
who showed that mitotic damage, although sensed by the cells, is repaired only in the 
subsequent G1 due to inaccessibility of the damaged structures in highly condensed 
mitotic chromosomes to the signaling and repair proteins (Giunta et al., 2010). The 
only well-defined mitotic checkpoint is the spindle assembly checkpoint, discussed in 
detail in the next section. 
 
1.4.6.2. Spindle Assembly Checkpoint (SAC) 
 
As cells progress through mitosis, SAC ensures the fidelity of chromosome 
segregation. SAC is activated when spindle assembly is interfered with. It acts as both 
an intrinsic checkpoint to monitor stable kinetochore (KT)-microtubule (MT) 
interactions and is also activated in response to extrinsic stresses such as presence of 
DNA damage and microtubule poisons. The primary reason of activation of SAC is 
lack of tension between KT-MT that arises due to improper connections. The main 
function of SAC is to arrest the cell cycle in prometaphase (when KT-MT interactions 
begin to ensure bi-orientation in metaphase) until all chromosomes are attached to the 
MTs arising from opposite poles. The main players of SAC include the MAD (mitotic 
arrest deficient, MAD1, 2 and 3) and BUB (budding uninhibited by benzimidazole, 
BUB1) family of proteins initially identified in yeast genetic screens as mutations that 
failed to arrest cell cycle in the presence of MT poisons (Hoyt et al., 1991), (Li and 
Murray, 1991). MAD2, MAD3 (BUBR1) and BUB3 along with Cdc20 form a mitotic 
checkpoint complex (MCC) that targets Cdc20 to prevent polyubiquitination and 
degradation of securin and cyclin B1 (Musacchio and Salmon, 2007). At the end of 
metaphase, Cdc20 mediated degradation of securin activates separase that allows 
sister chromatids to be pulled apart to the poles for equal segregation (Musacchio and 
Salmon, 2007). Proteolytic destruction of cyclin B1 allows inactivation of Cdk1 
thereby promoting mitotic exit (Musacchio and Salmon, 2007). Recently, Cdc20 
destruction was shown to be regulated by the MAD2 protein (Ge et al., 2009). MAD2 
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binds to Cdc20 and promotes its APC/C mediated degradation, allowing activation 
and maintenance of SAC in response to spindle poisons.  
 
Apart from these components, the SAC also employs the mitotic kinase Aurora B as 
one of its effector proteins. Syntelic (i.e., both sister kinetochores are attached to MTs 
emerging from the same pole) and merotelic (i.e., one kinetochore is bound by MTs 
from both the poles) attachments are corrected by Aurora B and require proteins like 
Ndc80 (Nezi and Musacchio, 2009). In an unperturbed mitosis, conditions favoring 
merotely arise frequently and are not sensed by SAC. They are therefore solely taken 
care of by Aurora B dependent correction mechanisms.  
 
1.4.6.2.1. Role of CHFR as a checkpoint 
 
CHFR is a known tumor suppressor protein with functions in mitotic checkpoint and 
as an E3 ligase. In addition to its role in mitotic stress prophase checkpoint (section 
1.4.5), it is also activated as a part of the SAC. Downregulation of CHFR results in 
several defects in chromosome segregation and cytokinesis and interferes with proper 
metaphase kinetochore localization of SAC proteins Mad2 and BUBR1 (Privette and 
Petty, 2008). The CHFR protein is also suspected to be a target of APCCdh1 due to the 
presence of a KEN motif (Privette and Petty, 2008). Thus, it is believed to have many 
mitotic checkpoint functions and thought to be regulated in a similar way like other 
mitotic proteins. 
 
1.5. AURORA KINASES 
 
Aurora kinases are a family of highly conserved ser/thr protein kinases that are 
involved in different processes of cell cycle progression. They are required for events 
such as mitotic entry, centrosome separation, assembly of bipolar spindle apparatus, 
chromosome compaction and segregation, spindle assembly checkpoint and 
cytokinesis.  
 
The Aurora gene was first identified from Drosophila melanogaster in a screen for 
mutants that were defective in spindle-pole behavior (Glover et al., 1995) and from 
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S.cerevisiae, Ipl1 (increase in ploidy 1), in a screen for mutants defective in 
chromosome segregation (Chan and Botstein, 1993). Two Aurora genes are present in 
Drosophila, C.elegans and Xenopus and one in each fission (S.pombe) and budding 
yeast (S.cerevisiae) (Fu et al., 2007). The Aurora family in humans includes three 
members, namely A, B and C. The human Aurora kinases are highly conserved in 
their catalytic domains, with 67-76% identity, but have a varying N-terminal region 
(Bischoff and Plowman, 1999). The activation loop present in the catalytic domain 
contains a highly conserved thr (T) residue that is responsible for activation of the 
kinase (Fig. 18).  
 
 
 
 
Figure 18- Structure of 
Aurora kinases. Upper 
panel: the position of 
various regions in Aurora 
kinases is shown. Asterisk 
marked T represents the thr 
residue whose 
phosphorylation regulates 
the activity of Aurora 
kinases. (Adapted from 
Carmena M. and   
Earnshaw C., 2003).  
Lower panel: Sequence of 
the activation motif is shown highlighting the presence of the highly conserved thr 
residue. (Adapted from Katayama et al., 2003) 
 
 
Despite their sequence similarity, the three proteins have different sub-cellular 
localization and functions. This is attributed to the different set of proteins they 
interact with throughout mitosis (Table III). 
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 Substrate Cellular 
localization 
Functions 
AurA PP1, p53, Cdh1, 
TPX2, Ajuba, 
RasGAP, BRCA1, 
TACC3, HURP, 
CENP-E 
Centrosome, 
mitotic spindle 
Centrosome 
maturation and 
separation, spindle 
assembly, 
chromosome 
compaction and 
cytokinesis  
AurB Histone H3, 
INCENP, CENP-
A, vimentin, 
MCAK, survivin 
Centrosome, 
central spindle, 
chromosome arms 
Chromosome 
alignment and 
segregation, 
cytokinesis, MT 
dynamics, SAC 
AurC 
 
AurB, INCENP Central spindles, 
chromosome arms 
Spermatogenesis, 
SAC, cytokinesis 
 
 
Table III- Aurora kinases interact with different proteins, have different sub-
cellular localizations and perform different functions during mitosis. (Adapted from 
Bolanos-Garcia, 2005) 
 
 
Apart from the conserved T-loop residue, the Aurora kinases also possess specific 
motifs that control their degradation once they are no more required. Aurora proteins 
are degraded by the mitosis specific APC/C E3 ligase in a proteasome dependent 
manner. APC/C mediated destruction of proteins requires the presence of conserved 
motifs, such as the KEN-motif, the D (destruction)-box and a GxENbox (Castro et al., 
2005). Aurora A and B possess both the D-box and the D-box activating box 
(DAD/A-box), while Aurora C lacks the complete A-box sequence (Fig. 18). The 
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three kinases are regulated throughout the cell cycle by reversible phosphorylations 
and protein-protein interactions, although, least is known about Aurora C.  
 
In this section, I briefly review Aurora B and Aurora C and provide a detailed review 
of function and regulation of Aurora A. 
 
1.5.1. Aurora C (AurC) 
 
AurC is the third member of the human Aurora kinase family identified by library 
screening of kinases expressed in mouse sperm and eggs (Tseng et al., 1998) and 
homology search with AurB (Kimura et al., 1999). AurC shares 83% homology with 
AurB and only 71% with AurA (Katayama et al., 2003). Like other members of the 
family, expression of AurC at the mRNA and protein level peaks during the G2-M 
transition (Katayama et al., 2003). The region to which AurC gene maps is 
translocated and deleted in many human cancers and also AurC is overexpressed in 
many human cancer cell lines (Bernard et al., 1998), (Kimura et al., 1999). AurC is 
highly expressed in mammalian testis (Tseng et al., 1998) (Bernard et al., 1998) 
(Kimura et al., 1999) and is associated with the function of spermatogenesis 
(Kimmins et al., 2007). Human AurC localizes to the centrosomes during mitosis, 
suggesting a role in centrosome regulation (Kimura et al., 1999). It has recently been 
shown to localize to centromeres and to the spindle midzone at anaphase in mouse 
oocytes. Deletion of AurC resulted in production of large polyploid oocytes, 
indicating a function in cytokinesis (Yang et al., 2010). During mitosis, human AurC 
is capable of complementing the functions of AurB, as it is also a known member of 
the chromosome passenger complex (CPC) and has been shown to interact with 
INCENP an AurB activator (Li et al., 2004). AurC directly binds to survivin and is 
required for cytokinesis (Yan et al., 2005) Furthermore, AurC is regulated by an 
inhibitory phosphorylation at T171 by PKA (Chen and Tang, 2002). Thus, AurC 
likely performs many functions that were initially associated with AurB. More work, 
however, is required to understand the regulation of AurC during mitosis and meiosis.  
 
 
 
Introduction 
45	  
1.5.2. Aurora B (AurB) 
 
Human AurB was identified in a PCR reaction screen for kinases overexpressed in 
tumors (Bischoff et al., 1998). Like AurA, it is also cell cycle regulated with 
expression and activity peaking at mitosis (Terada et al., 1998), (Bischoff et al., 
1998). AurB is a component of the CPC complex along with INCENP, survivin and 
borealin that regulate mitosis in several ways (Carmena and Earnshaw, 2003). AurB 
is regulated by phosphorylation and interaction with other proteins. Binding of 
INCENP to AurB increases its kinase activity and is additionally responsible for 
proper localization of AurB to centromeres during mitosis (Katayama et al., 2003). 
The C.elegans Tousled-like kinase (TLK1) is both a substrate and activator of AurB 
(Han et al., 2005). Moreover, the checkpoint kinase Chk1 phosphorylates AurB and 
increases its activity at least in vitro, contributing to its activation in response to taxol 
(Zachos et al., 2007). AurB was shown to be highly active in the presence of a 
phosphatase inhibitor, okadaic acid (Sugiyama et al., 2002), indicating the 
requirement for phosphorylation in its activation. AurB interacts with phosphatases 
such as PP1 and PP2A that dephosphorylate it at the end of mitosis (Sugiyama et al., 
2002), (Sun et al., 2008). The microtubule end-binding protein (EB1) shields the T-
loop of AurB from dephosphorylation by PP2A (Sun et al., 2008). 
 
AurB is involved in several different mitotic events, such as chromosome bi-
orientation, chromosome condensation and segregation, SAC and cytokinesis 
(Carmena and Earnshaw, 2003). Bi-orientation is important to ensure enough tension 
is generated from the captured kinteochores. During an unperturbed mitosis, incorrect 
attachments such as monotelic and syntelic attachments occur naturally. AurB detects 
such improper attachments by phosphorylating and regulating substrates like 
Hec1/Ndc80 and MCAK (mitotic centromere-associated kinesin) (Carmena et al., 
2009). AurB regulates KT-MT interactions by phosphorylating and recruiting 
kinetochore components such as CENP-E (Murata-Hori and Wang, 2002), (Kim et al., 
2010). AurB is also an essential component of SAC and maintains the checkpoint 
under condition of low tension arising due to incorrect KT-MT attachments (Carmena 
and Earnshaw, 2003). It is negatively regulated by BubR1, one of the SAC 
components, to facilitate stable KT-MT interaction (Lampson and Kapoor, 2005). 
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AurB facilitates condensation of mitotic chromosomes by phosphorylating histone H3 
at S10 (Gurley et al., 1978) and S28 (Goto et al., 2002). AurB also controls sister-
chromatid cohesion by regulating the localization of the shugoshin protein (Carmena 
et al., 2009). Recently, AurB was shown to regulate the recruitment of separase to 
mitotic chromosomes (Yuan et al., 2009), an enzyme that is responsible for 
dissolution of the cohesin complexes at the end of metaphase.  
 
AurB is also required for late mitotic events. It re-localizes from the centromeres to 
the spindle midzone in anaphase and finally to the midbody of the dividing cell. AurB 
regulates the contraction of the acto-myosin ring by phosphorylating the 
centralspindilin complex (Carmena et al., 2009). The kinase is also required for 
regulating abscission timing, as active AurB persists at the chromatin bridge formed 
between the daughter nuclei (Steigemann et al., 2009). AurB phosphorylates vimentin 
at S72 and this is required for cytokinesis (Goto et al., 2003). AurB also regulates 
proteins like MgcRacGap, MKLP-1 and condesnin I in order to facilitate events of 
chromosome resolution and cytokinesis (Kitzen et al., 2010). Thus, AurB functions in 
early to late mitotic events by interacting with different proteins (Fig. 19), distinct 
form those of AurA (see below).  
 
 
 
 
 
Figure 19- AurB regulators 
during mitosis. Kinases are 
shown in red, phosphatases in 
blue and phosphorylation events 
are depicted with arrows. (See 
text for details). (Adapted from 
Carmena et al., 2009) 
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1.5.3. Aurora A (AurA) 
 
AurA is the first member of the human Aurora kinase family identified from 
Drosophila mutants that were defective in spindle-pole behavior (Glover et al., 1995). 
The gene-encoding AurA is located on chromosome 20 and this region is often 
amplified in several human tumors. The gene codes for a 403 amino acid protein of 
molecular weight of 46 kDa. AurA differs significantly from AurB and C with respect 
to its localization and function during mitosis. The protein is activated by 
phosphorylation of the T288 residue situated in the catalytic domain. AurA carries out 
important functions during mitosis by interacting with a number of different proteins 
(Fig. 20). Its downregulation results in delayed mitotic entry, monoploar spindles and 
defects in chromosome condensation (See Results Part 3). 
 
 
 
 
 
Figure 20- AurA regulators during G2 and mitosis. Kinases are shown in red, 
phosphatases in blue and phosphorylation events are depicted with arrows. (See text 
for details). (Adapted from Carmena et al., 2009) 
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In this section, I review the mechanisms of regulation of AurA and its functions in 
details. 
 
1.6.  FUNCTIONS OF AURORA A 
 
AurA is involved in several different events required for both entering mitosis and 
mitotic progression. Here, I briefly describe the main roles of AurA in cell cycle 
progression. 
 
1.6.1. Mitotic entry 
 
AurA is required for the G2 to M-phase transition and multiple mechanisms of this 
have been suggested. Cdk1 is the bona fide G2-M kinase whose activation drives 
mitotic entry. Cdk1 is activated by the concerted actions of Cdc25 phosphatases 
(Murray, 2004) and mitotic kinases such as AurA and Plk1 (Lenart et al., 2007), 
(Hansen et al., 2004). AurA is shown to facilitate mitotic entry either by directly 
regulating the activity of Cdk1 (Krystyniak et al., 2006), (Liu and Ruderman, 2006) or 
indirectly through phosphorylation of Cdc25B (Dutertre et al., 2004), placing it 
upstream of Cdk1. Recently, however, Cdk1 was shown to mediate activation of 
AurA at the G2 to M-phase transition (Van Horn et al., 2010). A more defined 
mechanism for AurA regulated mitotic entry exists that involves its G2-interactor 
Bora (Seki et al., 2008b) Bora was shown to interact with and activate AurA in G2, 
resulting in the phosphorylation of T210 in Plk1 at the G2-M transition. This, in turn, 
triggers the Plk1-Cdc25-Cdk1 positive feedback loop leading to activation of Cdk1 
and mitotic entry (Seki et al., 2008b). 
 
1.6.2. Mitotic progression 
 
AurA protein level and kinase activity increase from G2 until end of mitosis (Bischoff 
et al., 1998), (Krystyniak et al., 2006) (Results Part 1 of this thesis) and is associated 
with important events governing mitotic progression. AurA is associated with the 
centrosomes and spindle MTs throughout mitosis (Fig. 21). It plays an important role 
in centrosome maturation by phosphorylating TACC (transforming acidic coiled-
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coil), which is then recruited to the centrosomes and interacts with microtubule-
associated protein (MAP) Msps/ch-TOG that promotes the growth of MTs 
(Marumoto et al., 2005), (Kinoshita et al., 2005) AurA also helps in centrosome 
separation by phosphorylation of Eg5, a kinesin-like motor protein (Giet et al., 
1999). Interaction of AurA with TPX2 results in its recruitment to the spindle MTs 
where it facilitates assembly of bipolar spindles. AurA is also associated with 
chromosome alignment at the metaphase plate. AurA phosphorylates CENP-A, a 
kinetochore-specific H3 variant and promotes proper KT-MT attachment required for 
chromosome alignment and segregation (Marumoto et al., 2005), (Kunitoku et al., 
2003). Recently, AurA has also been shown to phosphorylate CENP-E, a kinetochore 
motor protein (Kim et al., 2010). This releases PP1 from CENP-E and allows 
congression of polar chromosomes towards the centre of the cell, thereby ensuring 
proper chromosome alignment at the metaphase plate. AurA also plays a role in 
regulating late mitotic events as depletion of AurA from metaphase cells results in 
abnormal cytokinesis and generation of multinucleated cells (Marumoto et al., 2003). 
Thus, by phosphorylating different proteins, AurA regulates their localization and 
function during mitosis.  
 
 
 
Figure 21 – Localization of AurA. AurA is localized to the centrosomes in G2 and to 
the spindle microtubules during early and late mitotic events. HeLa cells were stained 
with DAPI and AurA specific antibody and imaged using fluorescence microscopy.  
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1.6.3. AurA and cancer 
 
AurA is considered a potential oncogene as it is found amplified in numerous human 
tumors (Bischoff et al., 1998), (Zhou et al., 1998), (Tanner et al., 2000). Both gene 
amplification and overexpression of AurA have been linked to cellular 
transformation. Overexpression of AurA in mouse NIH-3T3 gives rise to tumors 
when injected in nude mice (Bischoff et al., 1998), (Zhou et al., 1998). 
Overexpression of AurA has been associated with resistance to taxol (Anand et al., 
2003), cisplatin and UV (Wang et al., 2006). How AurA promotes tumorigenesis is, 
however, not very clear. One of the suggested mechanisms is disruption of cell cycle 
checkpoints. Both AurA gene amplification and overexpression are shown to override 
the SAC triggered by nocodazole (Jiang et al., 2003) and taxol (Anand et al., 2003). 
This has shown to be independent of kinase activity (Jiang et al., 2003) and to result 
in an abnormal cytokinesis leading to centrosome amplification, multinucleation and 
ultimately to aneuploidy. Another mechanism contributing to AurA mediated 
aneuploidy is via tetraploidization due to deregulated cytokinesis and centrosome 
amplification (Marumoto et al., 2005), (Meraldi et al., 2002). This response is 
amplified in cells with dysfunctional p53 where cells fail to arrest in the subsequent 
G1, entering another round of replication (Meraldi et al., 2002). Also direct regulation 
of p53 stability and function by AurA favors aneuploidy in AurA overexpressed 
environment.  
 
Fig. 22 summarizes the mechanisms of AurA-dependent aneuploidy.  
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Figure 22- Overexpression of AurA leads to aneuploidy. Overexpression of AurA, 
either as a consequence of gene amplification or by other means, disrupts mitotic 
progression, apparently by blocking the ability of chromosomes to achieve a normal 
orientation on the spindle. Despite the difficulties with chromosome alignment, these 
cells exit mitosis because AurA overexpression also inactivates the spindle-assembly 
checkpoint. The cells ultimately fail in cytokinesis, producing tetraploid progeny. If 
the cells also lack p53, they continue through subsequent cell cycles, ultimately 
becoming polyploid and, eventually, aneuploid, with amplified centrosomes. AurA 
could also potentially contribute to carcinogenesis in other ways that are not shown 
here. Dysregulation of AurB might also lead to aneuploidy and cancer (lower left), 
but the mechanism is much less explored than that for AurA. (Adapted from Carmena 
and Earnshaw, 2003) 
 
 
 
Introduction 
52	  
AurA overexpression has also been associated with increased cell proliferation and 
survival in response to cisplatin and UV (Wang et al., 2006). This has been shown to 
occur due to evasion of apoptosis via upregulation of Bcl-2, an apoptotic antagonist. 
Another possible mechanism shown for AurA overexpression-induced tumorigenesis 
is via increased epithelial-to-mesenchymal transition (EMT) by direct 
phosphorylation of MAPK by AurA in nasopharyngeal cancer (Wan et al., 2008). 
AurA was also shown to be a downstream target of MAPK in pancreatic cancers, 
where MAPK induces AurA expression (Furukawa et al., 2006). This suggested a 
possibility of existence of a feedback loop between the two, where initial 
overexpression of AurA by MAPK leads to further activation of the latter by direct 
phosphorylation (Wan et al., 2008). Increased cell migration in laryngeal cancer was 
also attributed to AurA overexpression leading to increased Akt1 phosphorylation 
(Guan et al., 2007). AurA overexpression was also associated with hyperactivation of 
the MEK/ERK signaling pathway (Tseng et al., 2009). Recently, AurA 
overexpression was shown to enhance E2F1 transcription activity and protein 
stability. It also induced increase of the microRNA cluster miR-17-92 through E2F1 
transcription factor (He et al., 2010). A gene amplification and mRNA overexpression 
independent pathway is also known to play a role in AurA induced transformation. 
This occurs via stabilization of the protein by increased phosphorylation at the S51 
residue (Kitajima et al., 2007). 
 
Thus, AurA overexpression promotes aneuploidy by deregulating SAC and p53, it 
promotes tumor proliferation by facilitating increased cell survival due to interference 
with apoptotic pathways and by promoting increased transcription of genes and, 
finally, promotes EMT by hyperphosphorylation of MAPK. Certainly, more work will 
be needed to unravel other molecular mechanisms by which AurA can promote 
cellular transformation and tumorigenesis.  
 
1.6.3.1. Role of AurA-TPX2 complex in cancer 
 
A recent review in the field has reassessed the potential of AurA alone as an oncogene 
(Asteriti et al., 2010). The authors maintain that a clearly defined role of AurA in 
promoting tumorigenesis is controversial and that the studies so far conducted have 
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found alterations in other pathways as an outcome of AurA overexpression. They 
suggest a more direct role of AurA by assessing the potential of AurA-TPX2 complex 
deregulation in cancers. Several studies have found overexpression of TPX2 in human 
cancers (Warner et al., 2009), (Satow et al., 2010). Many tumors have also been found 
to overexpress both AurA and TPX2 providing evidence of AurA-TPX2 complex as a 
functional unit in cancer progression (Asteriti et al., 2010). Mechanistically, the 
presence of an AurA-TPX2 functional complex has been envisioned to promote 
tumorigenesis by the three outcomes illustrated in Fig. 23: 
 
 
Figure 23- Possible outcomes of AurA-TPX2 deregulation in cancer progression. 
Increased AurA (A) or TPX2 (B) abundance, both expected to cause abnormal 
phosphorylation of AurA substrates, or overexpression of both (C); the latter scenario 
yields excessive abundance of the whole complex, which can then act as an oncogenic 
holoenzyme. (Adapted from Asteriti et al., 2010) 
 
 
Recently, another study pointed to the role in cancer for an AurA mutant that is 
defective in binding TPX2 (Bibby et al., 2009), reinforcing the idea of the 
involvement of AurA regulators in facilitating tumorigenesis. Accordingly, in the 
study presented in this thesis, we observed loss of the TPX2-AurA interaction upon 
DNA damage, a mechanism that explains the inhibition of AurA activity detected in 
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response to genotoxic stress, in the face of unvaried protein level of the kinase. This 
may suggest that an unscheduled accumulation of AurA protein can occur in the 
absence of TPX2, making cells unresponsive to the presence of DNA damage, as they 
move on in mitosis with severe chromosome segregation defects. The fate of such 
aneuploid cells was, however, not assessed in the study presented in the thesis. Such 
an AurA overexpression-dependent insensitivity towards DNA damage has been 
shown previously (Wang et al., 2006). Moreover, it was shown that kinase activity is 
not required for AurA-mediated overriding of the SAC, suggesting a possible 
explanation of the role of accumulated AurA protein, which is devoid of kinase 
activity, in genetic instability (Jiang et al., 2003). 
 
In conclusion, AurA-TPX2 complex deregulation could be one of the main pathways 
the alteration of which leads to tumorigenesis. It will be a great deal of interest for the 
future studies to understand the potential of this complex as a therapeutic target.  
 
1.6.3.2. AurA as a chemotherapeutic target  
 
As Aurora kinases are frequently found overexpressed in human cancers, they serve 
as attractive candidates of chemotherapeutic interventions. Downregulation of both 
AurA and B results in multiple mitotic defects and aneuploidy, ultimately leading to 
apoptosis. Many drugs targeting these kinases are currently in phase I and II clinical 
trials, but unfortunately, selectivity to AurA alone has not been successfully achieved 
so far. Drugs such as Hesperadin, MLN8054, MLN8237 are under phase I evaluation 
studies and have shown to result in phenotypes arising from inhibition of all three 
Aurora kinases, but show severe side effects (Kitzen et al., 2010). 
 
VX-680 (MK-0457) so far is the most advanced Aurora inhibitor in clinical testing. It 
is currently under Phase I trial in patients with refractory leukemias and in Phase II 
trial with patients of advanced colorectal cancer (Miglarese and Carlson, 2006).  
 
Table IV below provides information of drugs targeting the Aurora kinases.  
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Table IV- Aurora kinase inhibitors in clinical trials. (Adapted from Mountzios et al., 
2008) 
 
 
1.6.4. Role of AurA in regulation of translation 
 
mRNA and protein level of several cell cycle proteins are highly regulated to ensure 
the proper timing of initiation and conclusion of cell cycle events. Translation of 
mRNA coding for genes required specifically during mitosis is one of such control 
mechanisms. Translational regulation, in addition to other factors, depends on the 
length of the poly(A) tail of the mRNA. Longer poly(A) tail promotes translation 
while shortening results in translation inhibition (Stutz et al., 1998). AurA is known to 
regulate the translation process via polyadenylation of mRNAs. AurA positively 
regulates Xenopus oocyte maturation in response to hormonal stimulation via 
phosphorylation of CPEB (cytoplasmic polyadenylation element binding protein) 
(Sarkissian et al., 2004). Phosphorylation of CPEB by AurA results in recruitment of 
CPSF (cleavage and polyadenylation specific factor) (Mendez et al., 2000) to promote 
polyadenylation at the 3’ end of the mRNAs. In addition, it was postulated that an 
AurA-mediated polyadenylating activity in mitotic cell extracts is responsible for 
translation of cyclin B1 and Cdk1 mRNAs (Sasayama et al., 2005) and it was shown 
that cyclin B/Cdk1 controls translation of mitotic proteins by regulating their 
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recruitment to the polysomes, specifically during mitosis (Le Breton et al., 2003). In 
conclusion, AurA can modulate translation and hence provide an additional 
mechanism by which its overexpression can lead to mitotic abnormalities leading to 
tumorigenesis.  
 
1.7.  REGULATION OF AURORA A 
 
 
1.7.1. Phosphorylation 
 
Like other mitotic protein kinases, AurA is also regulated by reversible 
phosphorylation throughout mitosis. Three important sites of phosphorylation were 
mapped by subjecting recombinant AurA protein expressed in Sf9 cells and incubated 
with mitotic Xenopus extracts to mass spectrometric analysis (Littlepage et al., 2002). 
This identified S53, S349 (S51 and S342 in human AurA) and T295 (T288 in human 
AurA) as the major phosphorylated residues in AurA (Littlepage et al., 2002). 
T295/T288 resides in the catalytic domain of the kinase and phosphorylation of this 
residue results in increased kinase activity. It was initially shown that PKA could 
phosphorylate T288 in vitro and this resulted in increased AurA kinase activity 
(Walter et al., 2000) leading the authors to suggest that PKA may have a 
physiological role in the activation of AurA. Studies conducted elsewhere (Littlepage 
et al., 2002) and in our laboratory (Ferrari et al., 2005) disproved this claim, opening 
the possibility that other kinases could be involved in the process of AurA activation 
(Zhao et al., 2005). Also, since PKA activity is low during mitosis when AurA kinase 
activity peaks, this makes PKA less likely to activate AurA in vivo (Ferrari et al., 
2005). Dephosphorylation of S53/S51 by PP2A, which belongs to ser/thr PP2 family, 
is required for the degradation of AurA (Horn et al., 2007), indicating that this site has 
an important role in the stability of AurA. The S349/S342 residue resides close to the 
PP1 binding motif in AurA. Recombinant AurA carrying mutation of S342 to Ala 
shows activity similar to the WT, whereas mutation of this residue to Asp completely 
abolishes enzymatic activity (Littlepage et al., 2002), (Ferrari S, unpublished data). 
Moreover, in Xenopus, phosphorylation of S349 caused reduction of AurA kinase 
activity and was shown to be required for the process of oocyte maturation (Pascreau 
et al., 2008). In contrast to these findings, S342 phosphorylation was found important 
for the kinase activity of AurA as the overexpressed S342A mutant from mitotic 
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COS-7 cells showed less than half of the kinase activity as that of WT when used on 
histone H3 as a substrate (Zhao et al., 2005). This shows that phosphorylation of S342 
might be important for AurA kinase activity. Although a few in vitro data are 
available regarding the role of this residue in AurA regulation, no clear-cut evidence 
is present in vivo in human cells. Future work will be required to unequivocally 
establish the significance of S342 phosphorylation in AurA regulation. 
 
1.7.2. Interaction partners 
 
AurA interacts with several different proteins throughout G2 and mitosis that directly 
contribute to its phosphorylation, activation, localization, function and degradation. In 
this section I mention the most important proteins that are required for regulation of 
AurA. 
 
1.7.2.1. General AurA interactors 
 
1.7.2.1.1. p53 
 
p53 is a known tumor suppressor required for preventing generation of transformed 
phenotypes by regulating processes of cell division and apoptosis (Chen et al., 2002). 
Most human tumors have mutated p53 status, implicating its effect in preventing 
cancer initiation/progression. p53 is also associated with the centrosome (Chen et al., 
2002) and its downregulation results in centrosome amplification (Fukasawa et al., 
1996), a phenotype significantly frequent in cells overexpressing AurA (Zhou et al., 
1998). A direct relation between these two proteins in regulating centrosome 
amplification has been shown. Whereas AurA overexpression was shown to interfere 
with normal mitosis giving rise to multinucleation and centrosome amplification, 
deletion of p53 promoted cell cycle progression due to abrogation of the G1 
checkpoint (Meraldi et al., 2002). p53 directly binds to N-terminal Aurora box in 
AurA and regulates its kinase activity in transactivation-independent manner (Chen et 
al., 2002). This interaction suppresses AurA kinase activity and also its ability to 
induce centrosome amplification. In addition to AurA being regulated by p53, AurA 
directly modulates the stability of p53 by phosphorylating it. AurA was shown to 
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phosphorylate p53 at S315 resulting in increased ubiquitination and degradation of 
p53 by Mdm2 (Katayama et al., 2004). Also, it was shown to phosphorylate p53 at 
S215 and interfere with its DNA binding and transactivation functions (Liu et al., 
2004). Thus, deregulation of p53 stability and function by AurA-mediated 
phosphorylations has been suggested as a major route of cellular transformation 
resulting from AurA overexpression. The feedback regulation of the two proteins, 
therefore, significantly affects the functionality of cell cycle checkpoints. 
 
1.7.2.1.2. Protein Phosphatase 1 (PP1) 
 
AurA is bound to PP1 throughout the cell cycle but the binding is maximum during 
mitosis when AurA protein level peaks. AurA has two PP1-binding motifs 
(R/K)(V/I)XF): one includes the catalytic lysine residue (K169VLF) and the second is 
immediately adjacent to S342 (K343VEF) (Katayama et al., 2001). A feedback 
regulation exists between the two proteins, such that, the active AurA phosphorylates 
PP1 to promote its own activation while, if PP1 is active, it can dephosphorylate the 
kinase. This dephosphorylation is thought to be at the T288 site in AurA, although no 
direct in vivo evidence is available to support this claim.  Control of the AurA-PP1 
interaction may occur through phosphorylation at S342, an event that may decrease 
binding of PP1 to the K343VEF motif, thereby maintaining T288 phosphorylated and, 
in turn, AurA active (Littlepage et al., 2002). This, however, still remains to be 
confirmed at both in vitro and in vivo levels. Interestingly, interaction with PP1 also 
seems to be indispensible for AurA as PP1 non-binding mutants of AurA are less 
active than the WT, suggesting that a balance between the 
phosphorylation/dephosphorylation states is finely tuned throughout the cell cycle 
(Katayama et al., 2001). The C-terminal region of PP1 inhibitor 2 (I-2) has also been 
shown to directly stimulate AurA kinase activity, at least in vitro (Satinover et al., 
2004). 
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1.7.2.2. AurA interactors in G2 
 
1.7.2.2.1. Bora 
 
Bora, identified as an interactor of AurA, is highly conserved from C.elegans to 
humans. It is a nuclear protein that, upon Cdk1 activation, translocates to the 
cytoplasm and functions by interacting with AurA. It was initially identified due to its 
phenotypic similarity to AurA mutants and found to be a substrate and activator of the 
kinase (Hutterer et al., 2006). In subsequent studies, Bora was also found to activate 
Plk1 at the G2-M transition (Seki et al., 2008b). Bora is degraded at the end of G2 in 
Plk1 dependent manner through the βTrCP ubiquitin ligase (Seki et al., 2008a), thus 
allowing AurA to bind TPX2 , its important mitotic regulator. 
 
1.7.2.2.2. Ajuba 
 
Ajuba is a LIM domain containing protein that was identified as an AurA interacting 
partner by a yeast two-hybrid screen (Hirota et al., 2003). LIM domain represents a 
double zinc-finger domain that was initially found in transcription factors like 
C.elegans Lin-11, rat Isl-1 and C. elegans mec-3 and therefore called LIM (Goyal et 
al., 1999). It was found to be promoting Xenopus oocyte maturation (Goyal et al., 
1999). Ajuba interacts with AurA and is required for activation of the kinase at the 
centrosomes in late G2 as depletion of Ajuba results in absence of T288 
phosphorylation of AurA and delay in mitotic entry (Hirota et al., 2003). 
 
1.7.2.2.3. HEF1 (Human Enhancer of Filamentation 1) 
 
HEF1 is a docking protein that plays an important role in controlling signaling at the 
focal adhesions (Pugacheva and Golemis, 2005). In addition, it also has a role in cell 
cycle regulation as it was found associating with the mitotic spindles (Law et al., 
1998). Downregulation of HEF1 resulted in appearance of monopolar spindles while 
overexpression caused multipolar spindle formation (Pugacheva and Golemis, 2005), 
phenotypes similar to those arising from deregulated AurA levels. HEF1 interacts 
with AurA specifically during the G2 phase and allows activation of the kinase by 
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promoting autoactivation (Pugacheva and Golemis, 2005). AurA was found to be 
more active in cells overexpressing HEF1. HEF1 is also a substrate of AurA and is 
phosphorylated at S296 (Pugacheva and Golemis, 2005). Thus, in G2, HEF1 
interaction activates AurA by increasing its autophosphorylation. As cells enter 
mitosis, phosphorylation of HEF1 at S296 by activated AurA causes dissociation of 
the complex. This provides a remarkable example of how regulation of signaling 
affects cell cycle progression. 
 
1.7.2.2.4. PAK1 (p21 Activated Kinase 1) 
 
The PAK family of protein kinases is a multifunctional class with roles in cell 
migration, cytoskeletal reorganization, focal adhesion and cell cycle regulation (Zhao 
et al., 2005). PAK1 localizes to the centrosomes where it interacts with AurA. It is the 
only kinase so far known to phosphorylate AurA at T288 and S342, an event that is 
necessary for AurA activation. Interaction of PAK1 with AurA at the centrosomes 
promotes centrosome duplication and cell cycle progression (Zhao et al., 2005). 
 
1.7.2.3. AurA interactors in mitosis 
 
1.7.2.3.1. TPX2 
 
TPX2 (Targeting Protein for Xenopus kinesin-like protein 2) is a microtubule-
associated protein first identified as the protein required for targeting Xklp2 (Xenopus 
kinesin-like protein 2) to the spindle poles (Wittmann et al., 1998). TPX2 was later 
found to interact with AurA and proved to be its substrate (Kufer et al., 2002). So far 
it remains the best-characterized AurA regulator.  
 
Until mitosis begins, TPX2 is kept unavailable through binding to importin α and β. 
As soon as NEBD takes place, Ran-GTP mediates the release of TPX2, which is then 
free to bind AurA (Fig. 24) (Gruss and Vernos, 2004). Binding of TPX2 to AurA is 
mediated via its N-terminal domain (NTD) that interacts with C-terminal domain 
(CTD) of AurA and targets it to the spindle microtubules (Kufer et al., 2002). Within 
the NTD of TPX2, amino acids 1-43 are essential and sufficient for binding and 
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activating the kinase (Bayliss et al., 2003). Briefly, binding of TPX2 to AurA 
stretches its activation segment in a way that makes AurA competent to bind 
substrates and additionally protects the T-loop site T288 from PP1-dependent 
dephosphorylation (Bayliss et al., 2003). Mechanistically, binding of TPX2 pulls the 
activation segment such that the T288 moves into a buried position and becomes 
unavailable to the phosphatases. This, in addition, also exposes the nearby T287 
residue that acts as a continuous substrate for the surrounding phosphatases, further 
protecting the T288 phosphorylation (Bayliss et al., 2003). Thus, TPX2 locks AurA in 
an active conformation. Active AurA, in turn, phosphorylates TPX2 and allows its 
spindle-associated functions to be carried out (Eyers and Maller, 2004), (Kufer et al., 
2002). Recently, Plk1 was shown to promote activation of AurA in vitro, by directly 
phosphorylating TPX2 at S204 in Xenopus (Eckerdt et al., 2009). Furthermore, an 
AurA mutant associated with human tumors and unable to bind TPX2 was found to 
be mislocalized and misregulated (Bibby et al., 2009). Thus, interaction of AurA with 
TPX2 is essential for AurA activation and events such as chromatin-induced MT 
nucleation, spindle pole separation and for establishing proper spindle length. 
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Figure 24- Regulation of AurA activity by TPX2 and Ran-GTP. As cells enter 
mitosis, TPX2 is in a complex with importins α or β. A gradient of Ran–GTP 
surrounding chromosomes (lower right) promotes the release of TPX2 from the 
importin. TPX2 then binds to AurA, which has been kept inactive by PP1. TPX2 
interferes with PP1 action, enabling the kinase to autophosphorylate and activate 
itself and other substrates, including TPX2. TPX2 then also targets the kinase to 
microtubules proximal to the centrosome. (Adapted from Carmena and Earnshaw, 
2003) 
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1.7.2.3.2. Astrin 
 
Astrin was identified as a microtubule associating non-motor protein by mass-
spectrometry performed on microtubules that were extracted from mammalian cells 
(Mack and Compton, 2001). It was found to interact with AurA by a yeast two-hybrid 
screen (Du et al., 2008). Astrin binding to AurA regulates its localization at the 
spindle microtubules, as depletion of astrin caused complete dissociation of AurA 
from spindles while the centrosomal localization was unaffected (Du et al., 2008). 
Depletion of astrin also caused an increase in the formation of multipolar spindles, 
possibly through misregulation of AurA (Du et al., 2008). Thus, apart from the known 
mitotic regulator of AurA, TPX2, that also controls its localization, astrin represents 
yet another protein directly influencing the localization and function of AurA.   
 
1.7.2.3.3. RASSF1A (Ras Association Domain Family 1A) 
 
RASSF1A is a potential tumor suppressor protein found mutated in most human 
cancers and may mediate its tumor suppressing activity either by promoting apoptosis 
or interfering with cell cycle progression (Agathanggelou et al., 2005), (Dammann et 
al., 2005). It is primarily centrosomal localized in interphase (Guo et al., 2007) and 
relocalizes to the mitotic spindle as cells enter mitosis (Liu et al., 2008). AurA 
interacts with RASSF1A at the centrosomes and mitotic spindles and this interaction 
results in activation of AurA (Liu et al., 2008). AurA localization or stability, 
however, was not affected by this interaction (Liu et al., 2008). The exact functional 
significance of this requires further work.   
 
Apart from these known interaction proteins, I could identify some novel AurA 
interactors during mitosis using proteomics approach. The outcome of this study is 
presented in detail in the Results Part 3. 
 
 
 
 
 
Introduction 
64	  
1.7.3.  Degradation of AurA 
 
1.7.3.1. Role of APC/C complex 
 
Like many other cell cycle regulated proteins, AurA is degraded at the end of mitosis 
through ubiquitin-dependent proteolysis via the proteasome pathway. Initial studies of 
this mechanism identified the APC/C complex as key player (Honda et al., 2000), 
(Walter et al., 2000) with the Cdc20 subunit being able to bind AurA (Farruggio et al., 
1999). Later on, however, the direct involvement of Cdh1 in the process of AurA 
degradation was demonstrated, thus ruling out any roles for Cdc20 (Taguchi et al., 
2002). Proteins that are degraded by Cdh1 possess special recognition motifs like an 
RxxL containing D-box (destruction box) and a KEN-box (composed of amino acids 
K-E-N). Human AurA has one D-box stretch in the NTD and four similar stretches in 
the kinase domain (none of them being a functional destruction box) (Honda et al., 
2000) and a KEN-motif. In Xenopus and human AurA it was shown that destruction 
of AurA does not require the KEN-motif but requires the C-terminal D-box (Arlot-
Bonnemains et al., 2001), (Castro et al., 2002), (Crane et al., 2004), a short N-
terminus region called the A-box (Littlepage and Ruderman, 2002) and 
dephosphorylation of S51 residue in the A-box (Littlepage and Ruderman, 2002). 
Phosphorylation of S51 renders the kinase stable and dephosphorylation by PP2A is 
required for its destruction at the end of mitosis (Horn et al., 2007). 
 
In addition, AurA destruction is also controlled by Plk1. Phosphorylation mediated 
activation of Cdc14A phosphatase by Plk1 leads to dephosphorylation and activation 
of Cdh1 at the end of mitosis, allowing AurA degradation (van Leuken et al., 2009). 
Thus in addition to regulating other processes of the cell cycle, phosphorylation also 
plays a key role in the destruction of key mitotic players during and at the end of 
mitosis through timely activation of either Cdc20 or Cdh1, respectively.  
 
1.7.3.2. Role of CHFR E3 ligase 
 
CHFR has been shown to prevent chromosomal instability by directly regulating 
AurA protein level (Yu et al., 2005). As a part of SAC, it was shown to delay mitotic 
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progression, an event that was accompanied by the presence of inactive AurA at 
centrosomes (Summers et al., 2005). CHFR can bind AurA through its C-terminal 
cysteine-rich region and this leads to ubiquitination of AurA (Yu et al., 2005). In 
Chfr-null MEFs, AurA overexpression-induced tumorigenesis was observed. Similar 
results were recently confirmed in human MCF10A cells where siRNA mediated 
downregulation of CHFR resulted in increased AurA protein level, followed by 
promotion of centrosome amplification (Privette and Petty, 2008). These data suggest 
that AurA stability is strictly monitored by more than one E3 ligase, indicating the 
importance of maintaining regulated AurA protein level to prevent chromosome 
instability. 
 
1.7.3.3. Alternative AurA degradation pathway 
 
In addition to the well-known ubiquitin-dependent proteasome degradation of AurA, 
an alternative ubiquitin-independent pathway is also involved in AurA destruction. 
AurA interacts with AurA kinase interacting protein 1 (AURKIP1), a negative 
regulator of the kinase and antizyme1 (Az1), member of the ubiquitin-independent 
degradation pathway. When in complex with AurA, AURKIP1 prevents 
polyubiquitination of the kinase and facilitates binding to Az1, thus promoting its 
degradation by the proteasome in an ubiquitin and cell-cycle independent manner 
(Lim and Gopalan, 2007b), (Lim and Gopalan, 2007a). 
 
1.7.4. AURORA A AND DNA DAMAGE  
 
1.7.4.1. Role of G2 checkpoint in regulating AurA 
 
Apart from being regulated by a myriad of proteins in G2 and during mitosis, AurA is 
also regulated by DNA damage induced in G2 phase of the cell cycle. Three reports 
until now confirm this finding.  
 
The first among these suggested that AurA activity decreased by damage induced G2 
checkpoint in a cyclin B/Cdk1-dependent manner (Marumoto et al., 2002). The 
authors showed that overexpression of AurA could lead to bypass of this checkpoint 
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and cause premature entry into mitosis. Another study showed that upon DNA 
damage AurA was not activated and did not phosphorylate Cdc25B at S353 (Cazales 
et al., 2005). It was also shown that ectopic expression of AurA resulted in bypass of 
the checkpoint that was Chk1 dependent as the use of Chk1 inhibitor UCN-01 
resulted in activation of AurA and hence phosphorylation of Cdc25B on S353. 
Previous work from my lab also showed that AurA is a target of the G2 checkpoint 
(Krystyniak et al., 2006). Inhibition of the kinase occurs in a Chk1-dependent manner, 
although Chk1 does not directly phosphorylate AurA. Inhibition of AurA was shown 
to cause accumulation of cells in G2, while reintroducing the WT kinase, but not the 
KD mutant, bypassed this arrest. This bypass was shown to be due to reactivation of 
Cdk1, placing Cdk1 downstream of AurA.  
 
These results similarly concluded that AurA is a bona fide target of the G2 checkpoint 
and its inactivation prevents premature entry into mitosis. 
 
1.7.4.2. AurA regulation by mitotic DNA damage 
 
My thesis work was dedicated to extend the observations on DNA damage-dependent 
control of AurA to the M-phase of the cell cycle, where nothing is known about the 
regulation of AurA by genotoxic damage. The main aim was to understand if AurA is 
also a target of mitotic DNA damage and, if this is the case, what could be the 
underlying mechanism of its regulation. Details of this work are presented in the 
Results section (Part 1 and 2). 
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ABSTRACT 
In this chapter we introduce proteins controlling transition through the cell division 
cycle, with particular focus on the controllers of mitosis, and we describe their role in 
the development of cancer.  
The essay begins with a historical perspective on the discoveries that led to the 
formulation of “The Cell Theory” and the understanding of mechanisms controlling 
cell cycle transitions. This is followed by an in-depth description of pathways that 
monitor the appropriate completion of events in each phase of the cell division cycle 
(the checkpoints) and an analysis of the many dysfunctions that alter these 
mechanisms and account for the occurrence of cancer. The essay is concluded by 
some considerations on the opportunity of putting effort, both in basic research and 
drug discovery programs, on the full clarification of the G2/M checkpoint, which is 
the only checkpoint that tumors in the body and experimental systems have in 
common. The rationale to this suggestion is that combinations of low-dose radio- or 
chemotherapy and selective G2/M checkpoint inhibitors will be more effective in 
achieving tumor clearance than current conventional protocols. 
 
 83	  
1. INTRODUCTION: HISTORICAL PERSPECTIVE 
1.1 The Cell Theory 
Much like the introduction of first reflecting telescope opened the way to the 
discovery of the immensely far, so the early microscopes facilitated initial inspections 
of the extremely small. Using a prototype microscope to observe slices of cork bark, 
in 1665 the British physicist Robert Hooke first reported on structures that he named 
“cells” [1,2] (see also: http://www.roberthooke.org.uk/). It was, however, not before 
the technical improvement of microscopes, allowing for correction of chromatic 
aberration, and the advance of tissue preparation techniques that the German botanist 
Matthias Schleiden and the physiologist Theodor Schwann in 1838 and 1839, 
respectively, enunciated the “Cell Theory”. The essential concept of the Cell Theory 
is that cells are the basic units of all living organisms. In 1852 the pathologist Robert 
Remak, examining the behavior of frog eggs, reported that cells give rise to new cells 
through a process of cleavage that always starts with the nucleus [2]. This concept 
was further developed and elaborated by the Polish/German pathologist Rudolph 
Virchow, who proposed that every cell derives from a pre-existing cell in a 
continuous series of generations and is known for the aphorism “Omnis cellula e 
cellula” that he borrowed from the French chemist François Vincent Raspail 
(http://www.britannica.com/eb/article-7719/Rudolf-Virchow). The findings of 
Virchow and his contemporaries not only contributed to definitely dismiss the 
principle of spontaneous formation of organisms but also introduced the concept that 
diseases are likely explainable through alterations of the physiological state of cells, 
thus introducing the concept of cellular pathology. The subsequent identification of 
cellular organelles and subcellular compartments, which was rendered possible 
towards the end of the nineteenth century by improvements in tissue fixation and 
staining, expanded the notion that cells are merely composed of nucleus and 
protoplasm, thus opening the way to a functional description of cells as we know 
them today [1]. 
 
1.2 Cell Fusion Experiments 
Knowledge of the cell’s architecture prompted studies aimed at understanding the 
internal wiring of cells and the mechanisms controlling their life and propagation. 
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In 1847 Schwann observed that when cells are close to each other their walls tend to 
coalesce but nuclei remain separated [3]. Such multi-nucleated cells (heterokaryon) 
are known as syncytia and their formation occurs both during development and in the 
mature organism [3]. Alternatively, cell fusion may be followed by nuclear fusion, in 
which case the deriving cell is a synkaryon [3]. 
The plasmodium Physarum polycephalum was used as model system in early cell 
fusion studies due to its ability of forming syncytia during its life cycle. Rush and 
coworkers noted that fusion of microplasmodia, each exhibiting synchronous mitosis 
but lacking synchrony in division with respect to each other, resulted in a large 
plasmodium in which the first mitosis occurred synchronously. This led the authors to 
postulate the existence of factors that are able to advance cells to mitosis [4]. At the 
same time, improvement of mammalian cell culturing techniques rendered possible 
the generation of artificial heterokaryons in the laboratory [5]. Using Sendai virus-
mediated fusion of cells, Rao and Johnson conducted pioneering studies aimed at 
assessing the inter-dependence of cell cycle transitions. Specifically, the authors 
addressed the mechanism controlling DNA synthesis and mitosis in mammalian cells 
[6,7]. To this end, they fused cells that were either in the same stage or in different 
stages of the cell division cycle and observed the extent to which transition through 
the cycle was altered. Fusing S-phase with G1-phase cells in ratio 1:1 would drive the 
G1 nucleus to initiate DNA synthesis within 2 hrs from fusion, as compared to the 12 
hrs needed by G1/G1 fused cells to initiate DNA replication [6]. Similarly, upon 
fusion of mitotic cells with a G1, an S or a G2 population of cells the authors 
observed the rapid occurrence of interphase chromatin condensation, a phenomenon 
referred as premature chromosome condensation or PCC [7]. Finally, fusion of S-
phase cells with a G2 population did not induce re-replication of DNA in the G2 cells. 
The authors noted that all these effects were dosage-dependent, in the sense that the 
observed rate of fusion-induced progression to the next phase of the cell cycle was 
directly proportional to the number of most advanced cells used for the fusion. 
Together with the observations made in Physarum, the implication of these studies to 
the understanding of the regulation of cell division was enormous: in essence, the 
evidence provided by Rao and Johnson led to the concept that factors promoting entry 
into S- or M-phase must exist in cells that are about to replicate their genome or to 
divide, respectively. Such factors, in turn, act in a context-independent manner, in the 
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sense that once they are triggered they execute cell cycle transitions regardless of 
whether the cell is ready to perform such action.  
 
1.3 Regulation of cell cycle transitions 
The following years witnessed the convergence of genetic and biochemical studies 
that made use of different model systems to identify components of the machinery 
controlling cell cycle transitions. Pioneering investigation on the yeast S. cerevisiae 
conducted by Hartwell and collaborators led to the discovery of a number of new 
genes responsible for the execution of various steps of mitosis [8]. On the other hand, 
Nurse and colleagues identified 27 recessive mutants in S. pombe that were unable to 
complete the cell division cycle at restrictive temperature: 14 such genes were shown 
to participate in DNA synthesis, nuclear division and cell plate formation [9]. These 
studies led the authors to conclude that DNA synthesis and nuclear division form a 
cycle of mutually dependent events (for a detailed account of those studies see [10]). 
Despite the significant contribution of these investigations to the elucidation of the 
network of genes that control key cell cycle transitions, genetic approaches could not 
elucidate the mechanism by which such transitions are executed. It was only through 
biochemical analysis of protein function that molecular mechanisms could be 
understood. Initial studies performed on extracts of the plasmodium Physarium 
revealed that the increased activity of a protein kinase that was able to phosphorylate 
histone H1 correlated with entry into mitosis. Of particular notice, the authors 
observed that addition of the purified H1 kinase to plasmodia accelerated the 
initiation of mitosis [11].  
On another front, experiments conducted on the frog Rana pipiens showed that 
injection into immature oocytes of the cytoplasm obtained from oocytes that were 
artificially induced to mature by administration of progesterone, led the former to 
mature and divide. Such substance was initially indicated as “Maturation Promoting 
Factor” [12] and later re-named M-phase Promoting Factor or MPF. Initial 
biochemical characterization of such factor showed that it consisted of a heat-labile 
protein [13]. This was later purified and demonstrated to possess protein kinase 
activity [14], in agreement with the evidence obtained from Physarum. The key 
contribution of Hunt’s laboratory to the field came from serendipitous observations 
made using the eggs of the see urchin Arbacia. It was known that fertilization of eggs 
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correlates with increase in the rate of synthesis of proteins for which maternal mRNA 
provides the source. Hunt and collaborators detected a protein that was regularly 
synthesized and degraded in a manner that corresponded to transition through the 
phases of the cell division cycle: this protein was named “Cyclin” [15]. Subsequent 
work from a number of laboratories led to the identification of all other members of 
the cyclin-family and, most importantly, to the demonstration that cyclins are the 
regulatory subunits of cyclin-dependent kinases (CDKs) [10]. Our current 
understanding of the role of cyclins, cyclin-dependent kinases and their inhibitors 
(CKIs) is schematically illustrated in Fig. 1.   
 
 
 
Figure 1. Regulation of cell cycle transitions. 
Transition through the cell cycle is orchestrated by protein complexes constituted by 
regulatory (the cyclins, Cyc) and catalytic subunits (the cyclin-dependent kinases, 
CDKs). The two major transitions, consisting of entry into S-phase and into Mitosis, 
respectively, are controlled by the S-phase promoting factor (SPF) and the M-phase 
promoting factor (MPF) (see text for details). The time of action of Cyclin-dependent 
kinase inhibitors (CKIs, depicted within the circle) is also shown.  
 
 
2. CELL CYCLE CONTROLLERS AS ONCOGENES 
Considering both the complexity of the pathways controlling transition through the 
cell division cycle and the variety of proteins involved in this process, it is evident 
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that failure of a single wheel at any point in this mechanism may either impair or 
accelerate growth. Since extensive literature on the deregulation of classic cell cycle 
controllers (i.e., cyclins, CDKs and CKIs) and their targets (pRb and p53) already 
exists, here we will provide a brief account of the most significant work in this field 
and will rather concentrate to discuss some of the most intriguing pathways that 
operate at the onset of mitosis and are involved with the development of cancer. 
Early studies in mouse model systems showed that over-expression of Cyclin D1 and 
E1 led to hyperplasia and to the development of carcinomas [16,17], suggesting that 
both cyclins might be oncogenes. However, it was later observed that ablation of 
Cyclin D1 [18,19] as well as inactivation of the partner subunits Cdk4 or Cdk6 [20-
22] was not sufficient to block progression through the cell cycle, pointing to the 
existence of redundant pathways. Similarly, Cyclin B1 knock-out did not affect early 
development, with embryos reaching mid-gestation, whereas Cyclin B2-null mice 
showed no phenotype at all [23]. Somehow more severe was the phenotype resulting 
from Cyclin A2 ablation, where embryogenesis could not go over the blastula stage 
[24]. Lack of the Cyclin A partner Cdk2 did not appear to affect viability of the 
animals [25], likely due to the compensating role played by Cdk1 [26], whereas 
Cdk4/Cdk2 double knock-out resulted to be embryonic lethal [27]. Once these 
compensatory functions began to be appreciated, it appeared clear that only the 
generation of compound knock-out mice would have helped clarifying the 
overlapping roles of Cyclins and Cdks (for a review see [28]). 
Substantially, the same trend was observed upon ablation of individual Cyclin-
dependent kinase-inhibitors [28]. In all cases, with the notable exception of p57Kip2 
[29,30], lack of CKIs expression did not affect viability of the animals but, 
interestingly, rendered them prone to the development of cancer (reviewed in [28]).  
Analysis of human tumors revealed that the most common alterations affect 
controllers of the G1/S transition, encompassing overexpression of cyclins (D1 and 
E1) and CDKs (CDK4 and CDK6) as well as loss of CKI (INK4A, INK4B and 
KIP1). Genetic analysis showed that such alterations occurred at the chromosomal 
level, with frequent amplification of cyclin D1 or CDK4, translocation of CDK6 and 
deletions of INK4 genes. Cases of epigenetic inactivation of INK4 were also reported 
[31]. 
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3. MITOSIS 
Mitosis is a highly regulated process that ensures equal distribution of the duplicated 
genome to the daughter nuclei, thus allowing new generations of cells to inherit a 
complete set of genetic information. Mitosis comprises five phases consisting of 
prophase (initial chromosome condensation and nuclear envelope breakdown), pro-
metaphase (association of condensed chromatids with fibers of the mitotic spindle), 
metaphase (complete attachment of chromatids to spindle microtubules and 
congression to the metaphase plate), anaphase (sister-chromatid separation) and 
telophase (chromosome decondensation and reformation of the nuclear envelope), 
which is followed by cytokinesis. Accurate transmission of genetic information 
requires the mechanisms controlling entry, transition through, and exit from mitosis to 
operate with great precision. Since cancer is a disease characterized by uncontrolled 
proliferation, genomic instability and aneuploidy, deregulation of the mechanisms 
controlling cell division greatly enhances the chance of occurrence of a tumor. 
Checkpoints are control mechanisms that operate during progression through the cell 
cycle and are set in place to prevent transition from one phase to the next until certain 
conditions are satisfied [32]. Whereas the G1/S checkpoint is often lost in cancer cells 
as result of loss of p53 function, the checkpoints controlling the onset and the 
transition through mitosis are fully functional in every cell type so far examined [33]. 
The major point of control put in place prior to mitosis is the G2 checkpoint, whereas 
the spindle-assembly checkpoint operates during mitosis. The G2 checkpoint is in 
charge of controlling the completion of DNA replication as well as the status and the 
topology (i.e., catenation) of the duplicated genetic material. The mitotic checkpoint 
delays the metaphase-to-anaphase transition in response to improper kinetochore-
microtubule attachment and tension at the site of attachment. 
In the next sections we will dissect the mechanism of action of the checkpoints 
mentioned above and we will highlight the defects that contribute to tumorigenesis. 
 
3.1 The G2 checkpoint 
Definition of “G2 checkpoint” given here conglobates a number of control 
mechanisms that are put in place by the cell to ensure fidelity and accuracy of the 
steps preceding cell division and that are necessary to the correct execution of mitosis. 
Some of the pathways that we have grouped under the definition “G2-checkpoint” 
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have been proposed by others as genuine “checkpoints” per se. This tendency has led 
to the unnecessary proliferation of possible points of control during progression to 
mitosis. We will present evidence indicating that such pathways are rather 
“subroutines” of the same program. 
 
3.1.1 DNA damage  
Integrity of the genome is the first condition to the survival of all organisms. Damage 
to DNA is a continuous threat posed by the intrinsic inaccuracy of the DNA 
replication machinery, by the oxidative environment in which we live as well as by 
the genotoxic stress that is caused by inhaled cigarette smoke, ultraviolet light and 
dietary factors. In order to maintain genomic stability, a network of proteins has 
evolved with the function of sensing and repairing DNA damage. Processing of 
different lesions that result from the distinct mechanism of action of genotoxic agents 
is accompanied by the generation of signals that delay the onset of mitosis [34]. This 
is known as the DNA damage response (DDR) [35]. To the purpose of this 
discussion, we will examine how signals that originate at sites of DNA damage 
impinge onto the cell cycle machinery, and we refer the reader to specialized 
literature for an in-depth view of mechanism of DNA repair [36]. 
The upstream signaling components of the DDR pathway are ATM (Ataxia 
telengiectasia-mutated) and ATR (ATM- and Rad3-related), two members of the 
PI3K (phosphatidyl-inositol-3-OH kinase) family. The common view attributes to 
ATM the ability of detecting and coordinating initial processing of physical damage 
to DNA (particularly double strand breaks), whereas ATR is preferentially involved 
in the response to DNA replication stress [35]. However, since initial processing of 
damaged DNA leads to the generation of structures similar to those produced during 
DNA replication, concomitant activation of ATM and ATR has been reported at sites 
of damage [37]. ATM/ATR-dependent phosphorylation of the downstream 
checkpoint kinases 1 and 2 (CHK1 and CHK2) allows transducing in a rapid and 
consistent manner the damage signal to effector-proteins that control DNA repair, cell 
cycle progression and apoptosis [38]. As we learned from the scheme presented in 
Fig.1, the master regulator of the G2/M transition is CycB/CDK1. One branch of the 
DDR negatively regulates CycB/CDK1 through activation of the WEE1 kinase and 
inhibition of the CDC25 phosphatases. Briefly, signals from damaged DNA (as well 
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as from incomplete DNA replication) impinge on WEE1 through checkpoint kinases 
[39] and result in the phosphorylation of two negative sites in CDK1 ATP-binding 
domain, in a manner that blocks its catalytic activity (reviewed in [40]). In parallel, 
CHK1/CHK2 driven phosphorylation of CDC25C, the phosphatase responsible for 
dephosphorylation of the negative sites in CDK1 ATP-binging domain, leads to 14-3-
3-mediated nuclear export of the phosphatase [41,42], thus blocking its function. This 
two-pronged pathway [43], by converging on the same target, contributes to hold 
CDK1 in check for the time that DNA damage is being addressed. In addition to 
inhibition of CycB/CDK1, inactivation of other mitotic kinases operating upstream or 
in parallel to CycB/CDK1, like Aurora A [44] and the Polo-like kinase Plk1 [45], is 
an important determinant of the DNA damage-induced G2/M arrest (reviewed in 
[40]). 
 
 
 
Figure 2. The DNA damage response. 
DNA damage caused by genotoxic agents is initially detected by dedicated protein 
complexes (the sensors, grey ovals) that facilitate initial processing of the damage and 
recruitment of protein kinases of the PIKK family (ATM/ATR). The latter trigger a 
phosphorylation cascade that targets checkpoint kinases (CHK1/CHK2) as well as the 
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tumor suppressor p53 (not shown). CHK1- and CHK2-dependent phosphorylation of 
WEE1 and CDC25, as well as inactivation of Aurora-A leads to inhibition of CDK1 
and G2/M arrest (see text for details).  
 
 
The impact of a defective or loose DDR to the development of cancer is exemplified 
by a number of syndromes that, among the many dysfunctions presented by the 
patients affected by such syndromes, are characterized by cancer predisposition. This 
is the case of Ataxia telengiectasia (AT), a disorder caused by mutations of the gene 
encoding ATM [46] and Nijmegen Breakage Syndrome, where the NBS1 component 
of the MRE11-RAD50-NBS1 complex that is responsible for activation of ATM is 
deficient [47]. ATLD is a rare disorder caused by hypomorphic mutations of MRE11 
component of the MRN complex with patients displaying similar symptoms of AT 
patients [48]. Hypomorphic mutations in Artemis, a protein involved in the pathway 
addressing repair of double-strand breaks, lead to predisposition to lymphomas [49]. 
Mutation of the familial breast cancer genes BRCA1 or BRCA2, which are important 
mediators of signals in the DDR, predispose to breast and ovarian cancer [50]. 
Fanconi anemia is an multigenic autosomal recessive condition where patients display 
hypersensitivity to interstrand DNA crosslinks due to defects in the coordination of 
repair [51]. Fanconi patients display increased incidence of solid tumors as well as 
leukemia [52,53], Another autosomal recessive disease, Xeroderma pigmentosum 
(XP), is characterized by defective nucleotide excision repair (NER) of DNA damage 
caused by UV-radiation and the early onset of skin cancer [54]. Predisposition to 
sarcoma, breast cancer and brain tumors was described in Li-Fraumeni Syndrome 
patients, who carry inherited mutations in p53 and heterozygous germ line mutations 
of the CHK2 gene [55]. Bloom Syndrome patients carry mutations in the BLM gene 
that codes for a helicase necessary to the maintenance of genome stability [56]. BLM 
mutations increase the risk of colorectal cancer [57]. Germline defects in one of the 
four genes encoding for proteins that correct base mismatches in DNA (mismatch 
repair or MMR) lead to inactivation of this pathway and is the hallmark of hereditary 
non-polyposis colorectal cancer (HNPCC) [58]. 
Over-expression of essential mitotic kinases was proposed to result in facilitated 
bypass of the DNA damage-induced G2/M checkpoint and, in turn, to promote 
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tumorigenesis. This is the case of NEK2 [59], a kinase that regulates centrosome 
separation [60], PLK1 [61], a kinase that controls centrosome maturation and the 
activity of the APC/C among other multiple aspects of mitosis [40] and Aurora A [62-
64], a kinase that controls ploidy [40]. 
In conclusion, defects in the pathways responsible for DNA damage recognition, 
DNA repair as well as the associated signaling, lead to the development of cancer. 
The latter appears to be a consequence of the fact that mutations in key components of 
such pathways impair the ability of cells to arrest before division, thus allowing the 
progressive accumulation of damage in the genome. 
 
3.1.2 DNA decatenation  
Catenations in DNA typically arise after replication or occur accidentally during 
interphase. Resolving entanglements is absolutely essential to prevent chromosomal 
missegregations and aneuploidy. This process, known as decatenation, is mediated by 
topoisomerases of the class II subtype that, in a two-step reaction, cleave and re-close 
pairs of complementary DNA strands before the onset of mitosis [65]. Failure to 
decatenate chromatids prevents entry into mitosis until DNA entanglements have 
been resolved [66]. Whether this triggers a checkpoint is controversial, since cells 
normally reach mitosis with chromatids still entangled at the centromeric region [67]. 
Early studies suggested the decatenation checkpoint to be distinct from the G2 DNA 
damage checkpoint [66]. Such conclusion was based on the comparison of the effects 
of catalytic inhibitors (ICRF-193) and classic poisons of topoisomerase II (etoposide). 
Whereas the former inhibit different steps of the catalytic process of DNA incision, as 
for instance the intrinsic ATPase activity of topoisomerase II, thus sequestering the 
enzyme from turnover [68,69], the latter bind and stabilize the enzyme-DNA 
complex, thus exposing cleaved double-strand ends [69]. In the case of topoisomerase 
II poisons, it was observed that the massive amount of DNA damage produced by 
these compounds resulted in a strong activation of the ATM pathway [70]. On the 
contrary, the mitotic delay caused by catalytic inhibitors of topoisomerase II was 
initially shown to be ATM-independent, although it appeared to require ATR and 
BRCA1 [71]. Recently, however, a reassessment of this issue led to the conclusion 
that ICRF-193 induces ATM activation in human lung cancer cell lines [72] and this 
is accompanied by a fully-fledged DNA damage response [73].  
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In addition to the involvement of ATR, evidence that the RecQ helicase Werner 
(WRN) is also implicated in the decatenation checkpoint was derived from the 
observation that in the absence of a functional helicase, cells do not undergo mitotic 
delay in response to catalytic inhibitors of topoisomerase II [74].  
Just like the failure of other checkpoints in the cell promotes carcinogenesis, loss of 
the mechanism controlling DNA decatenation is another major route to development 
of cancer [72,75].  
 
3.2 The mitotic checkpoint 
3.2.1 Microtubule network  
Drugs targeting the microtubule network, such as nocodazole or taxol, affect 
processes that occur at the onset of mitosis like centrosome separation, alignment of 
chromosomes on the metaphase plate and separation of the sister chromatids at 
anaphase. This is associated with induction of stress responses in the cell.  
The early-mitotic checkpoint, also known as Chfr-checkpoint (Checkpoint-protein 
with FHA and Ring-finger domain), operates in late G2. This pathway was initially 
described to selectively monitor the extent of centrosome separation [76], an event 
required for the formation of a bipolar mitotic spindle. However, selective inhibitors 
of centrosome separation that do not affect the overall architecture of the microtubule 
network, like monastrol [77], do not trigger the Chfr-checkpoint. Therefore, lack of 
centrosome separation is likely not the specific trigger of this pathway, which rather 
responds to perturbation of the microtubule network architecture. 
The Chfr protein is a ubiquitin ligase that ubiquitinates PLK1 [78] and Aurora-A [79] 
thus blocking the cascade of events that result in CDK1 activation. Homozygous and 
heterozygous Chfr-knockout mice develop spontaneous and carcinogen-induced 
tumors, indicating that Chfr is a genuine tumor suppressor gene [79]. Moreover, cells 
derived from Chfr-null mice display aneuploidy, chromosomal segregation defects 
and cytokinesis failure [79]. The CHFR gene was found to be frequently inactivated 
in human cancers due to aberrant hypermethylation of the promoter [80,81]. 
 
3.2.2 Spindle Assembly  
The Spindle Assembly Checkpoint (SAC) pathway includes three classes of proteins: 
Mitotic-Arrest Deficient (MAD), Budding Uninhibited by Benzimidazole (BUB) and  
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Monopolar Spindle (MPS). The corresponding genes (MAD1, MAD2 and MAD3; 
BUB1 and BUB3 and MPS1) were identified in mutants of the budding yeast S. 
cerevisiae that were unable to arrest in mitosis in the presence of spindle poisons 
[82,83] (for a detailed description of the SAC pathway see [84]). Spindle poisons are 
drugs currently used in chemotherapy that either stabilize microtubules by directly 
binding to tubulin (taxanes and colchicine), thus preventing microtubule 
polymerization, or facilitate microtubules depolymerization (nocodazole), thereby 
preventing the formation of correct bipolar spindles. In the presence of spindle 
poisons, SAC proteins act to prevent entry and progression through mitosis. To 
understand this mechanism, we will take a short digression and explain the cascade of 
events that trigger anaphase. 
In an unperturbed mitosis, SAC proteins are sequentially recruited to kinetochores of 
unattached chromosomes [85]. This results in the formation of the so-called Mitotic 
Checkpoint Complex (MCC) that includes the two complexes MAD1/MAD2 and 
BUB3/BUB-R1 (BUB-R1 being the human orthologue of S. cerevisiae Mad3). Both 
complexes are able to bind CDC20 and in this manner prevent its interaction with the 
APC/Cyclosome, a multi-subunit E3-ligase that initiates the degradation of CYC-B 
and securin. Upon stable attachment of all kinetochores to microtubules that have 
nucleated from opposite centrosomes (a phenomenon named bi-orientation), CDC20 
is released from MCC and binds to APC/C. APC/C-dependent destruction of CYC-B 
impairs the activity of CDK1, whereas degradation of securin releases separase. The 
latter initiates the proteolysis of cohesins, proteins that hold chromatids together, thus 
triggering the transition from metaphase to anaphase [86]. In the case of lack of 
proper kinetochore-microtubule attachment or lack of tension at the site of 
attachment, release of CDC20 from MCC is blocked [84]. Control of MCC formation 
as well as amplification of the SAC signal is orchestrated by the protein kinases 
MPS1, Aurora-B, MAPK, PLK1, CYC-B/CDK1 and NEK2. The role of Aurora-B is 
paradigmatic of the case of merotelic attachment (i.e., microtubules originating from 
opposite poles that make contact with a single sister kinetochore): in this setting, 
persistent Aurora-B activity leads to release of attachment, in a manner that likely 
depends on phosphorylation of MCAK (mitotic centromere-associated kinesin), a 
protein that is able to depolymerize microtubules [87-89]. This, in turn, causes release 
of tension and prevents anaphase. Aurora-B overexpression has been documented in a 
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number of human cancers [90] and a recently developed inhibitor selective to this 
kinase has confirmed Aurora-B as interesting target in cancer therapy [91]. 
The first indication that gene mutations affecting the spindle checkpoint may result in 
aneuploidy was derived from the comparison of cells displaying either microsatellite 
instability (MIN) or chromosomal instability (CIN). Whereas the former present a 
normal spindle assembly checkpoint, the latter do not. The authors showed that 
expression of either of the two naturally occurring BUB1 mutants converted the 
normal checkpoint status of MIN cells to the defective one of CIN cells [92]. A study 
on five families presenting mosaic variegated aneuploidy, a rare human disorder [93], 
established the causal connection between BUB1B biallelic mutations and CIN in 
humans. Animal studies showed that transient MAD2 over-expression is sufficient for 
the initiation of tumorigenesis through the promotion of aneuploidy [94]. 
Accordingly, MAD2 over-expression has been reported in a number of human 
cancers [95] and shown to correlate with poor prognosis [96,97].  
However, as shown for DNA damage, where the properties of genotoxic agents are 
exploited in therapeutic protocols despite the established link between DNA damage 
and mutagenesis [98], also in the case of the spindle checkpoint, processes conferring 
selective growth advantage to cancer cells may be their “Achilles’ heel”. In this 
respect, studies on human cancer cell lines have shown that suppression of the spindle 
assembly checkpoint, either through reduced expression of BUBR1 or MAD2 or 
through inhibition of BUBR1 kinase activity, was lethal due to massive chromosome 
loss [99]. This indicates that disabling SAC signaling is a feasible approach in 
anticancer therapy [100]. 
 
4. PERSPECTIVE  
The dogma that radiation eliminates cancer cells by triggering apoptosis has prompted 
studies on the mechanism of action of DNA-damaging agents and the search for 
radiomimetic drugs. This dogma has been recently challenged by observations on the 
behavior of cancers that develop in the human body. The essence of the challenging 
argument is that solid cancers are unlikely to retain the property to self-destruct by 
apoptosis because it is precisely through inactivation of the apoptotic machinery and 
promotion of aggressive vascularization that cancer cells manage to recover from 
latency and form solid tumors. This suggests that radiation and drugs that cause tumor 
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shrinkage in vivo must operate by mechanisms other than apoptosis. Indeed, 
oncologists and radiation biologists have observed that in tumors undergoing radio- or 
chemotherapy, cells die when they try to divide and, typically, daughter chromosomes 
break when they attempt to separate during mitosis [101]. For this reason significant 
effort in basic research and drug discovery programs is put to the elucidation of the 
checkpoint that tumors in the body and experimental systems, like cultured cancer 
cells, have in common: this is the G2/M checkpoint.  
It is believed that in the near future, treatment of cancer patients with a combination 
of tolerable dosages of conventional radio- or chemotherapy and selective drugs that 
inactivate the key cell cycle checkpoints will likely be the avenue to achieve clearance 
or at least shrinkage of solid tumors [33,100].  
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3. AIM OF MY THESIS PROJECT(S) 
 
3.1. AIM 1 
 
Aurora A (AurA) is a protein kinase required for entry into mitosis and for mitotic 
progression. It was previously shown in my lab and by others that AurA is a target of 
the G2 checkpoint. Exposing cells to DNA damage in G2 causes inhibition of the 
kinase in a Chk1 dependent manner resulting in a prolonged arrest of cells in G2 and 
delay in mitotic entry. Reintroducing the WT but not the KD AurA mutant allowed 
cells to enter mitosis by reactivation of Cdk1. This study revealed that AurA is highly 
regulated by G2 DNA damage and placed AurA upstream of Cdk1.  
 
The aim of my project was to extend this study further to understand a) 
regulation of AurA in response to mitotic DNA damage and b) study the fate of 
execution of mitosis after DNA damage. 
 
3.2. AIM 2 
 
The process of mitosis has been studied for more than two decades and still many 
secrets are yet to be revealed. AurA is just one of those many known (and unknown) 
proteins that ensure fidelity of mitosis. Many novel proteins are constantly being 
discovered that broaden our current view of these processes.  
 
My second project aimed to identify novel interactors of AurA by mass 
spectrometry in order to gain a better understanding of the role of AurA during 
mitosis.  
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4. RESULTS 
 
PART 1 
 
Understanding the Mechanism of Regulation of 
Protein Kinase Aurora A in Response to Mitotic DNA 
Damage
Results Part 1 
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4.1. Mitotic DNA damage targets the Aurora A/TPX2 
complex 
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ABSTRACT 
 
We have previously shown that the DNA damage-induced G2 arrest is contributed by 
inhibition of Aurora A (AurA) and that transduction of active AurA into arrested cells 
allows bypassing the block through reactivation of CDK1. In this study, we 
investigated the mechanism of DNA damage-induced AurA inhibition. We provide 
evidence that ionizing radiation (IR) administered in mitosis, a time when AurA 
protein and enzymatic activity reach peak levels, impairs interaction with the partner 
TPX2, leading to inactivation of the kinase through dephosphorylation of AurA T-
loop residue, T288. We find that decreased AurA-TPX2 complex formation in response 
to irradiation results from reduced cellular levels of TPX2, an effect that is both 
contributed by increased APC/CDH1-dependent protein degradation and decreased 
translation of TPX2 mRNA. 
 
 
  
Keywords: Aurora A, DNA damage, mitosis, TPX2, translation 
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INTRODUCTION 
 
The genetic information contained in DNA is duplicated and faithfully segregated into 
daughter cells during a cycle of cell division. Errors in DNA replication or in the 
repair of damaged DNA underlie the process of carcinogenesis.1 In normal cells, the 
status of DNA is continuously monitored by a myriad of proteins that are able to 
recognize distinct types of damage and address their repair. In parallel to repair, cells 
mount a response that slows down or arrests the cell cycle through the activation of 
signaling pathways impinging on cell cycle controllers.2  
In response to incomplete DNA replication or DNA damage occurring in G2, 
progression to mitosis is arrested in an ATM/ATR-dependent manner.2 In antephase, 
a time spanning from the conclusion of G2 to the initiation of chromosome 
condensation,3,4 cells respond to DNA damage5 or microtubule poisons6 through the 
activation of a checkpoint that is not mediated by PI-3K-like kinases. The execution 
of this checkpoint instead, depends on two proteins, the CHFR E3 ligase7 and the p38 
MAPK.8 Cells containing a wild-type antephase checkpoint undergo chromosome 
decondensation and revert to a G2-like state,5 whereas cells lacking a functional 
CHFR progress into mitosis.9 Damage occurring upon completion of antephase does 
not normally cause reversion to an early stage of the cell cycle but rather triggers 
mitotic arrest through activation of the spindle assembly checkpoint (SAC),10,11 
though exceptions have been reported.12 Contrary to mammalian cells, mitotic DNA 
damage in X. laevis and DT40 cells prevents spindle assembly in an ATM/ATR-
dependent manner.13 This was proposed as an additional pathway monitoring 
chromosome breaks that have escaped the G2/M checkpoint. 
The Auroras are mitotic kinases first identified in yeast and Drosophila as regulators 
of centrosome separation, bipolar spindle formation, chromosome segregation and 
cytokinesis.14 Three human Aurora genes have been described, namely Aurora A, B 
and C. Aurora A (AurA) protein level and kinase activity peak at G2 and remain high 
throughout mitosis.15,16 The timing and extent of AurA activation is controlled by 
interaction with a variety of proteins. Interaction with protein phosphatase 1 (PP1) 
results in the reciprocal control of enzymatic activity,17 whereas binding to Bora in 
G218 supports AurA activation. Accordingly, depletion of Bora causes insufficient 
AurA activation and multiple spindle defects.19 The PLK1-dependent degradation of 
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Bora, which is mediated by the βTrCP ubiquitin ligase,19 facilitates full AurA 
activation in mitosis through interaction with TPX2,20 an event that is contributed by 
PLK1-mediated TPX2 phosphorylation.21 Interaction with TPX2 maintains the kinase 
in an active conformation by protecting the T-loop site T288 from 
dephosphorylation.20,22 Another important component of the machinery controlling 
AurA activation seem to be the focal adhesion protein HEF1, which interacts with the 
centrosomal kinases AurA and Nek2 and supports their activation.23 Finally, the 
protein kinase PAK, which localizes to centrosomes in mitosis, has been reported to 
phosphorylate and activate AurA.24 
 
To identify the molecular mechanism of AurA inhibition in response to genotoxic 
stress, we examined the effect of IR on mitotic cells, where AurA protein level and 
enzymatic activity is maximal. We found that IR led to a reduction of AurA/TPX2 
complex. This was the result of decreased TPX2 protein expression, depending on 
both accelerated protein degradation as well as failure to recruit TPX2 mRNA to 
actively translating polysomes. As a consequence, deprotection of AurA T-loop site 
T288 caused its rapid dephosphorylation. Although cells succeeded in completing 
mitosis under these conditions, they displayed severe chromosome segregation 
defects. 
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RESULTS 
 
Inhibition of Aurora A kinase activity in response to mitotic DNA damage 
We initially decided to examine the effect of DNA damage on AurA during transition 
through mitosis. Using HeLa cells synchronized by double-thymidine block (DTB) 
release (Fig. S1A and S1B), we observed that AurA protein reached highest levels in 
mitosis (9-10h), in a manner similar to that observed for Cyclin B1 (Fig. 1A).16 
Furthermore, TPX2 appeared to be maximally expressed in mitosis (Fig. 1A). The 
enzymatic activity of AurA, measured using a model peptide substrate,25 followed the 
pattern of protein expression, reaching a peak of activity when the expression of the 
activating partner TPX2 was maximal (Fig. S1C).  
To assess the effect of genotoxic damage on mitotic AurA, synchronized cells were 
treated with nocodazole (200 ng/ml, 7h) and irradiated (9 Gy, 10h). Flow cytometric 
analysis showed that nocodazole effectively maintained cells in mitosis for the 
duration of the experiment (Fig. S1D). Despite the forced permanence in mitosis, IR 
caused a decrease in AurA kinase activity, as indicated by dephosphorylation of the 
T-loop site T288 (Fig. 1B, 12h-14h).25-27 Under such conditions, AurA protein levels 
remained unchanged at the time points examined.  
 
Mitotic DNA damage does not affect the completion of mitosis 
In response to mitotic DNA damage, we observed rapid loss of the H3-pS10 signal 
(Fig. 2A), indicative of chromatin decondensation. This could result from either 
reversal to a G2-like state or a premature exit from mitosis. To distinguish between 
these two possibilities, we examined a number of parameters. Flow cytometric 
analysis of the cell cycle distribution did not show any significant differences between 
control and irradiated cells (Fig. S2A). CDK1 phosphorylation at the inhibitory site 
Y15, which is high in G2 cells (Fig. S2B, S2C), displayed a similar time-dependent 
decrease in untreated and irradiated cells (Fig. 2B), although it was incomplete in the 
latter. Time-lapse microscopy showed that cells in metaphase at the time of irradiation 
or 1h post-irradiation were equally able to complete mitotic division (Fig. S2D). 
Finally, we quantified early (pro- and metaphase) and late (ana- and telophase) 
mitotic figures in control or irradiated cells (Fig. 2C). Although at 1h post-irradiation 
the proportion of early vs. late mitotic figures was inverted as compared to controls, 
Results Part 1 
109	  
likely due to the decreased entry into mitosis of cells that received irradiation while 
still at the G2/M transition, late mitotic figures were detectable at this time point. This 
indicates that irradiation during mitosis does not cause reversion to a G2-like state. 
To assess the quality of the mitosis executed by irradiated cells, we stained DNA with 
DAPI. We found a significant increase in misaligned metaphase chromosomes after 
IR, as well as chromosome bridges and lagging chromosomes in anaphase (Fig. S3A-
C). We also noticed that after cytokinesis, lagging chromosomes led to the formation 
of micronuclei to a significantly larger extent in irradiated cells as compared to 
controls (Fig. S3D-E). Taken together, these data confirm previous findings10 and 
show that, although cells are able to complete mitosis with damaged DNA, this leads 
to increased chromosome segregation defects. 
 
Mitotic damage affects TPX2 protein level and Aurora A/TPX2 complex 
formation 
Binding of TPX2 exerts a double effect on AurA: it stretches its activation segment in 
a way that makes AurA competent to bind substrates and it additionally protects the 
T-loop site T28822 from PP1-dependent dephosphorylation.28 Considering this, we 
asked whether the observed IR-induced loss of phosphorylation at T288 (Fig. 1B) was 
dependent upon the release of TPX2 and consequent deprotection of the AurA T-loop 
site. To this end, we first examined whether PP1 is activated by mitotic DNA damage, 
monitoring the extent of phosphorylation at the inhibitory site T320;29 
dephosphorylation at this site is closely associated with activation of PP1. In 
synchronized cells, CDK1-dependent phosphorylation of T320 was maximal at 10h 
post-release (Fig. S4). Irradiation of mitotic cells caused an almost complete 
dephosphorylation of T320 within 1h, indicative of PP1 activation, which coincided 
with a rapid decrease in TPX2 levels (Fig. 3A). On the other hand, CycB1 appeared to 
be degraded less efficiently in irradiated cells as compared to control cells (Fig. 3A). 
A similar pattern of PP1 activation was observed in double-thymidine synchronized 
cells treated with nocodazole at 7h and irradiated at 10h post-release (Fig. 3b). In this 
setting and relative to control cells, the level of TPX2 protein was clearly decreased 
1h after administration of IR, with the effect more pronounced at subsequent time 
points; the level of AurA and Cyclin B1 remained unchanged at these later times (Fig. 
3B). In agreement with the finding that a lower amount of TPX2 was present upon 
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DNA damage (Fig. 3B, 12h IR), immunoprecipitation of AurA from nocodazole-
arrested cells showed that the amount of AurA-bound TPX2 was decreased upon 
irradiation (Fig. 3C, 12h IR). 
 
Effect of mitotic damage on TPX2 protein stability 
Considering that TPX2 is normally degraded at mitotic exit by APC/C in a CDH1-
dependent manner30 and that DNA damage causes premature activation of CDH1 in 
G2,31 we asked whether the rapid decrease in TPX2 level that we observed upon 
irradiation of mitotic cells reflected an untimely activation of CDH1. RNAi-mediated 
CDH1 downregulation (Fig. 4A) led to an evident rescue of TPX2 protein levels in 
irradiated and control cells (Fig. 4B). This was also the case for another CDH1 target, 
namely AurA (Fig. S5). To substantiate these data and confirm the ubiquitination-
dependent degradation of TPX2, synchronized cells were irradiated in mitosis and 
treated with the proteasome inhibitor MG-132 15 min after irradiation. Analysis of 
cells extracts by SDS-PAGE showed that the presence of MG-132 led to a significant 
rescue of TPX2 levels (Fig. 4C). 
Among the possible reasons for rapid changes in protein level is an increase in the 
rate of proteolytic degradation. To assess whether this was the case for TPX2, we 
determined its half-life (T1/2) in control and IR-treated mitotic cells. The data showed 
an accelerated degradation of TPX2, which was only evident at early time points (Fig. 
5A-B). 
Taken together, this data show that, although premature activation of the APC/C-
CDH1 by irradiation may affect the initial rate of TPX2 degradation, effects on 
protein stability are likely not sufficient to fully explain the effect of IR on steady 
state levels of TPX2 protein.   
 
TPX2 expression is not affected by mitotic DNA damage 
The observations above led us to ask whether transcriptional effects may have a role 
in the response of TPX2 to IR. To this end, we quantified TPX2 mRNA by real-time 
quantitative PCR. Analysis of samples showed no difference (11h) or a small decrease 
(12h) in TPX2 mRNA levels in IR treated cells as compared to control cells (Fig. 
6A); such small effects at 12h following IR were not observed for AurA mRNA (Fig. 
6B). In contrast, the level of CycB1 mRNA appeared to be increased by DNA damage 
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at both time points examined (Fig. 6C). The transcriptional response to IR displayed 
by AurA and CycB1 closely matched the pattern of protein expression observed by 
Western blotting (Fig. 3A). In contrast, the large difference between the pattern of 
TPX2 mRNA and protein expression and steady state protein levels suggested a post-
transcriptional mode of regulation in this case. 
Since IR did not apparently affect the stability of TPX2 mRNA (Fig. 6A), we 
analyzed the proportion of TPX2 mRNA actively associated with polysomes and 
hence being used for translation. Upon fractionation of ribosomes on sucrose 
gradients, we observed that TPX2 mRNA was less efficiently recruited to polysomes 
in DNA-damaged cells as compared to non-irradiated controls (Fig. 6D). This 
indicates that the translation of TPX2 mRNA is likely hindered upon irradiation of 
mitotic cells. 
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DISCUSSION 
 
DNA damage-induced arrest at the G2/M transition of the cell cycle is contributed by 
inhibition of CDK1 as well as other mitotic kinases.32 We have previously shown that 
AurA, which controls ploidy by ensuring spindle bi-polarity,33 is inhibited in response 
to the generation of double strand breaks in G2.16  
In the present study we addressed the molecular mechanism by which DNA damage 
response pathways restrain AurA activity. To this end, we decided to examine cells 
transiting through mitosis, the time of maximal AurA activation. To correctly 
interpret the cellular response observed, we first addressed how genotoxic stress 
affects transition through mitosis. Separate lines of evidence derived from flow 
cytometry, analysis of phosphorylation of the CDK1 inhibitory site Y15 and, 
particularly, time-course visual scoring of cells, demonstrated that the molecular 
events examined in our study were not attributable to a DNA damage-induced 
reversion to a G2-like state. The data showed that irradiated mitotic cells were able to 
transit through mitosis, in accordance with previous studies.10 These cells, however, 
showed significantly higher chromosome segregation defects followed by the 
formation of micronuclei.  
In cells synchronized with nocodazole, which allowed maintaining constant levels of 
AurA during the course of the experiment, we observed a DNA damage-dependent 
inhibition of AurA activity, as visualized by dephosphorylation of the activating T-
loop site T288.25,26 In most kinases, phosphorylation of the T-loop site is of key 
importance for supporting enzymatic activity.32,34 The concomitant rapid activation of 
PP1 observed in irradiated cells led us to hypothesize an involvement of TPX2 in the 
mechanism of AurA inhibition by DNA damage. This reasoning was based on 
published evidence according to which physical interaction between AurA and TPX2 
not only facilitates activation of the kinase22 but additionally protects the T-loop site 
T288 of activated AurA from dephosphorylation by PP1.28 In support to our hypothesis, 
we could demonstrate that dephosphorylation of T288 in irradiated cells correlated with 
a decreased amount of TPX2 detectable in AurA immunocomplexes. Western blot 
analysis carried out at time points subsequent to irradiation revealed that the overall 
level of TPX2 was lower in irradiated than in control cells. This was particularly 
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evident upon nocodazole treatment, thus evidencing the net effect of DNA damage 
over pathways normally activated at mitosis.  
We found that the fast degradation of TPX2 in response to IR occurred in an APC/C-
CDH1-dependent manner. Published evidence indicates that DNA damage in the G2 
phase of the cell cycle leads to premature APC/C-CDH1 activation.31 Our 
observations on the degradation of TPX2 show that also mitotic DNA damage may 
lead to unscheduled activation of CDH1. The fact that AurA was not degraded under 
these conditions may be explained by the finding that degradation of CDH1 targets 
occurs in a sequential manner depending on their extent of ubiquitination.35 Premature 
activation of CDH1 is also supported by the decreased rate of CycB1 degradation that 
we observed upon irradiation, an event that is likely the consequence of CDH1-
dependent inactivation of CDC20, in addition to IR-dependent increase of CycB1 
mRNA level. The amount of CycB1 remaining upon irradiation did not, however, 
hinder the completion of mitosis by causing reversion to a G2-like state. Indeed, it 
was recently shown that, although the proteolysis of CycB1 is necessary for mitotic 
exit,36 graded levels of mitotic cyclins delay, but do not block, mitotic exit in a dose-
dependent manner.37 
A careful evaluation of the rate of TPX2 degradation revealed an initial rapid decrease 
of the protein's half-life in response to damage. We reasoned, however, that this could 
not entirely account for the effect of IR on the level of TPX2 in the cell. Upon 
examination of possible effects of DNA damage on mRNA, we observed that the 
overall level of TPX2 mRNA did not vary in response to ionizing radiation, indicating 
that changes in mRNA stability were also to be ruled out as explanation for the 
diminished overall level of TPX2 protein.  
In addition to the mere stability of mRNA, other mechanisms contribute to control 
translation. It is known that in response to hormonal stimulation of oocyte maturation 
in Xenopus, translationally quiescent mRNAs coding for regulators of the meiotic 
division undergo first elongation of their short poly(A) tails and, subsequently, 
translation.38 In general, poly(A) tail elongation facilitates translation, whereas 
shortening or removal of poly(A) tails correlate with silencing.39 It is also established 
that ribosomes are tightly associated with microtubules and that localized translation 
of a conserved group of mRNAs enriched on microtubules plays an important role at 
the onset of mitosis.40 Among these is the mRNA coding for TPX2.41 Considering that 
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poly(A) tail elongation in Xenopus42 and mammalian cells43 was shown to depend on 
phosphorylation events catalyzed by AurA, it is conceivable that the DNA damage-
dependent inhibition of AurA activity observed in our study may result in decreased 
polyadenylation of mRNAs coding for mitotic regulators. Interestingly and in support 
to this reasoning, we found that DNA damage hampered the recruitment of TPX2 
mRNA on polysomes, the actively translating population of ribosomes. Poly(A) tail-
binding protein (PABP) along with its interacting partner eIF4G has been reported to 
displace the inhibitory protein eIF4E-BP1 from eIF4E, and in such manner favor cap-
dependent mRNA translation.44 Based on our data we hypothesize that decreased 
polyadenylation may be the cause of reduced recruitment of TPX2 mRNA on 
polysomes. Further work will be required to address this possibility. 
Along this line of speculation, it is conceivable that CDK1 may also play a role in the 
control of TPX2 mRNA translation. High CDK1 activity was reported to promote 
recruitment to polysomes of mRNAs coding for mitotic regulators, at least in sea 
urchins.45 Whether also the recruitment of TPX2 mRNA is controlled in this manner 
was not assessed by the authors, though the DNA damage-dependent inhibition of 
CDK1 activity in mitosis,12 indirectly observed in our study by activation of PP1, 
would support such possibility. On the other hand, the previously reported inhibition 
of general translation mediated by phosphorylation of eIF2-alpha upon UV damage,46 
a mechanism that was recently claimed to reduce Cdc25B mRNA translation,47 cannot 
be invoked to explain our results. We observed a selective effect of IR on the 
translation of TPX2 mRNA and the resulting protein but not a general inhibition of 
translation, as evidenced by unvaried protein level of other mitotic players such as 
AurA or CycB1. 
 
In conclusion, this study exposes the molecular mechanism that controls AurA in 
response to genotoxic damage. The data show that irradiation of cells during mitosis 
leads to inhibition of AurA activity through failed association with its partner TPX2, 
leading to dephosphorylation of the AurA T-loop site T288. Degradation of TPX2 
through APC/C-CDH1 ubiquitination partially contributes to reduce TPX2 protein 
level in the initial phases of the response to DNA damage. Additionally, we observed 
a selective inhibition of TPX2 mRNA loading on polysomes in response to IR. 
Considering that each ribosome on the polysome is actively engaged in producing 
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TPX2 polypeptide, the reduced loading of TPX2 mRNA on polysomes, along with 
the rapid protein degradation, probably explains the effects of IR on steady state 
levels of TPX2 protein. In turn, failed replenishment of the rapidly turning-over TPX2 
pool leads to PP1 dependent dephosphorylation and inactivation of AurA.  
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MATERIALS AND METHODS 
 
Antibodies and chemicals 
The following antibodies were used: AurA (Pab 35, purified rabbit polyclonal; 35C1, 
mouse monoclonal16); AurA-pT288 (Biosource; rabbit polyclonal); TPX2 (GenWay, 
mouse monoclonal); PP1 (Santa Cruz Biotech., mouse monoclonal); PP1-pT320 (Cell 
Signaling Tech., rabbit polyclonal); H3-pS10 (Millipore; rabbit polyclonal); Cyclin B1 
(Upstate Biotech. Inc., mouse monoclonal); MSH2 (Santa Cruz Biotech., rabbit 
polyclonal sc-494); CDK1-pY15 (Cell Signaling Tech., rabbit polyclonal); CDH1 
(Santa Cruz Biotech., mouse monoclonal sc-56312); CHK2-pT68 (Santa Cruz 
Biotech., rabbit polyclonal sc-16277-R); HRP-conjugated anti-mouse or anti-rabbit 
secondary antibodies (GE-Healthcare); Alexa Flour-488 and -594 conjugated 
secondary antibodies (Invitrogen).  
Thymidine (SynGen Inc.) was dissolved in PBS and filter-sterilized. Nocodazole 
(Sigma) and MG132 (Calbiochem) were dissolved in DMSO and stored in aliquots at 
-20 oC. Cycloheximide (CHX) (Calbiochem) was dissolved in ethanol and stored at -
20 oC. 
 
Cell culture and siRNA treatment 
HeLa cells were maintained and synchronized by a double-thymidine block (DTB) 
release as described.16 For RNAi experiments, cells were seeded in 6-cm dishes and 
immediately transfected with 10 nM CDH1 siRNA (Sigma) using the Lipofectamin 
RNAiMAX reagent (Invitrogen) for 24h, followed by synchronization with DTB.  
 
Flow cytometry 
Cell cycle analysis by flow cytometry was performed upon propidium iodide (PI, 
Molecular Probes) staining of DNA as described.16 Cells were examined using a Dako 
CyAnTM ADP instrument and Summit software. 
Immunofluorescence 
Indirect immunofluorescence was performed with cells grown on glass cover slips. At 
indicated time points, cover slips were rinsed in PBS, fixed in 100% ice-cold 
methanol and stored at -20°C. Cover slips were blocked with 3% milk-PBS and 
gently shaken (15-20 min, RT). Overnight incubation with primary antibodies was 
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carried out in a wet chamber at 4°C. The next day, cover slips were washed twice in 
3% milk-PBS (10 min) with gentle shaking and probed with secondary antibodies (1h, 
RT in the dark).  Cover slips were finally washed twice with PBS (10 min), rinsed in 
ddH2O and mounted on Vecta-shield DAPI (Vector Labs) solution. Cells were 
observed with a Leica DMRB microscope equipped with a 100W HBO lamp for 
fluorescence. High-resolution pictures were taken with oil-immersion lenses (HCX 
PL APO 63X) and images were captured with a Leica DFC 360 FX camera. Images 
were obtained using the Leica Application Suite® software.  
 
Calculation of mitotic index 
Synchronized HeLa cells stained with DAPI and H3-pS10 polyclonal antibody were 
imaged with a Leica DMRB microscope as described above. At least 300 cells were 
counted for each time point from two independent experiments. H3-pS10 positive cells 
were considered as mitotic. Standard deviation was determined from the percent 
values of the two sets.  
 
Time-Lapse Microscopy 
HeLa cells were grown on 3.5-cm glass-bottom dishes (Mat Tek). Cells were imaged 
on an Olympus IX81 fluorescence microscope equipped with an external temperature 
control chamber and CO2 cylinder set to maintain the cells at 37°C with 5% CO2. 
Images were captured every 2 min using a CCD camera (Orca AG, Hamamatsu) 
using the cellR® software (Olympus).  
 
Western blotting, immunoprecipitation and kinase assay 
Whole-cell extracts (WCE) were prepared using a modified RIPA buffer (50 mM 
Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% Na-
deoxycholate, 0.1% SDS, 0.5 mM Na-orthovanadate, 0.1 mM phenylmethylsulfonil 
fluoride, 1 mM benzamidine) or immunoprecipitation (IP) buffer.16 For IP cells were 
lysed and proteins resolved as described.16 For kinase activity assay, 
immunoprecipitated proteins were additionally washed with 2x 1ml NEB3 buffer (50 
mM Tris-HCl, 10 mM MgCl2, 100 mM NaCl and 1 mM DTT) and assays performed 
as described.25  
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Polysome profiling and RT-PCR 
Cell pellets from a synchronized population of HeLa cells treated in the presence or 
the absence of IR were prepared as described.48 Total RNA was isolated from cell 
pellets using the GenEluteTM Mammalian Total RNA Kit (Sigma) and quantified 
using a spectrophotometer. RNA from the 80S or the polysome fractions was 
extracted with TRIzol-LS (Invitrogen) according to the manufacturer's instructions. 
cDNA was synthesized using SuperScript III reverse transcription (Invitrogen) from 1 
μg RNA. Target genes expression levels were determined by qPCR using a Fast 
EvaGreen master mix (Biotium) and with the following primer pairs:  
TPX2 Fwd: 5’-ATAGATTCATGGTTTGAGGAGAAG-3’  
TPX2 Rev: 5’-CTTTGTAGTAAGTGTTGTCAACTG-3’  
AurA Fwd: 5’-TCCAGGAGGACCACTCTCTG-3’   
AurA Rev: 5'-GGGAATGTGAATTCAACCCGTG-3' 
CycB1 Fwd: 5'-GAATGGACACCAACTCTACAAC-3' 
CycB1 Rev: 5'-TGACAGTCATGTGCTTTGTAAGTC-3' 
The house-keeping gene porphobilinogen deaminase (PBGD) was used as control and 
amplified with the following primers:  
Fwd: 5'-CAACGGCGGAAGAAAACAG-3’  
Rev: 5’-TCTCTCCAATCTTAGAGAGTG-3’. 
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FIGURE LEGENDS 
 
Figure 1 - Inhibition of AurA kinase activity in response to mitotic damage. 
(A) The expression of selected mitotic proteins in DTB-released HeLa cells was 
analyzed at the indicated time-points after release. AS: asynchronous. PP1 was used 
as loading control. 
(B) Western blot analysis of total (AurA) and active (AurA-pT288) AurA protein 
kinase in cells synchronized by the DTB-release method. CHK2-pT68 was used as 
read-out for the DNA damage response. 
 
Figure 2 - Irradiation of mitotic cells does not impair the completion of mitosis. 
(A) DTB-synchronized HeLa cells were irradiated (9 Gy) at 10h post-release and 
analyzed by Western blot at subsequent time-points for a mitotic marker (H3-pS10) 
and DNA damage response (CHK2-pT68). MSH2 was used as loading control. 
(B) DTB-synchronized HeLa cells left untreated or irradiated (9 Gy, 10h) were 
analyzed by immunofluorescence for dephosphorylation of Y15 in CDK1 as marker of 
mitotic entry. At least 200 events from 3 different fields per time-point were scored.  
(C) Quantification of early (pro- and metaphase) and late (ana- and telophase) mitotic 
events in control and irradiated cells. Three different fields from two independent 
experiments were counted for each time-point.  
 
Figure 3 - Effect of mitotic DNA damage on TPX2 protein level and AurA/TPX2 
complex formation. 
(A) DTB-synchronized HeLa cells were irradiated (9 Gy) at 10h post-release and 
analyzed by Western blot at subsequent time-points for PP1 activation 
(dephosphorylation of T320), the expression of mitotic markers (TPX2, AurA and 
CycB1) and the DNA damage response (CHK2-pT68). MSH2 was used as loading 
control. 
(B) DTB-synchronized HeLa cells were treated with nocodazole (200ng/ml) at 7h and 
irradiated (9 Gy) at 10h post-release. PP1 activation as well as the expression of 
mitotic markers (CycB1, AurA and H3-pS10), the level of TPX2 and the activation of 
the DNA damage response (CHK2-pT68) were analyzed by Western blot.  
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(C) AurA was immunoprecipitated from WCEs shown in b) using a purified 
polyclonal antibody. AurA and its partner TPX2 were revealed with specific 
monoclonal antibodies. IgG(H), stained with Ponceau Red, was used as loading 
control. 
 
Figure 4 - Mitotic damage affects TPX2 protein stability. 
(A) HeLa cells were transfected with a specific siRNA to CDH1 for 24h, DTB-
synchronized and either left untreated or irradiated (9 Gy) at 10h post-release. 
Expression of CDH1 was examined at the indicated time points. MSH2 was used as 
loading control. 
(B) Cells treated as in a) were examined for the rescued expression of TPX2 as well 
as for activation of the DNA damage response (CHK2-pT68) following irradiation. 
PP1 was used as loading control. 
(C) DTB-synchronized HeLa cells were irradiated (9 Gy) at 10h post-release and 
either left untreated or treated with MG-132 (10 mM) 15 min post-IR. The rescued 
expression of TPX2 and the activation of the DNA damage response (CHK2-pT68) 
were examined by Western blot. PP1 was used as loading control. 
 
Figure 5 - Effect of mitotic damage on TPX2 protein half-life. 
(A) CHX (10 mg/ml) was added to DTB-synchronized HeLa cells at the time of 
irradiation (9 Gy, 10h). The expression of TPX2 and the activation of the DNA 
damage response (CHK2-pT68) were examined at the indicated time-points. PP1 was 
used as loading control. One experiment representative of three independent 
determinations is shown. 
(B) TPX2 half-life was determined from quantification of the time-points shown in a) 
using ImageJ Analysis Software and PP1 as loading control. 
 
Figure 6 - Effect of damage on mRNAs encoding mitotic proteins and on the 
recruitment of TPX2 mRNA to polysomes. 
(A-C) Real-time PCR was performed at the indicated time points for quantification of 
TPX2, AurA and CycB1 mRNA obtained from control cells or cells treated with IR. 
(D) Real-time PCR was performed at the indicated time point to quantify the TPX2 
mRNA associated with the polysomal fraction (B) of a sucrose gradient. Data from 
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one of two independent experiments are shown. The fold-change over the TPX2 
mRNA associated with the 80S ribosome fraction (set to 1) is shown. 
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SUPPLEMENTARY MATERIAL TO: 
 
 
Mitotic DNA damage targets the Aurora A/TPX2 complex 
 
Payal Bhatia1, Mirco Menigatti1, Michele Brocard2, Simon Morley2 and Stefano 
Ferrari1,3 
 
 
 
 
SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure S1 - HeLa cells synchronization and AurA kinase activity. 
(A) Flow cytometric analysis of HeLa cells synchronized by the DTB-release protocol 
(see Material and Methods). DNA was stained with PI. 
(B) DTB-synchronized HeLa cells were released and fixed at the indicated time 
points. Staining with the H3-pS10 antibody was used to determine the mitotic index. 
At least 300 cells were counted for each time-point. Data from one of two 
representative experiments are shown. Green: H3-pS10; blue: DAPI. 
(C) Kinase activity assay for AurA immunoprecipitated from extracts of DTB-
released HeLa cells.  
(D) Flow cytometric analysis of HeLa cells synchronized by DTB-release, treated 
with nocodazole (200 ng/ml) at 7h and irradiated (9 Gy) at 10h post-release. DNA 
was stained with PI. 
 
Supplementary Figure S2 - Effect of IR on the transition through mitosis. 
(A) Flow cytometric analysis of HeLa cells synchronized by DTB and irradiated (9 
Gy) at 10h post-release. DNA was stained with PI. 
(B) CDK1 activation at mitosis in cells treated as in a) was determined by the pattern 
of dephosphorylation of the inhibitory site Y15. At least 200 cells were counted for 
each time-point. 
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(C) A representative field of the events plotted in b) is shown. Green: CDK1-pY15; 
blue: DAPI. 
(D) Live cell imaging of HeLa cells synchronized by DTB and irradiated (9 Gy) at 
10h post-release. Transition through mitosis was imaged for a period of 1h in cells 
examined at the time of irradiation (0h) or 1h upon irradiation (1h). 
 
Supplementary Figure S3 - Chromosome alignment and segregation defects caused 
by irradiation. 
(A) Misaligned (arrowheads) or lagging chromosomes (arrows) were scored in 
metaphases from control cells or cells treated with IR (9 Gy). At least 100 metaphases 
were counted from two independent experiments. DNA was stained with DAPI. 
(B-C) Statistical analysis of the events visualized in a). 
(D) Micronuclei (arrows) formed upon mitotic exit in control or IR-treated cells. At 
least 200 events were counted from two independent experiments. DNA was stained 
with DAPI. 
(E) Statistical analysis of the events visualized in d). 
 
Supplementary Figure S4 – Mitotic inactivation of PP1. 
Mitotic phosphorylation at the site T320 in PP1, indicative of inhibition of phosphatase 
activity, revealed by Western blot analysis of WCE obtained from DTB-released 
HeLa cells. 
 
Supplementary Figure S5 – Effect of CDH1 downregulation on AurA protein 
stability. 
HeLa cells were transfected with an siRNA specific to CDH1 for 24h, DTB-
synchronized and either left untreated or irradiated (9 Gy) at 10h post-release. 
Expression of AurA was examined at the indicated time point. MSH2 was used as 
loading control. 
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PART 2- UNPUBLISHED DATA 
 
Cell Cycle Progression Post DNA Damage Induced 
During Prometaphase  
(Continuation of 1st part of the results presented above) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results	  Part	  2	  
143	  
4.2 CELL CYCLE PROGRESSION POST DNA DAMAGE INDUCED 
DURING PROMETAPHASE 
 
AIM 
DNA damage induced in cells transiting through mitosis results in different cellular 
fates, such as cell cycle arrest or reversion to G2, depending upon the point at which 
damage is caused. Earlier reports have suggested that the cell cycle arrest observed in 
response to DNA damage in prometaphase is due to activation of spindle assembly 
checkpoint (SAC) (Choi and Lee, 2008), (Mikhailov et al., 2002). The aim of this part 
of my study was to clearly establish how cells respond to damage administered in 
prometaphase. As we observed that damage induced during metaphase does not 
impede cell cycle progression and that cells completed mitosis much like the control 
cells, although with marked increase in chromosomal abnormalities (see above), we 
decided to study the effect of damage during prometaphase to get a full picture of the 
DNA damage response in mitotic cells.  
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4.2.1. RESULTS  
 
4.2.1.1. DNA damage induced in mitotic cells generates double-stranded breaks 
(DSBs) 
 
In order to understand the effect of DNA damage on mitotic cells, we first examined 
whether damage induced by IR in synchronized mitotic cells resulted in the formation 
of DSBs. To this end, cells were synchronized with DTB followed by nocodazole and 
irradiated 2h before fixation for immunofluorescence. Nuclei were stained with γ-
H2AX antibody, to score for the presence of DSBs and H3-pS10 antibody, to identify 
mitotic cells. As shown in Fig.1, IR-induced damage resulted in the formation of 
DSBs (γ-H2AX foci) (Fig. 1B), which were absent in the non-irradiated control cells 
(Fig. 1A).   
 
Figure 1- IR administered in mitosis results in DNA damage induced DSBs. HeLa 
cells were synchronized with DTB and nocodazole (7h, 200 ng/ml) and either A) left 
untreated or B) treated with 9 Gy IR at 10h and analyzed at 12h. Blue: DAPI, Red: γ-
H2AX and Green: H3-pS10.  
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 4.2.1.2. DNA damage induced in nocodazole-arrested cells does not block cells in 
mitosis 
 
Previous studies have established that damage induced in nocodazole-treated cells 
result in either mitotic arrest, due to activation of the spindle assembly checkpoint 
(SAC) (Choi and Lee, 2008), (Mikhailov et al., 2002) or a reversion to G2-like state 
(Chow et al., 2003), upon removal of nocodazole. In order to establish the fate of 
mitotic cells in our experiments, namely to determine whether or not cells remain 
blocked in mitosis after DNA damage, we performed Western blotting and flow-
cytometry. Cells were synchronized with nocodazole and, immediately after releasing 
into fresh medium, damage was induced with IR (9 Gy) and analyzed at the indicated 
time points. As shown in Fig. 2A, probing with the mitotic marker H3-pS10 showed 
that cells were not apparently blocked in mitosis, since H3-pS10 phosphorylation 
disappeared with time, indicative of chromosome decondensation. DSBs induced 
upon administration of the topoisomerase-II inhibitor etoposide gave a similar result 
(Fig. 2B). In addition, as determined by flow-cytometry (Fig. 2C), we could confirm 
that cells progressed into the next cell cycle much like control cells, despite the 
presence of damage: should the cells have reverted to a G2-like state, the G2-M peak 
of damaged cells would have been higher as compared to the controls.  
 
To clearly distinguish mitotic exit from reversion of cells to G2, we performed time-
lapse imaging of cells. As shown in Fig. 2D, damaged cells appeared to exit mitosis 
without arresting or reverting to a G2-like state. These results indicated that DNA 
damage induced in mitosis does not cause cell cycle arrest and cells complete mitosis 
much like the controls.  
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Figure 2- Irradiation of mitotic cells does not impair completion of mitosis. A) HeLa 
cells were treated with nocodazole (200 ng/ml) for 14h, released into fresh medium 
and immediately treated with IR (9 Gy) and collected at the indicated time points. B) 
HeLa cells were treated with nocodazole (400 ng/ml) for 15h followed by a 1h 
treatment with etoposide (5 μM), released into fresh medium and collected at the 
indicated time points. C) Cells were treated as in b) and analyzed by flow-cytometry. 
DNA was stained with PI. D) Cells were synchronized by DTB and nocodazole (7h, 
200 ng/ml), left untreated or treated with IR at 10h (9 Gy) for 2h and imaged every 5 
min for 3h after release from nocodazole.  
 
 
4.2.1.3. Cell cycle progression occurs with increased chromosomal segregation 
defects  
 
As cells completed mitosis despite the presence of damage, we attempted to assess the 
status of the daughter cells that originated from a mitotic-irradiated mother cell. As 
shown in Fig. 3, synchronized and IR-treated HeLa cells stained with DAPI, H3-pS10 
and γ-H2AX showed the presence of chromosomal bridges and micronuclei. The 
DNA in the bridges appeared to be condensed chromatin, as seen by H3-pS10 staining. 
The micronuclei, in contrast, had decondensed DNA but retained the damage-induced 
γ-H2AX foci. This indicated that mitosis proceeded despite the presence of 
unrepaired damaged structures and resulted in severe chromosomal abnormalities.  
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Figure 3- Chromosome segregation defects caused by irradiation of mitotic cells. 
HeLa cells were synchronized as in Fig. 2D and fixed for immunofluorescence 3h 
post release. Arrows depict chromosome bridges and arrowhead depicts micronuclei. 
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4.2.2. DISCUSSION 
 
Mitotic DNA damage is known to have multiple effects on cell cycle progression. 
Some studies have shown that cells can revert to an interphase like state (Chow et al., 
2003) while others have suggested an arrest in mitosis due to SAC activation (Choi 
and Lee, 2008), (Mikhailov et al., 2002). We reassessed this issue by following cells 
that received DNA damage while being in mitosis and that were then released from 
the mitotic block. To this end, we used either a single nocodazole-treatment approach 
or a combination of synchronizing agents (DTB together with a brief nocodazole 
treatment). In particular, using the latter approach we obtained mitotic 
synchronization by nocodazole avoiding unwanted effects caused by prolonged 
treatment with the drug, such as mitotic slippage (Brito and Rieder, 2006). In the case 
of long nocodazole treatment (16h), the results of flow cytometry (Fig. 2C, Control) 
confirmed that cells were healthy. As a measure of the presence of DNA damage in 
condensed mitotic chromosomes, we relied on γ-H2AX foci formation. Both, the 
presence and persistence of these foci clearly indicated sensing of DNA damage and 
activation of the DNA damage response in mitotic cells (Fig. 1 and 3). However, 
despite the presence of DNA damage, cells were capable of exiting mitosis as judged 
by the loss of H3-pS10 signal (Fig. 2A, B) and the distribution of cells in different 
cell cycle phases, as indicated by the flow-cytometry profile (Fig. 2C). These data 
suggest that although mitotic cells sense DNA damage, they do not arrest or slow 
down transition through mitosis, possibly due to the reduced chance of repairing DNA 
in the highly condensed chromosomes. Much in accordance with our results, a recent 
study clearly showed that damage induced during mitosis is not addressed at this time 
of the cell cycle; rather, cells first complete mitosis, and then damage is repaired in 
the following G1. This is most likely due to impaired access of proteins to the break 
sites in highly condensed chromatin (Giunta et al., 2010). The persistence of γ-H2AX 
foci in newly divided cells seen here fully supports the above findings.  
 
As the damaged cells exited mitosis, we attempted to identify possible phenotypes 
caused by the persistence of unrepaired DNA structures. Interestingly, there was a 
dramatic increase in the percentage of cells with mis-segregated chromosomes, 
including lagging chromosomes at metaphase and the presence of DNA bridges at 
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anaphase; the latter remained even after the cells had decondensed their chromosomes 
and divided (Fig. 3). Also, the later time points analyzed showed an increased 
occurrence of micronuclei (Fig. 3). Micronuclei are known to be manifestations of the 
DNA that form the anaphase bridges and of the whole lagging chromosomes. In our 
experimental conditions, these chromosomal aberrations could either be a direct effect 
of DNA damage on the chromosomes or could be at least in part contributed by the 
loss of functional AurA-TPX2 complex (Results Part 1), suggesting a role of this 
complex in late mitotic events.  Further work, such as introduction of enzymatically 
active AurA in DNA damaged cells, would allow assessing whether this phenotype 
can be rescued and, in turn, would provide more insights into the function of the 
AurA-TPX2 complex in chromosome segregation and cytokinesis.   
 
Clearly, other important issues remain to be addressed, such as the destiny of daughter 
cells carrying gross chromosomal aberrations. It is conceivable that such cells would 
arrest in the next G1 in the attempt to repair the damage, or that they continue cycling 
at the expense of increased aneuploidy or, finally, that they undergo apoptosis. 
Although purely speculative, the first possibility seems to be the most unlikely: 
indeed, even if repair is attempted, it may not prove to be beneficial to aneuploid cells 
that contain micronuclei. On the other hand, the possibility that cells irradiated during 
mitosis may undergo apoptosis during the following cell cycle is an interesting 
concept for cancer therapy. Understanding the molecular mechanism that underlies 
this outcome would provide the rationale for clinical trials where combination of 
taxanes and radio-mimetic agents have been employed (Choy et al., 1998), (Milas et 
al., 1999), (Cmelak et al., 2007), a treatment that would be particularly suited in the 
case of resistance to taxol, as observed in AurA (Scharer et al., 2008), (Anand et al., 
2003) and TPX2 (Warner et al., 2009) overexpressing tumors.  
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4.2.3. CONCLUSIONS 
 
This part of the study shows that administering damage to mitotic cells does not cause 
cell cycle arrest, as previously suggested by others (Mikhailov et al., 2002), (Choi and 
Lee, 2008), (Chow et al., 2003). We report that cells are fully able to complete mitosis 
after irradiation-induced damage, albeit with severe chromosomal segregation defects. 
A similar observation was made when damage was induced in metaphase cells 
(Results section, Part 1).  
 
Taken together with the results presented in 1st part of this study, where we show that 
irradiation of mitotic cells results in reduced AurA kinase activity, we speculate that 
the chromosomal segregation defects observed in this second part of the study, where 
the outcome of mitotic cells irradiation was examined, is partially contributed to by 
the reduced functionality of the AurA-TPX2 complex. These results suggest that the 
possible connection between inhibition of AurA kinase activity and the appearance of 
chromosomal aberrations upon irradiation of taxol-treated cells should be explored for 
its practical implications in cancer therapy.       
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4.2.5. MATERIALS AND METHODS 
 
Antibodies and chemicals 
The following antibodies were used: PP1 (Santa Cruz Biotech., mouse monoclonal); 
H3-pS10 (Millipore; rabbit polyclonal), γ-H2AX (Millipore, mouse monoclonal) and 
MSH2 (Santa Cruz Biotech., rabbit polyclonal sc-494). 
Thymidine (SynGen) was dissolved in PBS and filter-sterilized. Nocodazole (Sigma) 
and etoposide (Alexis Biochem.) were dissolved in DMSO and stored in aliquots at -
20°C.  
 
Cell culture and synchronization  
HeLa cells were maintained in DMEM (GIBCO) supplemented with 5% fetal calf 
serum (FCS, GIBCO), penicillin (10,000 U/ml) and streptomycin (10,000 µg/ml) 
(GIBCO) at 37°C and 5% CO2. Cells were synchronized with double-thymidine block 
(DTB) release method. Briefly, cells were treated with 2 mM thymidine for 16h after 
24h of plating. Cells were washed twice with PBS and released for 8h in fresh 
medium followed by a 2nd thymidine treatment for 16h. Cells were released in fresh 
medium and nocodazole (200 ng/ml) was added 7h post-released followed by IR (9 
Gy) at 10h post-release. Cells were collected at indicated time points.  
HeLa cells were also synchronized by nocodazole alone. Briefly, cells were treated 
with 200 ng/ml nocodazole for 14h or 400 ng/ml nocodazole for 16h, 24h after 
plating. Cells were released from nocodazole block and immediately treated with IR 
and collected at the indicated time points. Where indicated cells were treated with 5 
µM etoposide for 1h before release into fresh medium. 
 
Western blotting  
Whole-cell extracts (WCE) were prepared using immunoprecipitation (IP) buffer (50 
mM Tris–HCl, pH 7.5, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 
mM Na-pyrophosphate, 0.5 mM Na-orthovanadate, 1 mM benzamidine, 0.1 mM 
PMSF, 1% Nonidet P-40).  Briefly, cells were washed with cold PBS twice and 
incubated in the lysis buffer on ice for 5 minutes and then scraped. Cleared lysates 
were obtained by centrifuging the tubes at 13,000 rpm for 15 minutes at 4°C. Samples 
were boiled in 1X Laemmeli-buffer (50 mM Tris-Cl pH-6.8, 100 mM DTT, 2% SDS, 
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0.1% BPB dye, 10% glycerol) at 95°C for 5 minutes before loading on SDS-PAGE 
gel.  
 
Time-lapse microscopy 
HeLa cells were grown on 3.5-cm glass-bottom dishes (Mat Tek). Cells were imaged 
on an Olympus IX81 fluorescence microscope equipped with an external temperature 
control chamber and CO2 cylinder set to maintain the cells at 37°C with 5% CO2. 
Images were captured every 5 min using a CCD camera (Orca AG, Hamamatsu) 
using the cellR® software (Olympus).  
 
Immunofluorescence 
Indirect immunofluorescence was performed with cells grown on glass coverslips. At 
indicated time points, coverslips were fixed in 100% ice-cold methanol and kept at -
20°C until processed. For blocking, coverslips were treated with 3% non-fat milk-
PBS solution (15-20 min) at RT with gentle shaking. This was followed by overnight 
treatment with the primary antibodies in a wet chamber at 4°C. The coverslips were 
washed twice in 3% non-fat milk-PBS (10 min) with shaking and probed with 
secondary antibodies (1h) at RT in dark.  Washings were done with PBS twice for (10 
min) with gentle shaking. The coverslips were then washed with Milli-Q water and 
mounted on Vecta-shield DAPI (Vector Labs) solution and sealed. Alexa Flour488 
and 594 conjugated secondary antibodies from Invitrogen were used at 1:1000 
dilution. Cells were observed with a Leica DMRB microscope equipped with a 100W 
HBO lamp for fluorescence. High-resolution pictures were taken with oil-immersion 
lenses (HCX PL APO 63X) and images were captured with a Leica DFC 360 FX 
camera. Merged images were obtained using the Image Overlay plugin of the Leica 
Application Suite® software. 
 
Flow Cytometry 
DNA analysis by PI staining was performed to determine the cell cycle distribution on 
samples collected before and after synchronization. Briefly, cells were trypsinized and 
resuspended in full medium, counted and transferred to a FACS tube. Cells were 
pelleted at 1500 rpm for 5 min and washed twice with PBS and fixed in 1ml ice-cold 
70% ethanol added drop wise with continuous mixing on a vortex mixer. Samples 
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were stored at 4°C until processed for analysis. For PI staining, 0.5 to 1×106 fixed 
cells were pelleted at 1500 rpm to remove ethanol and washed twice with PBS. Cells 
were resuspended in 500 µL PBS and treated with RNAse (100 μg/ml, Sigma) for 30 
min at RT. PI (20 μg/ml, Molecular Probes) was added and cells were left on ice in 
dark for 30 min prior to analysis. 10,000 events were acquired using Dako instrument 
and analyzed using the Summit software. 
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PART 3- ONGOING PROJECT 
 
Identification and Functional Evaluation of Novel 
Interacting Proteins of Aurora A  
(Project in collaboration with Dr. Dorothea Rutishauser and Dr. Bertran 
Gerrits, Functional Genomics Center, University of Zurich) 
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4.3. IDENTIFICATION AND FUNCTIONAL EVALUATION OF NOVEL 
INTERACTING PROTEINS OF AURORA A  
 
AIM 
AurA is an essential protein kinase required for a plethora of events taking place 
during the finely tuned process of mitosis. Till date many of its interacting proteins 
have been identified both from G2 and M-phase, thus enriching our understanding of 
the G2-M transition and mitotic entry. This part of my thesis was aimed at identifying 
a set of novel proteins that interact with AurA specifically during mitosis. These 
could either be substrates of AurA or proteins that act upstream to the kinase 
regulating its function and/or localization. The final goal was the elucidation of novel 
signaling pathways involving AurA, responsible for yet to be identified functions 
during mitosis. In addition, we reasoned that the newly identified proteins could be 
relevant elements of the process of tumorigenesis, as AurA is a potential oncogene.  
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4.3.1. RESULTS AND DISCUSSION 
 
We used mass-spectrometry (MS) to identify novel interacting partners of human 
AurA. Because AurA is regulated by direct interaction with p53, we chose MCF-7, a 
human breast cancer cell line as the model system that has a functional p53 status.  
 
The experiment was performed twice and selected results from both experiments are 
presented in the ‘Tables’ section. Both MS-experiments were carried out using the 
same extracts, the difference being, for the 1st experiment, extracts were not pre-
cleared with beads before IP was performed. Consequently, the list obtained 
contained many proteins non-specifically binding to the beads. The 2nd experiment 
was thus an improved version of the 1st one.  
 
4.3.1.1. IDENTIFICATION OF NEW INTERACTION PARTNERS OF 
AURORA A 
 
The following steps were performed: 
 
4.3.1.1.1. Synchronization of cells  
 
To obtain a mitotic population of cells, where both AurA kinase activity and protein 
level peak during the cell cycle, we carried out cell synchronization. Cdk1 is an 
important kinase required for entry into mitosis and blocking its activation results in 
arrest of cells in G2 phase. We employed an inhibitor, RO-3306, previously described 
to specifically inhibit Cdk1 and arrest cells at the G2-M boundary (Vassilev et al., 
2006). Following the treatment, cells were released into fresh medium without the 
drug and synchronization was tested at the indicated time points using flow-cytometry 
(Fig. 1A) and Western blotting approach (Fig. 1B). At 0h post-release we detected a 
reduced phosphorylation at T320 in PP1, a Cdk1 phosphosite (Wu et al., 2009), 
indicating inhibition of Cdk1. PP1 was phosphorylated again upon release from the 
inhibitor, indicating re-activation of Cdk1 and mitotic entry. Cells were purely mitotic 
approximately 15-30 min post-release with maximum level of AurA protein (and 
other mitotic proteins: TPX2 and cyclin B1) and highest level of PP1 and histone H3 
phosphorylations present (Fig. 1B). This synchronization approach, in addition, 
allowed us to detect microtubule interacting proteins as the spindles were kept intact, 
unlike those resulting from nocodazole treatment.  
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Figure 1- Synchronization of MCF-7 cells with RO-3306. A) MCF-7 cells were 
treated with 9 μM RO-3306 for 20h, released in fresh medium without the drug and 
harvested at indicated time points for flow-cytometry analysis. As: asynchronous, 
Noco: treatment with 400 ng/ml nocodazole for 16hrs, used as a positive control. B) 
WCE prepared from cells treated as in a) were run on SDS-PAGE gel and proteins 
were detected by Western blotting using specific antibodies.  
 
 
4.3.1.1.2. Immunoprecipitation of AurA and Silver Staining  
 
In order to identify novel interacting proteins, AurA was immunoprecipitated using a 
specific antibody from WCE of RO-3306 synchronized cells, as mentioned above. An 
equal amount of pre-immune serum was used for carrying out the control 
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immunoprecipitation (IP). Immunoprecipitates were run on an 8% SDS-PAGE gel 
and visualized using MS-compatible silver staining procedure as shown in Fig 2.  
 
 
 
 
Figure 2- Silver stained gel showing proteins seen after immunoprecipitation of AurA 
with pre-immune serum (Control) and specific antibody (Sample). Bands in the region 
marked with a bracket (between 200 kDa and 66 kDa) were excised from control and 
sample lanes and in-gel trypsinization was performed (see Materials and Methods).    
 
 
4.3.1.1.3. Proteins identified by mass-spectrometry  
 
Bands were carefully excised from the gel as described in Materials and Methods and 
further processed before injecting into the MS-instrument. The raw data obtained was 
used for performing a BLAST search against a human protein database (SwissProt) to 
identify the proteins. Table 1 shows a selection of proteins identified by the 2nd 
experiment that were considered most significant depending upon the number of 
unique peptides. Table 2 shows the most interesting mitotic proteins shortlisted from 
Table 1. Table 3 shows candidate proteins identified from the 1st MS-experiment 
(presented here using the same criterion like in Table 1). Table 4 lists proteins that 
were identified in both the screens. 
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4.3.1.2. SELECTION AND VALIDATION OF IDENTIFIED PROTEINS 
 
4.3.1.2.1. Primary Screening 
 
Of the list of proteins obtained, a primary selection was made based on three 
important criteria: first, number of unique peptides (Table 1) and proteins that 
appeared in both the screens (Table 4); second, relevance of identified proteins to cell 
cycle and mitosis; and third, novelty of the proteins. The preliminary screening 
strategy used to validate the selected candidates was to perform their downregulation 
in asynchronous cells using RNAi and identify any defects in mitotic entry and/or 
progression. We relied on two technical read-outs for this. First, flow-cytometric 
analysis was used to determine the distribution of cells in different phases of cell 
cycle after downregulation. Second, fluorescence microscopy was employed to 
visualize any mitotic defects arising due to downregulation. The following parameters 
were scored: defects in entry into mitosis, spindle defects (monopolar spindles, 
abnormal bipolar spindle apparatus), problems in chromosome compaction, alignment 
and segregation (misaligned metaphases, anaphase bridges) and defective cytokinesis 
(binucleate and multinucleate cells). Any defects observed would indicate a direct 
role of the protein in G2-M transition and/or in regulation of the mitotic process.  
 
The result of this primary screening is presented below. As a general rule, two siRNA 
oligonucleotides were tested for each target. Only oligonucleotides validated by the 
manufacturer (Qiagen) were used in single (AurA, Anillin and SIN3A).  
Stable HeLa cell line expressing mGFP-tubulin and mCherry-red-H2B plasmids was 
used for the primary screening experiments, referred to as HeLa* throughout this 
section.  
 
4.3.1.2.1.1. Effect of AurA downregulation on cell cycle progression 
 
4.3.1.2.1.1.1. As a control for the preliminary screening, we first analyzed the effect 
of loss of AurA on cell cycle progression and mitosis. AurA was downregulated in 
HeLa* cells and protein expression was examined by Western blotting 48h after 
transfection. The siRNA oligonucleotide used successfully downregulated AurA from 
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HeLa* cells (Fig. 3A). Next, the effect of AurA downregulation was tested by flow-
cytometry. As shown in Fig. 3B, a significant accumulation of cells in G2-M phase 
and increase in the percent of apoptotic cells (seen as the sub-G1 population indicated 
with an arrow) was observed when compared to the control. 
 
Upon direct visualization of cells by fluorescence microscopy, a significant increase 
in the percentage of mitotic cells (scored by counting cells with condensed 
chromosomes) was found (Fig. 3C, upper panel), indicating cell cycle arrest. In 
addition, most of the mitotic cells had defective centrosome separation (evident by 
increased occurrence of cells with monopoles) and showed lack of spindle bipolarity 
and normal spindle apparatus (Fig. 3C, lower panel). Also, there were defects in 
chromosome compaction and almost no metaphases were seen, indicating that cells 
were blocked from progressing further in mitosis. These results confirm published 
evidence and indicate that AurA is an essential kinase required for centrosome 
separation, formation of bipolar spindle and normal mitotic progression. We assumed 
that if a protein that interacts with AurA plays a role during mitosis, its 
downregulation might also result in similar phenotypes. 
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Figure 3- Effects of AurA downregulation. A) HeLa* cells were transfected with 10 
nM AurA siRNA oligonucleotide and analyzed by Western blotting 48h later. B) Cells 
were treated as in a) and fixed for flow-cytometric analysis. Ungated profiles are 
shown to evidence the presence of a sub-G1 population of cells upon RNAi treatment. 
C) Bar graph showing percent of mitotic and interphase cells in control and siRNA 
treated samples; fluorescence images showing mitotic figures from the same. 
 
 
4.3.1.2.1.1.2. We further tested the effect of AurA downregulation on cell cycle 
progression in synchronized cells. HeLa* cells were first transfected with AurA 
siRNA oligonucleotide and 24h later synchronized with a single thymidine block. 
Cells were analyzed by flow-cytometry at the indicated time points. As anticipated, 
cells with no siRNA were mitotic at 10h post release and started entering the 
subsequent G1 at 12h (Fig. 4A). In contrast, cells in which AurA was downregulated 
remained in G2-M even at 12h post release, indicating that cells were blocked from 
progressing further into mitosis. Also, the downregulation was toxic to the cells as 
there was a significant increase in apoptotic cells as compared to the control (Fig. 
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4B), confirming the data obtained from downregulation in asynchronous cells (Fig. 
3B). Together these results confirmed the previously established function of AurA in 
mitotic progression. 
 
 
 
 
 
Figure 4- Effect of AurA downregulation on synchronized cells. A) HeLa* cells 
were transfected with 10 nM AurA siRNA oligonucleotide and 24h later 2 mM 
thymidine was added to the cells for another 24h. Cells were released from the 
thymidine block into fresh medium and collected for flow-cytometry at indicated time 
points. B) Flow-cytometry profiles of a) were ungated to evidence the sub-G1 
population, shown with an arrow.   
 
 
4.3.1.2.1.2. Effect of downregulation of selected candidates 
 
The following proteins were shortlisted by the above-mentioned criteria and were 
tested by siRNA-mediated downregulation approach.  
 
4.3.1.2.1.2.1. SMARCA4 (SWI/SNF-related Matrix-associated Actin-dependent 
Regulator of Chromatin subfamily A member 4)/ BRG1 
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SMARCA4 is an ATPase associated with the SWI/SNF chromatin-remodeling 
complex. The protein is composed of several highly conserved domains (Fig. 5) and is 
an important regulator of transcription. 
 
 
 
Figure 5- Domain organization of SMARCA4. (Adapted from Trotter and Archer, 
2008) 
 
SMARCA4 has been associated with functions like transcriptional 
activation/repression, DNA repair, replication and recombination as it is a part of a 
number of protein complexes that regulate the chromatin (Trotter and Archer, 2008). 
SMARCA4 is also a known regulator of cell proliferation. It interacts with pRb tumor 
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suppressor protein and regulates transcription of genes required for S-phase entry, 
e.g., cyclin A and Cdk1 (Wong et al., 2000). Different large-scale proteomics studies 
showed that the protein is a target of ATM/ATR kinases upon DNA damage 
(Matsuoka et al., 2007), indicating its potential role is DNA repair processes.  
So far its role during mitosis is not known. We investigated its significance by 
employing RNA interference. SMARCA4 was downregulated from asynchronous 
HeLa* cells using two different siRNA oligonucleotides and cells were analyzed by 
flow-cytometry and fluorescence microscopy 48h post-transfection. As shown in Fig. 
6A, we did not observe cells accumulating in any one phase of the cell cycle, the 
distribution being similar to the control. There was, however, a slight increase in 8N 
population of cells (indicated by arrows), likely reflecting defects in cytokinesis.  
As observed by fluorescence microscopy, cells displayed many aberrant mitotic 
phenotypes (Fig. 6B). Cells had severe defects in chromosome compaction and 
alignment at the metaphase plate and although bipolarity was achieved, cells did not 
have a normal spindle apparatus. Occasionally, occurrence of binucleate cells 
(marked with white arrows) was seen, indicating problems in cytokinesis.  
Similar results in flow-cytometry and mitotic defects were obtained with both siRNA 
oligonucleotides confirming the specificity of downregulation. These preliminary data 
point towards a role of SMARCA4 in progression through rather than entry into 
mitosis. 
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Figure 6- Effects of SMARCA4 downregulation. HeLa* cells were transfected with 
10 nM SMARCA4 siRNA oligonucleotide and analyzed by A) flow-cytometry and B) 
fluorescence microscopy.  
 
 
4.3.1.2.1.2.2. ANILLIN 
 
Anillin is an actin-binding protein required for cytokinesis, specifically for the 
processes of furrow assembly, ingression (Oegema et al., 2000) and maintenance of 
the contractile ring structure through regulating localization of RhoA and myosin II 
(Zhao and Fang, 2005). Anillin is also cell cycle regulated like other mitotic proteins 
and is a substrate of the APC/Cdh1 E3 ligase complex (Zhao and Fang, 2005). 
 
In our experiment, downregulation of anillin did not result in any significant increase 
in binucleate cells as expected from the data already published (Oegema et al., 2000). 
There was, however, only a slight increase in 8N and 16N population of cells (Fig. 
7A, indicated by arrows). As shown by the fluorescence images (Fig. 7B), there were 
not many binucleate cells and also cytokinesis appeared to be normal. The 
explanation could be that the siRNA oligonucleotide used, either, did not work or the 
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concentration used did not sufficiently downregulate anillin to produce a phenotype. 
Further work using higher concentration of the siRNA oligonucleotide or different 
oligonucleotides will be required to test if the downregulation results in any mitotic 
phenotypes. In addition, RT-PCR will be performed to check the efficacy of the 
oligonucleotides employed. So far, we did not find any dramatic effect of anillin 
downregulation. 
 
  
 
 
Figure 7- Effects of anillin downregulation. A) HeLa* cells were transfected with 10 
nM anillin siRNA oligonucleotide and analyzed by flow-cytometry and B) 
fluorescence microscopy. 
 
 
4.3.1.2.1.2.3. SIN3A  
 
SIN3A gene product is a transcriptional co-repressor that was identified initially by its 
interaction with Myc family of transcription repressors and later found to interact with 
histone deacetylases (HDACs) forming large protein complexes (Dannenberg et al., 
2005). The SIN3A-HDAC complex regulates transcription by associating with a large 
number of transcription factors, such as p53 (Murphy et al., 1999) and Smad4, 
resulting in repression of their target genes. Deregulation of transcription by this 
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complex has been associated with cancers such as AML (Melnick and Licht, 2002). 
SIN3A is also annotated as a phosphoprotein and mitosis specific phosphorylation 
sites have been mapped (Dephoure et al., 2008). Its direct role in mitosis, however, is 
not known.  
 
For evaluation of its role in cell cycle progression, we performed siRNA-mediated 
downregulation of SIN3A. As shown in Fig. 8A, downregulation of SIN3A from 
asynchronous cells resulted in an apparent cell cycle arrest as the population of cells 
in S and G2 phase appeared to be significantly reduced as compared to the control. 
Whether or not there was an extended block in cell proliferation was not addressed at 
this time. Also, there was an increase in sub-G1 population (pointed by the arrow), 
indicating its requirement for cell survival. By direct observation of the cells using 
fluorescence microscopy (Fig. 8B), we observed a clear reduction of mitotic cells 
(Fig. 8B, lower panel), supporting the flow-cytometry profile. Although, a few mitotic 
cells were seen, they did not display any aberrant phenotypes (Fig. 8B, upper panel). 
These results indicate that SIN3A may be required for entry into mitosis rather than 
having a role in mitotic progression. Future experiments will aim at uncovering the 
significance of its interaction with AurA. It will be interesting to determine if SIN3A 
plays a role in the transcriptional regulation of AurA, if it regulates protein stability or 
if it has a more direct role in regulating AurA specific mitotic functions, especially 
entry into mitosis.   
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Figure 8- Effects of SIN3A downregulation. HeLa* cells were transfected with 10 
nM SIN3A siRNA oligonucleotide and analyzed by A) flow-cytometry and B) 
fluorescence microscopy.  
 
 
4.3.1.2.1.2.4. Cdc5L (Cell Division Cycle 5 Like protein) 
 
The Cdc5L protein is the human homolog of S.pombe Cdc5 protein involved in 
mitotic entry. Cdc5L is associated with pre-mRNA splicing and is also able to bind 
DNA in a sequence specific manner, indicating a role in transcription regulation (Lei 
et al., 2000). Overexpression of Cdc5L was shown to shorten G2 and reduce cell size, 
whereas expression of a dominant negative mutant resulted in delayed entry into 
mitosis (Bernstein and Coughlin, 1998). The protein thus provides a remarkable 
example of how transcription regulation and mitosis can be linked; the exact 
mechanism, however, remains elusive. As we found Cdc5L interacting with AurA, we 
asked whether Cdc5L might exert its mitotic specific functions by regulating AurA. 
As an alternative, Cdc5L could be an AurA substrate, since it was reported to undergo 
heavy phosphorylations during mitosis (Dephoure et al., 2008). 
 
Downregulation of Cdc5L was performed to understand its role in cell cycle 
progression. As seen in Fig. 9A, siRNA-mediated downregulation of Cdc5L resulted 
in a decrease in the G2-M peak as compared to the control. Also, there was an 
increase in sub-G1 population indicating that it is an essential protein. Direct 
visualization of cells by fluorescence microscopy (Fig. 9B) revealed that there were 
fewer mitotic cells (Fig. 9B, lower panel labeled with *) and those that managed to 
enter mitosis (may be due to incomplete downregulation) showed aberrant mitotic 
phenotypes. Clear defects in chromosome compaction, chromosome alignment and 
bipolar spindle assembly were seen with both the siRNA oligonucleotides tested, 
indicating that the effects are specifically resulting from to Cdc5L downregulation. In 
addition, the data suggest that Cdc5L is directly involved in mitotic entry and 
progression. It will, therefore, be very interesting to identify its role during mitosis 
with respect to AurA. The next immediate goal will be to observe localization of 
AurA in Cdc5L downregulated synchronized cells.  
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Figure 9- Effects of Cdc5L downregulation. HeLa* cells were transfected with 10 
nM Cdc5L siRNA oligonucleotide and analyzed by A) flow-cytometry and B) 
fluorescence microscopy.  
 
 
4.3.1.2.2. Secondary Screening 
 
Here, we tested some significant proteins identified by the 2nd MS-experiment for 
their interaction with AurA by immunoprecipitation (IP) and Western blotting 
approach. Localization of these proteins was tested by immunoflourescence (IF) 
technique. Downregulation of these (to determine any mitotic phenotypes) were not 
performed, as data in literature is already available. 
 
4.3.1.2.2.1. SAS-6 (Spindle Assembly Abnormal protein 6 homolog) 
 
SAS-6 is a coiled-coil protein first identified in C.elegans required for centriole 
formation (Dammermann et al., 2004), (Leidel et al., 2005). Its human homolog 
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HsSAS-6 is also associated with centrosome duplication. Downregulation of HsSAS-
6 results in monopolar spindle formation and overexpression leads to a multipolar 
spindle pattern (Leidel et al., 2005) due to its role in the formation of procentrioles 
(Strnad et al., 2007). It was also observed that SAS-6 levels are cell cycle regulated, 
being high in mitosis and degraded in an APC/Cdh1 dependent manner at the end of 
mitosis (Strnad et al., 2007). Human SAS-6 was identified as a phosphoprotein by a 
large-scale proteomics study of mitotic phosphorylations (Dephoure et al., 2008). So 
far, only one kinase has been identified for SAS-6, the Zyg1 kinase, a homolog of 
human Plk4 that phosphorylates C.elegans SAS-6 at S123 (Kitagawa et al., 2009). As 
both loss and overexpression of SAS-6 results in phenotypes similar to those observed 
upon deregulation of AurA levels, we decided to investigate the significance of this 
interaction. The fact that both AurA and SAS-6 are localized at the centrosomes 
makes their interaction more likely.  
 
In order to evaluate this further, we first reproduced the IP done for mass-
spectrometry to confirm AurA-SAS-6 interaction. As seen in Fig. 10, IP of AurA 
from asynchronous and mitotic WCE resulted in clear co-IP of SAS-6.        
 
  
 
Figure 10- SAS-6 interacts with AurA. AurA was immunoprecipitated from 
asynchronous (As) and mitotic (M) MCF-7 WCE using specific antibody and 
interaction with SAS-6 was determined using Western blotting. * and IgG(H) indicate 
equal loading of input and IP, respectively. 
 
 
We next examined the cell cycle regulated expression of SAS-6 protein in both MCF-
7 and HeLa cells. Cells were synchronized with DTB block and analyzed at the 
indicated time points. As shown in Fig. 11A, MCF-7 cells were mitotic mainly 8-10h 
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post release as indicated by phosphorylation of histone H3 and pattern of other cell 
cycle proteins. SAS-6 also appeared to be specifically high during mitosis and rapidly 
disappeared as cells entered the next cell cycle (Fig. 11B). A similar result was seen 
with synchronized HeLa cells (Fig. 11C). We next confirmed the interaction of AurA-
SAS-6 from HeLa cells. Surprisingly, although SAS-6 showed a clear cell cycle 
regulated expression in HeLa cells (Fig. 11C), the two proteins did not interact (data 
not shown). This could be a result of different p53 status of the two cell lines. Aim of 
the future studies will be to identify if SAS-6 is a substrate of AurA and test its 
localization by IF in MCF-7 cells.  
 
 
 
Figure 11- SAS-6 is cell cycle regulated. MCF-7 cells were synchronized by DTB 
and A) expression of selected mitotic proteins was analyzed at the indicated time 
points by Western blotting. As: asynchronous. MSH2 serves as the loading control. B) 
Extracts of a) were used to determine the expression of SAS-6, N: Nocodazole treated 
sample. PP1 serves as the loading control. C) Similar results were obtained with DTB 
synchronized HeLa cells. * represents Ponceau-red stained bands showing equal 
loading. 
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4.3.1.2.2.2. 53BP1 
 
53BP1, a protein involved in the DNA damage response, was initially identified as an 
interactor of p53 (Iwabuchi et al., 1994). Since its discovery, it has been shown to 
interact with a number of proteins directly involved in DNA damage response 
signaling. 53BP1 co-localizes with damage-induced foci of MRN complex and γ-
H2AX (Schultz et al., 2000), (Rappold et al., 2001), (Anderson et al., 2001). 
Moreover, it is known to be phosphorylated by ATM in response to IR (Rappold et 
al., 2001), (Anderson et al., 2001), (Xia et al., 2001). Most interestingly, it was found 
to be hyperphosphorylated during mitosis (Jullien et al., 2002), (Dephoure et al., 
2008) with a further increase upon activation of the spindle checkpoint (Jullien et al., 
2002), although 53BP1 downregulation did not impair mitotic progression (van Vugt 
et al., 2010). 53BP1 also associates with the kinetochores, most strongly to prophase 
and prometaphase chromosomes (Jullien et al., 2002). Thus, so far, 53BP1 has been 
found associated with mitosis without an identified function. 
 
With evaluation of 53BP1 in this study, we wanted to identify its role in AurA 
mediated mitotic events and/or in regulation of AurA itself. We first wanted to 
confirm the interaction of AurA with 53BP1 by IP. We found that the two proteins 
strongly interacted with each other in mitosis but also a significant interaction was 
seen in interphase (Fig. 12A). This was possibly due to titration of the antibody by the 
large amount of WCE used in IP experiments, rendering the antibody unable to detect 
varying amounts of AurA. This experiment will be repeated using increasing amounts 
of the antibody and fixed amounts of WCEs. In order to determine if 53BP1 is cell 
cycle regulated, we synchronized HeLa cells with DTB. The success of 
synchronization was tested using flow-cytometry (Fig.12B) and WCE obtained from 
synchronized cells were subjected to Western blot analysis. As shown in Fig. 12C, 
53BP1 protein level clearly fluctuated during the cell cycle, being low in S and G2 
phases and increased during mitosis and exit from mitosis. The interaction was also 
confirmed in HeLa cells and it clearly showed a cell cycle dependent pattern (Fig. 
12D).  
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Figure 12- 53BP1 is cell cycle regulated and interacts with AurA. A) AurA was 
immunoprecipitated from asynchronous (As) and mitotic (M) MCF-7 WCE using 
specific antibody and interaction with 53BP1 was determined using Western blotting. 
* and IgG(H), stained with Ponceau-red indicate equal loading of input and IP, 
respectively. B) Flow-cytometry analysis of HeLa cells synchronized with DTB-
release method. DNA was stained with PI. C) DTB synchronized HeLa WCE were 
subjected to Western blotting and 53BP1 and AurA were detected using specific 
antibodies. D) AurA was immunoprecipitated from HeLa WCE prepared as in c) and 
detected using specific antibodies. IgG(H) stained with Ponceau Red serves as 
loading control for the IP.   
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Further, we tested if 53BP1 co-localizes with AurA during mitosis. For this, we first 
tested if the antibody used could detect 53BP1 in both damaged and undamaged 
conditions. As shown in Fig. 13A, in the absence of damage, 53BP1 primarily showed 
a diffused staining in the nucleus. Upon IR-induced damage, 53BP1 specific foci 
were distinctly visible in interphase cells (Fig. 13B). This confirmed the specificity of 
the antibody. However, there were no foci in the condensed mitotic chromosomes 
(Fig. 14A), irrespective of the damage (Fig. 14B), as suggested previously (Jullien et 
al., 2002), (Giunta et al., 2010). Moreover, we could not detect 53BP1 staining in 
chromosomes that were misaligned during mitosis (Fig. 14A, B), contrary to the 
already published data that suggested 53BP1 to be kinetochore localized during 
mitosis and also in misaligned chromosomes (Jullien et al., 2002). 
 
 
 
 
Figure 13-53BP1 forms foci after IR-induced DNA damage. A) Fluorescent image 
showing 53BP1 staining in non-damaged cells. B) Fluorescent image showing 53BP1 
specific foci after IR (9 Gy) induced DNA damage. 
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Next, we tested its co-localization with AurA, although, by the results obtained above, 
it was clear that 53BP1 did not associate with mitotic structures such as the 
centrosomes and spindles, the sites of AurA localization. As anticipated, 53BP1 was 
not found co-localizing with AurA during mitosis, both in the absence or presence of 
damage (Fig. 14). A possible explanation could be that their interaction might be 
happening before cells enter mitosis (Fig. 12D) and continues in mitosis but with 
distinct AurA population that is not targeted to the centrosomes and mitotic spindles. 
Identifying AurA and 53BP1 after IP of TPX2 (to determine if 53BP1 interacts with 
spindle localized AurA or with a distinct AurA pool) would be an indication of this 
possibility.  Work in the future will aim to identify if 53BP1 is a substrate of AurA 
and if downregulation of 53BP1 has an effect on localization and/or activity of the 
kinase.  
 
 
 
Figure 14- 53BP1 localization during mitosis. A) Fluorescent image showing 
localization of AurA and 53BP1 during an unperturbed mitosis. B) Fluorescent image 
showing localization of AurA and 53BP1 after 30 min of IR-treatment (9 Gy) given to 
DTB synchronized cells at 10h post-release. DNA is stained with DAPI.  
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4.3.1.2.2.3. KAP-1 
 
KAP-1, also known as KRAB-associated protein 1, is a transcriptional regulator that 
functions to repress transcription. KAP-1 does not directly bind DNA, but instead acts 
as a scaffold that binds to proteins containing the KRAB-domain and to chromatin 
modifying proteins, like HDAC, and represses transcription by allowing chromatin 
modification to take place (Alter and Hen, 2008). Transcriptional repression by KAP-
1 is also mediated through its direct interaction and recruitment of heterochromatin 
protein 1 (HP1) to the target genes (Ryan et al., 1999). This is suggested to result in 
local gene silencing by formation of a heterochromatin-like complex within the 
euchromatin regions, resulting in repression of transcription (Ryan et al., 1999). 
 
KAP-1 is also a significant example of a link between chromatin regulated 
transcription and DNA damage response as it is phosphorylated by PI3K-like kinases 
in response to damage and also localizes to the sites of damage (White et al., 2006). 
During mitosis, chromosomes are maximally condensed thereby making any 
transcription unlikely. How transcription is regulated at this point is largely unknown. 
 
As we found KAP-1 interacting with AurA, we went on further to characterize the 
significance of this interaction. KAP-1 was found phosphorylated during mitosis 
(Olsen et al., 2006), (Beausoleil et al., 2006), (Molina et al., 2007), (Dephoure et al., 
2008) and AurA could be one of the kinases responsible for this. We first examined 
the interaction of the two proteins by IP. As shown in Fig. 15, KAP-1 did not appear 
to interact with AurA. It also did not seem to be cell cycle regulated as seen by the 
unvaried level in asynchronous and mitotic WCE inputs. A possible explanation for 
this finding could reside in the different scale of the two experiments: the large 
amount of cell extract used for MS might have contained a small amount of a bridging 
protein the concentration of which is too low in conventional IP experiments to allow 
detecting the AurA-KAP1 complex. More work will be needed to confirm and clearly 
establish the significance of this interaction. 
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Figure 15- KAP-1 does not interact with AurA. AurA was immunoprecipitated from 
asynchronous (As) and mitotic (M) MCF-7 WCE using specific antibody and 
interaction with KAP-1 was determined using Western blotting. * and IgG(H) 
indicate equal loading of input and IP, respectively. Lane 3 represents control IP 
from mitotic WCE using pre-immune serum.  
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4.3.2. CONCLUSIONS 
 
4.3.2.1. Primary screening 
 
AurA downregulation results in increase in the percentage of cells with monoploar 
spindles and a higher mitotic index, indicating a role in mitotic progression. 
 
Of the proteins analyzed so far, we found that downregulation of SMARCA4 and 
Cdc5L results in numerous mitotic phenotypes.  
 
SIN3A appears to have some role in entry into the cell cycle rather than mitotic 
progression. 
 
4.3.2.2. Secondary screening 
 
Proteins for which antibodies were available, such as SAS-6 and 53BP1 were 
confirmed to directly interact with AurA. 53BP1 was, however, not found co-
localizing with AurA during mitosis. 
 
Others, like KAP-1, could not be confirmed as AurA interactor. 
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4.3.3. OUTLOOK 
 
The goal of future studies will be to first complete the preliminary screening of the 
selected proteins in Table 1, using a similar approach as used for the others analyzed 
so far.   
 
Of the proteins analyzed, the aim will be to carry out confirmation experiments for 
SMARCA4 and Cdc5L, two proteins that appear to have a role in mitotic progression.  
First, the effect of their downregulation will be tested in synchronized cells to confirm 
their roles in mitosis. Both flow-cytometry and immunofluorescence (IF) will be 
employed to this end. The next goal will be to observe the effect of their 
downregulation on the localization of AurA. Downregulation will be performed in 
synchronized cells and localization of AurA will be tested by IF. A double 
knockdown of AurA with either SMARCA4 or Cdc5L will be performed to observe a 
rescue of the mitotic phenotypes observed. This will clarify if SMARCA4 or Cdc5L 
directly affect AurA and if they work together with AurA in the same pathway in 
regulating mitosis.  
Their interaction with AurA will be confirmed with techniques such as 
immunoprecipitation and in vitro pull-down experiments, as soon as specific 
antibodies will be available. Furthermore, the suitability of SMARCA4 and Cdc5L as 
AurA substrates will be examined.  
These preliminary experiments will be necessary to place SMARCA4 and Cdc5L 
proteins either upstream or downstream to AurA and help in understanding their role 
as components of AurA pathways.  
 
Since SAS-6 is a known regulator of centrosomes and 53BP1 localizes at 
kinetochores, understanding their roles in AurA regulated processes will be a novelty. 
It will be necessary to analyze if these proteins serve as AurA substrates. An 
interesting issue to examine will be whether AurA mediated phosphorylation plays 
any role in removal of 53BP1 from the condensed chromatin during mitosis. A similar 
approach consisting of protein downregulation and cell synchronization will be 
employed to test if loss of either protein results in AurA mislocalization or vice-versa.  
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Another interesting family of proteins identified by MS is that of the motor proteins. 
We found several KIF (Kinesin-like proteins) proteins that associate with the spindle 
microtubules during mitosis and contribute to the dynamic behavior of spindles. 
KIF11 or Eg5 is a known AurA interactor and substrate. Identifying more such 
proteins will be absolutely essential to further understand the role of AurA in 
regulating motor proteins during spindle formation and maintenance. 
 
We also found two novel centrosomal proteins, Cep192 and Cep170. Cep192 was 
found associating with AurA also by another MS-study (http://mitocheck.org). It will 
therefore be intriguing to analyze these proteins and find new pathways regulating 
AurA or being regulated by AurA during mitosis. 
 
A similar methodology will be employed for testing all other proteins that will show 
mitotic phenotypes (after completion of the primary screening) and interaction with 
AurA.  
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4.3.5. MATERIALS AND METHODS 
 
Antibodies and chemicals 
The following antibodies were used: PP1 (Santa Cruz Biotech, mouse monoclonal); 
H3-pS10 (Millipore, rabbit polyclonal), AurA (Pab 35, purified rabbit polyclonal; 
35C1, mouse monoclonal), 53BP1 (Santa Cruz Biotech, rabbit polyclonal), KAP-1 
(Santa Cruz Biotech, rabbit polyclonal), MSH2 (Santa Cruz Biotech, rabbit 
polyclonal), cyclin B1 (Upstate Biotech. Inc., mouse monoclonal). SAS-6 polyclonal 
antibody was a kind gift from Prof. Pierre Gonczy ISREC, Lausanne.  
Thymidine (SynGen) was dissolved in PBS and filter-sterilized. Trypsin (Promega) 
was dissolved in 25 mM ammonium bicarbonate and stored as aliquots at -20°C.  
 
Cell culture, synchronization and transfection  
HeLa* cell line stably expressing mGFP-tubulin and mCherry-H2B plasmids was 
kindly provided by Prof. Daniel Gerlich, Institute of Biochemistry, ETH, Zurich. The 
cells were maintained in DMEM (GIBCO) supplemented with 10% fetal calf serum 
(FCS, GIBCO), penicillin (10,000 U/ml), streptomycin (10,000 µg/ml) (GIBCO) and 
kept under selection with G418 and puromycin at 37°C and 5% CO2. Normal HeLa 
cells were maintained in DMEM (GIBCO) supplemented with 5% fetal calf serum 
(FCS, GIBCO) and penicillin (10,000 U/ml) and streptomycin (10,000 µg/ml) 
(GIBCO) at 37°C and 5% CO2. MCF-7 cells were maintained in MEM (GIBCO) 
supplemented with 10% fetal calf serum (FCS, GIBCO), 1% L-glutamine (GIBCO), 
penicillin (10,000 U/ml) and streptomycin (10,000 µg/ml) (GIBCO) at 37°C and 5% 
CO2.  
MCF-7 cells were synchronized in mitosis using Cdk1 inhibitor, RO-3306, treatment 
and release method. Briefly, cells were treated with 9 μM RO-3306 for 20h and 
released into fresh medium. MCF-7 cells were synchronized in G1/S phase by a 
double-thymidine block (DTB). Cells were treated with 2 mM thymidine (SynGen) 
for 16h after 24h of plating. Cells were washed twice with PBS and released for 9h in 
fresh medium followed by a 2nd thymidine treatment for 16h.  
HeLa* cells were synchronized with a single thymidine block. Briefly, cells were 
grown in 10-cm dishes and treated with 2 mM thymidine for 24h. Cells were released 
in fresh medium and harvested at different time points for western blot and flow 
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cytometry analysis. Normal HeLa cells were synchronized with DTB as mentioned 
above. 
For transfection, HeLa* cells were seeded in 6-cm dishes and immediately transfected 
with 10 nM siRNA oligonucleotides (Qiagen) using the Lipofectamin RNAiMAX 
reagent (Invitrogen) for 48h.  
 
Western blotting and Immunoprecipitation 
WCE were prepared using immunoprecipitation (IP) buffer (50 mM Tris–HCl, pH 
7.5, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM Na-
pyrophosphate, 0.5 mM Na-orthovanadate, 1 mM benzamidine, 0.1 mM PMSF, 1% 
Nonidet P-40).  Briefly, cells were washed with cold PBS twice and incubated in the 
IP buffer on ice for 5 minutes and then scraped. Cleared lysates were obtained by 
centrifuging the tubes at 13,000 rpm for 15 minutes at 4°C. For 
immunoprecipitations, the WCE were pre-cleared using Protein A Sepharose beads 
(50% slurry made in 50 mM Tris-HCl, pH 7.5) for 2h at 4°C. AurA was 
immunoprecipitated with purified AurA-Pab35 antibody for 3h at 4°C from the pre-
cleared WCE. IP was carried out in the presence of 50 μg/ml EtBr. Proteins were 
immobilized on Protein A Sepharose beads (50% slurry made in 50 mM Tris-HCl, pH 
7.5) for 2h at 4°C and washed 3 times with 1ml ice-cold IP Buffer. The samples were 
boiled in 1X Laemmeli-buffer (50 mM Tris-Cl pH-6.8, 100 mM DTT, 2% SDS, 0.1% 
BPB dye 10% glycerol) at 95°C for 5 minutes before loading on SDS-PAGE gel.  
 
Flow Cytometry 
DNA analysis by PI staining was done to determine different cell cycle stages on 
samples collected before and after synchronization. Briefly, cells were trypsinized and 
resuspended in full medium, counted and transferred to a FACS tube. Cells were 
pelleted at 1500 rpm for 5 min and washed twice with PBS and fixed in 1ml ice-cold 
70% ethanol added drop wise with continuous mixing on a vortex mixer. Samples 
were stored at 4°C until processed for analysis. For PI staining, 0.5 to 1×106 fixed 
cells were pelleted at 1500 rpm to remove ethanol and washed twice with PBS. Cells 
were resuspended in 500 µL PBS and treated with 100 μg/ml RNAse (Sigma) for 30 
min at RT. 20 μg/ml PI (Molecular Probes) was added and cells were left on ice in 
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dark for 30 min prior to analysis. 10,000 events were acquired using Dako instrument 
and analyzed using the Summit software.  
 
Immunofluorescence 
Indirect immunofluorescence was performed with cells grown on glass coverslips. At 
indicated time points, coverslips were fixed in 100% ice-cold methanol and kept at -
20°C until processed. For blocking, coverslips were treated with 3% non-fat milk-
PBS solution (15-20 min) at RT with gentle shaking. This was followed by overnight 
treatment with the primary antibodies in a wet chamber at 4°C. The coverslips were 
washed twice in 3% non-fat milk-PBS (10 min) with shaking and probed with 
secondary antibodies (1h) at RT in dark.  Washings were done with PBS twice for (10 
min) with gentle shaking. The coverslips were then washed with Milli-Q water and 
mounted on Vecta-shield DAPI (Vector Labs) solution and sealed. Alexa Flour488 
and 594 conjugated secondary antibodies from Invitrogen were used at 1:1000 
dilution. Cells were observed with a Leica DMRB microscope equipped with a 100W 
HBO lamp for fluorescence. High-resolution pictures were taken with oil-immersion 
lenses (HCX PL APO 63X) and images were captured with a Leica DFC 360 FX 
camera. Merged images were obtained using the Image Overlay plugin of the Leica 
Application Suite® software. 
 
Silver staining 
MS compatible silver staining procedure was used. Briefly, the gel was fixed in 
solution A (50% methanol, 5% acetic acid in water, 20 min), washed in solution B 
(50% methanol in water, 10 min) and rinsed in water two times (10 min) to remove 
the remaining acid. The gel was sensitized in solution C (0.02% sodium thiosulfate, 1 
min) and rinsed with water two times (1 min). This was followed by incubation in 
solution D (cold 0.1% silver nitrate solution, 20 min) in dark. The gel was developed 
in a fresh tray using solution E (0.04% formalin in 2% sodium carbonate) with 
intensive shaking. Once the desired intensity was reached, the gel was transferred in a 
fresh tray and developing was stopped with solution F (5% acetic acid). Solution F 
was changed a couple of times to ensure complete termination of developing. All 
steps were carried out at room temperature. The gel was stored at 4°C in solution G 
(1% acetic acid) until processed further.  
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In-gel trypsin digestion of proteins 
After silver staining, bands were excised from the gel using a clean blade into 
eppendorf tubes and destained with solution G (1% H2O2). The pieces were 
dehydrated three times using solution H (50% acetonitrile) followed by reduction of 
proteins using solution I (10 mM DTT in 25 mM ammonium bicarbonate, 45 min) at 
56°C. Alkylation of cysteines was carried out at room temperature by incubating the 
gel pieces in solution J (50 mM iodoacetamide in 25 mM ammonium bicarbonate, 1h) 
followed by washing with solution H two times. The gel pieces were dried in speed-
vacuum and incubated with solution K (25 mM ammonium bicarbonate) containing 
trypsin (200 ng, 10 min) followed by addition of a small volume of solution K. The 
tubes were incubated overnight at 37°C. Tubes were centrifuged to collect liquid from 
the top and solution L (50% acetonitrile in 5% tri-flouro acetate) was added to the 
tubes. The supernatant was collected in fresh tubes and this step was repeated. The 
supernatant was dried using speed-vacuum and tubes were stored at -80°C until 
processed for mass-spectrometry.   
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5. TABLES 
(From Results Part 3) 
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5.1. MS-TABLES 
Most interesting MS-identified proteins from TABLE 1 are grouped according to their 
function and/or the specific protein complexes they belong to. 
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TABLE 1 
* List of proteins identified by the mass-spectrometric approach, filtered using 
number of unique peptides.  
* TPX2, Plk1 and KIF11 proteins served as a positive control for the list obtained. 
 
 
IDENTIFIED PROTEINS 
 
ACCESSION 
NO. 
 
Mw 
(kDa) 
 
CONTROL 
 
SAMPLE 
SWI/SNF complex subunit (SMARCC1) Q92922 123 0 35 
Centromere protein F (CENPF) P49454 368 0 51 
Isoform Short of Probable ubiquitin 
carboxyl-terminal hydrolase FAF-X 
(USP9X) 
Q93008-1 290 0 41 
Isoform D of Protein SON P18583-5 267 0 34 
SMARCA4 isoform 3  B1A8Z4 181 0 35 
Isoform 1 of General transcription factor II-
I (GTF2I) 
P78347-1 112 0 33 
Kinesin-like protein KIF7 Q2M1P5 151 0 30 
Isoform 1 of Nuclear receptor coactivator 3 
(NCOA3) 
Q9Y6Q9-1 155 0 27 
Isoform 1 of Ataxin-2-like protein 
(ATXN2L) 
Q8WWM7-1 113 0 24 
Kinesin-like protein KIF14  Q15058 186 0 28 
Isoform 1 of Rho guanine nucleotide 
exchange factor 2 (ARHGEF2) 
Q92974-1 112 0 27 
"Isoform 1 of Arf-GAP with GTPase ANK 
repeat and PH domain-containing protein 3 
(AGAP3)" 
Q96P47-1 95 0 17 
E3 ubiquitin-protein ligase UBR5 (UBR5) O95071 309 0 32 
Isoform 1 of Melanoma inhibitory activity 
protein 3 (MIA3) 
Q5JRA6-1 214 0 27 
Lysine-specific demethylase 6A (KDM6A) O15550 154 0 24 
Kinesin-like protein KIF11 P52732 119 0 25 
Isoform 1 of Splicing factor 3B subunit 3 
(SF3B3) 
Q15393-1 136 0 19 
Isoform 1 of AT-rich interactive domain-
containing protein 1A (ARID1A) 
O14497-1 242 0 23 
Isoform 1 of SWI/SNF complex subunit 
SMARCC2 
Q8TAQ2-1 133 0 15 
Isoform 1 of Large proline-rich protein 
BAT3 
P46379-1 119 0 25 
Isoform 1a of Oxysterol-binding protein-
related protein 3 (OSBPL3) 
Q9H4L5-1 101 0 17 
Isoform 1 of Protein transport protein 
Sec16A  
O15027-1 234 0 24 
Histone acetyltransferase p300  Q09472 264 0 24 
Targeting protein for Xklp2 (TPX2) Q9ULW0 86 0 24 
Isoform 1 of Nuclear pore complex protein 
Nup214  
P35658-1 214 0 15 
Nuclear fragile X mental retardation-
interacting protein 2 (NUFIP2) 
Q7Z417 76 0 18 
Kinesin-1 heavy chain KIF5B P33176 110 0 20 
Isoform 4 of Plectin-1 (PLEC1) Q15149-4 516 0 18 
Isoform 1 of Serine/threonine-protein 
kinase Nek1  
Q96PY6-1 143 0 15 
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Isoform 1 of Protein polybromo-1 
(PBRM1) 
Q86U86-1 193 0 21 
N-acetyltransferase 10 (NAT10) Q9H0A0 116 0 15 
"Isoleucyl-tRNA synthetase cytoplasmic 
(IARS)" 
P41252 145 0 15 
Isoform 1 of Lysine-specific histone 
demethylase 1(KDM1) 
O60341-1 93 0 17 
Activity-dependent neuroprotector 
homeobox protein (ADNP) 
Q9H2P0 124 0 16 
Isoform 1 of Serine/arginine repetitive 
matrix protein 2 (SRRM2) 
Q9UQ35-1 300 0 17 
"cDNA FLJ76788 highly similar to Homo 
sapiens splicing factor 3b subunit 2 145kDa 
(SF3B2)" 
A8K485 100 0 11 
WD repeat and HMG-box DNA-binding 
protein 1 (WDHD1) 
O75717 126 0 13 
Isoform 1 of Centrosomal protein of 192 
kDa  
Q8TEP8-1 213 0 18 
Isoform Beta-2 of DNA topoisomerase 2-
beta (TOP2B) 
Q02880-1 183 0 15 
Cleavage and polyadenylation specificity 
factor subunit 1 (CPSF1) 
Q10570 161 0 17 
Cytoplasmic dynein 1 heavy chain 1 
(DYNC1H1) 
Q14204 532 0 11 
Isoform 1 of Chromodomain-helicase-
DNA-binding protein 4 (CHD4) 
Q14839-1 218 0 15 
Pre-mRNA-splicing factor SLU7  O95391 68 0 11 
Isoform 3 of Homeobox protein cut-like 1 
(CUX1) 
P39880-3 166 0 17 
WD repeat-containing protein 33 (WDR33) Q9C0J8 146 0 12 
Zinc finger protein 295 (ZNF295) Q9ULJ3 119 0 11 
Solute carrier family 4 sodium bicarbonate 
cotransporter member 7 (SLC4A7) 
B2CI53 127 0 10 
Isoform 1 of Guanine nucleotide-binding 
protein-like 3 (GNL3) 
Q9BVP2-1 62 0 10 
Probable ATP-dependent RNA helicase 
DDX20  
Q9UHI6 92 0 15 
Component of gems 4 (GEMIN4) P57678 120 0 15 
Isoform 1 of Genetic suppressor element 1 
(GSE1) 
Q14687-1 136 0 10 
Isoform 1 of AT-rich interactive domain-
containing protein 1B (ARID1B) 
Q8NFD5-1 236 0 10 
Isoform 1 of WD repeat-containing protein 
C2orf44  
Q9H6R7-1 79 0 9 
Nucleolar protein 56 (NOP56) O00567 66 0 6 
Ribonucleases P/MRP protein subunit 
POP1 
Q99575 115 0 12 
Ubiquitin carboxyl-terminal hydrolase 10 
(USP10) 
Q14694 87 0 10 
Isoform 1 of Tumor suppressor p53-binding 
protein 1 (TP53BP1) 
Q12888-1 214 0 11 
Isoform 2 of CAP-Gly domain-containing 
linker protein 1 (CLIP1) 
P30622-1 161 0 7 
6-phosphofructokinase type C (PFKP) Q01813 86 0 12 
Trophinin-associated protein (TROAP) Q12815 84 0 8 
Isoform 1 of Spermatogenesis-associated 
protein 5 (SPATA5) 
Q8NB90-1 98 0 10 
Isoform 1 of Interleukin enhancer-binding Q12906-1 95 0 5 
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factor 3 (ILF3) 
Cleavage stimulation factor 77 kDa subunit 
(CSTF3) 
Q12996 83 0 14 
NF-kappa-B-repressing factor (NKRF) O15226 78 0 7 
Isoform 1 of Regulator of nonsense 
transcripts 1 (UPF1) 
Q92900-1 124 0 7 
Isoform 2 of R3H domain-containing 
protein 1 (R3HDM1) 
Q15032-2 108 0 13 
Isoform 1 of PAX-interacting protein 1 
(PAXIP1) 
Q6ZW49-1 118 0 15 
CTTNBP2 N-terminal-like protein 
(CTTNBP2NL) 
Q9P2B4 70 0 15 
"Isoform 1 of Arf-GAP with GTPase ANK 
repeat and PH domain-containing protein 1 
(AGAP1)" 
Q9UPQ3-1 94 0 9 
Isoform 1 of U2-associated protein SR140 O15042-1 118 0 10 
Isoform Long of Adenomatous polyposis 
coli protein (APC) 
P25054-1 312 0 13 
Isoform 1 of PHD finger protein 3 (PHF3) Q92576-1 229 0 9 
Peroxisomal multifunctional enzyme type 2 
(HSD17B4) 
P51659 80 0 5 
"Isoform 1 of Putative splicing factor 
arginine/serine-rich 14 (SFRS14)" 
Q8IX01-1 120 0 12 
Isoform 1 of WD repeat-containing protein 
91 (WDR91) 
A4D1P6-1 83 0 13 
Isoform 2 of Kinesin-like protein KIF2A  O00139-2 75 0 13 
Isoform 1 of Mediator of RNA polymerase 
II transcription subunit 23 (MED23) 
Q9ULK4-1 156 0 13 
Nucleolar GTP-binding protein 2 (GNL2) Q13823 84 0 8 
Isoform 1 of CCR4-NOT transcription 
complex subunit 1 (CNOT1) 
A5YKK6-1 267 0 8 
Serine/threonine-protein kinase PRP4 
homolog (PRPF4B) 
Q13523 117 0 8 
Isoform 1 of 182 kDa tankyrase-1-binding 
protein (TNKS1BP1) 
Q9C0C2-1 182 0 11 
Cleavage and polyadenylation specificity 
factor subunit 2 (CPSF2) 
Q9P2I0 88 0 11 
Isoform 1 of DNA replication licensing 
factor MCM7 
P33993-1 81 0 7 
Isoform 1 of Transcription intermediary 
factor 1-beta (TRIM28) 
Q13263-1 89 0 7 
"cDNA FLJ53884 highly similar to mRNA 
decapping enzyme 1A (EC 3.-.-.-)" 
B4DHN9 59 0 8 
Nucleoprotein TPR P12270 267 0 8 
Isoform 1 of Angiomotin-like protein 1 
(AMOTL1) 
Q8IY63-1 107 0 7 
ATP-dependent RNA helicase DDX1 
OS=Homo sapiens GN=DDX1 
Q92499 82 0 5 
Isoform 1 of Zinc finger CCCH-type 
antiviral protein 1 OS=Homo sapiens 
GN=ZC3HAV1 
Q7Z2W4-1 101 0 8 
Nuclear pore complex protein Nup88  Q99567 84 0 9 
Nuclear receptor coactivator 6 (NCOA6) Q14686 219 0 7 
Isoform 1 of Round spermatid basic protein 
1-like protein (RSBN1L) 
Q6PCB5-1 94 0 7 
Isoform 1 of ATR-interacting protein 
(ATRIP) 
Q8WXE1-1 86 0 9 
Isoform 1 of Chromodomain-helicase- Q9P2D1-1 336 0 9 
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DNA-binding protein 7 (CHD7) 
Cell division cycle 5-like protein (CDC5L) Q99459 92 0 6 
116 kDa U5 small nuclear 
ribonucleoprotein component (EFTUD2) 
Q15029 109 0 6 
Isoform 1 of DNA repair protein RAD50  Q92878-1 154 0 7 
Werner syndrome ATP-dependent helicase  Q14191 163 0 8 
Isoform 1 of CCR4-NOT transcription 
complex subunit 3 (CNOT3) 
O75175-1 82 0 7 
Isoform 1 of Hyaluronan mediated motility 
receptor (HMMR) 
O75330-1 84 0 8 
Isoform Long of Dual specificity tyrosine-
phosphorylation-regulated kinase 1A 
(DYRK1A) 
Q13627-1 86 0 6 
Isoform 2 of Ubiquitin-associated protein 2-
like (UBAP2L) 
Q14157-1 104 0 9 
DNA repair endonuclease XPF (ERCC4) Q92889 104 0 9 
Paired amphipathic helix protein Sin3a  Q96ST3 145 0 7 
Isoform 1 of Actin-binding protein anillin 
(ANLN) 
Q9NQW6-1 124 0 5 
Isoform 1 of S phase cyclin A-associated 
protein in the endoplasmic reticulum 
(SCAPER) 
Q9BY12-1 158 0 6 
Probable E3 ubiquitin-protein ligase 
HERC2  
O95714 527 0 6 
Zinc finger CCCH domain-containing 
protein 11A (ZC3H11A) 
O75152 89 0 5 
"Isoform Alpha of Lamina-associated 
polypeptide 2 isoform alpha (TMPO)" 
P42166-1 75 0 9 
Isoform 1 of Codanin-1 (CDAN1) Q8IWY9-1 134 0 7 
Isoform 1 of Telomere-associated protein 
RIF1  
Q5UIP0-1 274 0 6 
"Isoform 1 of Proline-glutamic acid- and 
leucine-rich protein 1 (PELP1)" 
Q8IZL8-1 120 0 5 
Isoform 1 of Replication factor C subunit 1 
(RFC1) 
P35251-1 128 0 6 
Pre-mRNA-splicing factor SYF1 (XAB2) Q9HCS7 100 0 6 
Isoform 1 of Histone-lysine N-
methyltransferase MLL2  
O14686-1 564 0 5 
Isoform 1 of Probable E3 ubiquitin-protein 
ligase MYCBP2  
O75592-1 510 0 7 
Isoform 1 of ZZ-type zinc finger-containing 
protein 3 (ZZZ3) 
Q8IYH5-1 102 0 10 
Mastermind-like protein 1 (MAML1) Q92585 108 0 7 
Isoform 1 of Protein LAP2 (ERBB2IP) Q96RT1-1 158 0 5 
Isoform 2 of LisH domain and HEAT 
repeat-containing protein KIAA1468  
Q9P260-2 139 0 8 
Isoform 1 of Zinc finger MIZ domain-
containing protein 1 (ZMIZ1) 
Q9ULJ6-1 115 0 5 
Isoform 1 of Protein FAM83D  Q9H4H8-1 64 0 5 
Isoform 1 of TBC1 domain family member 
4 (TBC1D4) 
O60343-1 147 0 5 
CCAAT/enhancer-binding protein zeta 
(CEBPZ) 
Q03701 121 0 5 
Isoform 1 of Protein FAM83D  Q9H4H8-1 64 0 5 
Isoform 1 of TBC1 domain family member 
4 (TBC1D4) 
O60343-1 147 0 5 
Isoform 1 of 5'-3' exoribonuclease 2 
(XRN2) 
Q9H0D6-1 109 0 6 
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Probable ATP-dependent RNA helicase 
YTHDC2 
Q9H6S0 160 0 5 
TOX high mobility group box family 
member 4 (TOX4) 
O94842 66 0 6 
Serine/threonine-protein kinase PLK1  P53350 68 0 6 
Isoform 1 of Retinoblastoma-binding 
protein 5 (RBBP5) 
Q15291-1 59 0 7 
Activating signal cointegrator 1 (TRIP4) Q15650 66 0 7 
Isoform 1 of Centrosomal protein of 170 
kDa  
Q5SW79-1 175 0 7 
Isoform 1 of Pre-mRNA 3'-end-processing 
factor FIP1 (FIP1L1) 
Q6UN15-1 67 0 7 
Semaphorin-4C  Q9C0C4 93 0 6 
Isoform 1 of CCR4-NOT transcription 
complex subunit 10 (CNOT10) 
Q9H9A5-1 82 0 5 
Epidermal growth factor receptor substrate 
15-like 1 (EPS15L1) 
Q9UBC2 94 0 6 
Calcium-binding mitochondrial carrier 
protein Aralar2 (SLC25A13) 
Q9UJS0 74 0 6 
Isoform 1 of Spermatogenesis-associated 
protein 5-like protein 1 (SPATA5L1) 
Q9BVQ7-1 81 0 6 
"Isoform 1 of 6-phosphofructokinase liver 
type (PFKL) " 
P08237-1 85 0 5 
"Isoform 1 of 6-phosphofructokinase 
muscle type (PFKM)" 
P17858-1 85 0 6 
Stromal interaction molecule 1 (STIM1) Q13586 77 0 5 
Probable ATP-dependent RNA helicase 
DHX37 
Q8IY37 130 0 6 
Apoptosis-stimulating of p53 protein 1 
(PPP1R13B) 
Q96KQ4 120 0 6 
Isoform 1 of Activating signal cointegrator 
1 complex subunit 2 (ASCC2) 
Q9H1I8-1 86 0 6 
YEATS domain-containing protein 2 
(YEATS2) 
Q9ULM3 151 0 6 
Isoform 1 of C-jun-amino-terminal kinase-
interacting protein 3 (MAPK8IP3) 
Q9UPT6-1 147 0 7 
Isoform 1 of La-related protein 7 (LARP7) Q4G0J3-1 67 0 5 
Isoform 1 of Coatomer subunit alpha 
(COPA) 
P53621-1 138 0 5 
Isoform RF1/RF2 of Retrotransposon-
derived protein PEG10  
Q86TG7-1 80 0 5 
Mediator of RNA polymerase II 
transcription subunit 14 (MED14) 
O60244 161 0 5 
Isoform 1 of Mitotic checkpoint 
serine/threonine-protein kinase BUB1 beta 
O60566-1 120 0 7 
Isoform Long of Trifunctional purine 
biosynthetic protein adenosine-3 (GART) 
P22102-1 108 0 5 
Spindle assembly abnormal protein 6 
homolog (SASS6) 
Q6UVJ0 74 0 6 
Intron-binding protein aquarius (AQR) O60306 171 0 6 
Isoform 1 of Striatin (STRN) O43815-1 86 0 5 
Mediator of RNA polymerase II 
transcription subunit 24 (MED24) 
O75448 110 0 5 
Ubiquitin carboxyl-terminal hydrolase 
BAP1  
Q92560 80 0 5 
"Cleavage stimulation factor 64 kDa 
subunit tau variant (CSTF2T)" 
Q9H0L4 64 0 5 
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TABLE 2 
List of important MITOTIC proteins identified by the mass-spectrometric approach, 
filtered using number of unique peptides.  
 
 
IDENTIFIED PROTEINS 
 
ACCESSION 
NO. 
 
Mw (kDa) 
 
CONTROL 
 
SAMPLE 
Kinesin-like protein KIF7 Q2M1P5 151 0 30 
Kinesin-like protein KIF14  Q15058 186 0 28 
Kinesin-1 heavy chain KIF5B P33176 110 0 20 
Isoform 2 of Kinesin-like 
protein KIF2A  
O00139-2 75 0 13 
Kinesin-like protein KIF11 P52732 119 0 25 
Isoform 1 of Centrosomal 
protein of 192 kDa  
Q8TEP8-1 213 0 18 
Isoform 1 of Centrosomal 
protein of 170 kDa  
Q5SW79-1 175 0 7 
Isoform 1 of Rho guanine 
nucleotide exchange factor 2 
(ARHGEF2) 
Q92974-1 112 0 27 
Targeting protein for Xklp2 
(TPX2) 
Q9ULW0 86 0 24 
Isoform D of Protein SON P18583-5 267 0 34 
Serine/threonine-protein kinase 
PLK1  
P53350 68 0 6 
Spindle assembly abnormal 
protein 6 homolog (SASS6) 
Q6UVJ0 74 0 6 
Isoform 1 of Actin-binding 
protein anillin (ANLN) 
Q9NQW6-1 124 0 5 
Cell division cycle 5-like protein 
(CDC5L) 
Q99459 92 0 6 
Isoform 1 of Mitotic checkpoint 
serine/threonine-protein kinase 
BUB1 beta 
O60566-1 120 0 7 
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TABLE 3 
* List of proteins obtained from the 1st mass-spectrometric experiment, filtered using 
number of unique peptides.  
* TPX2 and chTOG proteins served as a positive control for the list obtained. 
 
 
IDENTIFIED PROTEINS  
 
ACCESSION 
NO. 
 
Mw 
(kDa) 
 
CONTROL 
 
SAMPLE 
U5 small nuclear ribonucleoprotein 200 kDa 
helicase (EC 3.6.1.-) 
U520 245 0 38 
Supervillin (Archvillin) (p205/p250) SVIL 248 0 23 
RRP5 protein homolog (Programmed cell 
death protein 11)  
RRP5 209 0 21 
EIF4G1 variant protein (Fragment) Q4LE58 178 0 23 
SMARCA4 isoform 2 Q9HBD4 188 0 18 
Cytoskeleton-associated protein 5 (Colonic 
and hepatic tumor over-expressed protein) 
(Ch-TOG protein) 
CKAP5 226 0 16 
CAD protein [Includes: Glutamine-dependent 
carbamoyl-phosphate synthase (EC 6.3.5.5); 
Aspartate carbamoyltransferase (EC 2.1.3.2); 
Dihydroorotase (EC 3.5.2.3)]  
PYR1 243 0 16 
"Hepatocellular carcinoma-associated antigen 
90 (TPX2 microtubule-associated homolog) 
(Xenopus laevis)" 
Q96RR5 89 0 17 
HEAT repeat-containing protein 1 (Protein 
BAP28)  
HEAT1 242 0 15 
Exportin-7 (Exp7) (Ran-binding protein 16)  XPO7 124 0 18 
Paired amphipathic helix protein Sin3a SIN3A 145 0 15 
Protein AATF (Apoptosis-antagonizing 
transcription factor) 
AATF 63 0 15 
Nuclear valosin-containing protein-like 
(Nuclear VCP-like protein)  
NVL 95 0 14 
ATP-dependent RNA helicase DHX8 (EC 
3.6.1.-) (DEAH box protein 8) (RNA helicase 
HRH1)  
DHX8 139 0 14 
Hypothetical protein DKFZp686E0722 
(Fragment) 
Q68DX7 239 0 15 
DNA (cytosine-5)-methyltransferase 1 (EC 
2.1.1.37) (Dnmt1) (DNA methyltransferase 
HsaI) (DNA MTase HsaI) (MCMT) (M.HsaI) 
DNMT1 183 0 10 
Activity-dependent neuroprotector (Activity-
dependent neuroprotective protein) 
ADNP 124 0 16 
Nardilysin precursor (EC 3.4.24.61) (N-
arginine dibasic convertase) (NRD 
convertase) (NRD-C) 
NRDC 132 0 8 
Protein KIAA1429 Q69YN4 202 0 11 
Chromodomain-helicase-DNA-binding 
protein 1 (EC 3.6.1.-) (ATP-dependent 
helicase CHD1) (CHD-1) 
CHD1 197 0 9 
Exportin-4 (Exp4) XPO4 130 0 11 
Nuclear pore complex protein Nup205 
(Nucleoporin Nup205) 
NU205 228 0 7 
HBS1-like protein (ERFS) HBS1L 75 0 10 
LIM domain only protein 7 (LOMP) (F-box 
only protein 20) 
LMO7 193 0 9 
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"Phospholipase C gamma 1" A2A284 149 0 11 
Actin-binding protein anillin ANLN 124 0 10 
Coiled-coil domain-containing protein 9 CCDC9 60 0 6 
Hypothetical protein DKFZp434K1531 Q8ND04 110 0 7 
Elongation factor Tu GTP-binding domain-
containing protein 1 
Q7Z2Z2 120 0 7 
Kinesin-like protein KIF20A (Rabkinesin-6) 
(Rab6-interacting kinesin-like protein) 
(GG10_2) 
KI20A 100 0 9 
RNA polymerase-associated protein CTR9 
homolog (SH2 domain-binding protein 1) 
CTR9 134 0 5 
Pre-mRNA-processing-splicing factor 8 
(Splicing factor Prp8) (PRP8 homolog) (220 
kDa U5 snRNP-specific protein) (p220) 
PRP8 274 0 8 
MutS homolog 3 (E. coli) A1L480 128 0 6 
"Presequence protease mitochondrial 
precursor (EC 3.4.24.-) (hPreP) (Pitrilysin 
metalloproteinase 1) (Metalloprotease 1) 
(hMP1)" 
PREP 117 0 6 
Novel protein Q5JXI5 95 0 9 
Nucleolar protein 9 NOL9 79 0 8 
Digestive organ expansion factor homolog DEF 87 0 8 
DNA ligase 3 (EC 6.5.1.1) (DNA ligase III) 
(Polydeoxyribonucleotide synthase [ATP] 3) 
DNL3 103 0 7 
Probable ATP-dependent RNA helicase 
DDX31 (EC 3.6.1.-) (DEAD box protein 31) 
(Helicain) 
DDX31 94 0 7 
Uncharacterized protein KIAA1033 K1033 136 0 7 
Periodic tryptophan protein 2 homolog PWP2 102 0 6 
Dedicator of cytokinesis protein 7 DOCK7 243 0 6 
"Neurolysin mitochondrial precursor (EC 
3.4.24.16) (Neurotensin endopeptidase) 
(Mitochondrial oligopeptidase M) 
(Microsomal endopeptidase) (MEP)" 
NEUL 81 0 5 
Rab GTPase-binding effector protein 1 
(Rabaptin-5) (Rabaptin-5alpha) (Rabaptin-4) 
(Renal carcinoma antigen NY-REN-17) 
RABE1 99 0 5 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A 
containing DEAD/H box 1 (EC 3.6.1.-) (ATP-
dependent helicase 1) (hHEL1) 
SMRCD 117 0 6 
TFIIH basal transcription factor complex 
helicase subunit (EC 3.6.1.-) (DNA-repair 
protein complementing XP-D cells) 
(Xeroderma pigmentosum group D-
complementing protein) (CXPD) (DNA 
excision repair protein ERCC-2) 
ERCC2 87 0 6 
Zinc finger CCHC domain-containing protein 
8 
ZCHC8 79 0 5 
Glutamine-rich protein 1  QRIC1 86 0 5 
Tyrosine-protein kinase-like 7 precursor 
(Colon carcinoma kinase 4) (CCK-4) 
PTK7 118 0 5 
mitochondrial precursor (IF-2Mt) (IF2(mt)) 
(IF-2(Mt))" 
IF2M 81 0 5 
Aspartyl/asparaginyl beta-hydroxylase (EC 
1.14.11.16)  
ASPH 86 0 6 
ATR-interacting protein (ATM and Rad3- ATRIP 86 0 6 
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related-interacting protein) 
Hepatocyte growth factor-regulated tyrosine 
kinase substrate (Protein pp110) (Hrs) 
HGS 86 0 6 
Protein bicaudal D homolog 2 (Bic-D 2) BICD2 94 0 6 
Zinc finger protein 574 ZN574 99 0 5 
Exocyst complex component 8 (Exocyst 
complex 84 kDa subunit) 
EXOC8 82 0 5 
Afadin (Protein AF-6) AFAD 206 0 6 
Transcription termination factor 1 (TTF-1) 
(TTF-I) (RNA polymerase I termination 
factor) 
TTF1 101 0 5 
Ubiquitin carboxyl-terminal hydrolase 36 (EC 
3.1.2.15) (Ubiquitin thioesterase 36) 
(Ubiquitin-specific-processing protease 36) 
(Deubiquitinating enzyme 36) 
UBP36 123 0 5 
Tetratricopeptide repeat protein 7B (TPR 
repeat protein 7B) (Tetratricopeptide repeat 
protein 7-like-1) 
TTC7B 83 0 5 
RNA polymerase II-associated protein 1 RPAP1 153 0 5 
"X-prolyl aminopeptidase (Aminopeptidase P) 
1 soluble" 
Q5T6H7 62 0 5 
CLIP1 protein A0AVD3) 162 0 6 
Coronin-7 (70 kDa WD repeat tumor rejection 
antigen homolog) 
CORO7 101 0 5 
CTTNBP2 N-terminal-like protein CT2NL 70 0 5 
NEDD8 ultimate buster 1 (Negative regulator 
of ubiquitin-like proteins 1) (Renal carcinoma 
antigen NY-REN-18) 
NUB1 71 0 5 
"A kinase anchor protein 1 mitochondrial 
precursor (Protein kinase A-anchoring protein 
1) (PRKA1)" 
AKAP1 97 0 5 
Long-chain-fatty-acid--CoA ligase 4 (EC 
6.2.1.3) (Long-chain acyl-CoA synthetase 4) 
(LACS 4) 
ACSL4 79 0 5 
IWS1 homolog (IWS1-like protein) IWS1 92 0 5 
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TABLE 4 
List of proteins found common in both MS-experiments. 
 
IDENTIFIED PROTEINS 
 
ACCESSION NO. 
 
Mw (kDa) 
SMARCA4 isoform 3 B1A8Z4 181 
Targeting protein for Xklp2 (TPX2) Q9ULW0  86 
Isoform 1 of Actin-binding protein anillin (ANLN) Q9NQW6-1 124 
Paired amphipathic helix protein Sin3A Q96ST3 145 
Cell division cycle 5-like protein (CDC5L) Q99459  92 
Isoform 1 of Protein polybromo-1 (PBRM1) Q86U86-1 193 
Kinesin-like protein KIF11 P52732 119 
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